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In this thesis, we identified neutralizing epitopes in the region of the severe acute 
respiratory coronavirus (SARS-CoV) spike (S) protein encoded by aa residues 1055 to 
1192 (SΔ10 protein fragment). To understand the mechanism of SARS-CoV 
neutralization by the anti-SΔ10 antibodies, a panel of monoclonal antibodies (mAbs) was 
generated. Epitope mapping revealed that the immuno-dominant region within SΔ10 lies 
between residues 1091 to 1130 and 1150 to 1192, which are part of the loop region 
between the heptad repeats 1 (HR1) and heptad repeats 2 (HR2) domains and the N-
terminal of the HR2 domain, respectively. The HR1 and HR2 domains have previously 
been shown to be important for the viral-cell fusion process. Using the cell-cell fusion 
inhibition and in vitro neutralizing assays, the mAbs were shown to neutralize SARS-
CoV infection and inhibit cell-cell fusion. Taken together, the results suggest that the 
mechanism of neutralization of SARS-CoV infection by these mAbs is due to the 
inhibition of the viral-cell fusion step during viral entry. 
As these mAbs target highly conserved regions in the C terminal of S, which is 
known as the S2 domain, two representative mAbs, 1A9 and 1G10, were selected for 
evaluation of cross-neutralizing properties. A recent report suggests that the bat SL-CoV 
Rf1 and Rp3 strains could have undergone a recombination event to yield the civet 
SARS-CoV SZ3 strain which in turn spills over to human during the SARS epidemic. By 
use of lentiviral pseudotyped particles carrying S on the surface, both mAbs targeting the 
N-terminal HR2 domain (mAb 1G10) and the loop region between the HR1 and HR2 
domains were shown to cross-neutralize the civet SARS-CoV (SZ3 strain) and bat SL-
VIII 
 
CoV (Rf1 and Rp3 strains). In order to gain a better understanding of the mechanism of 
virus neutralization of mAbs 1G10 and 1A9, escape viruses were generated. From the 
results, two mutations (N1056K and D1128A) in S of the escape viruses generated using 
mAb 1A9 showed a synergistic effect on the escape activity in pseudovirus assay. Taken 
together, the results suggest that a novel conserved region in the loop domain between the 
HR1 and HR2 domains is important for the SARS-CoV and SL-CoV viral-cell fusion 
process. 
The most obvious genomic difference between the human epidemic SARS-CoV 
strains and the animal and early human SARS-CoV strains is that the ORF8 acquired a 
29-nt deletion, resulting in the coding of two proteins, 8a and 8b, instead of a single 8ab 
protein. Using over-expression systems and co-immunoprecipitation experiments, the 
viral-viral interaction profiles of all the three proteins (8a, 8b and 8ab) were found to be 
different, and more interestingly, 8b was found to down-regulate E in a post-translational 
manner. Infection studies further showed that 8b is expressed late during infection and 
has mutually exclusive localization with E in infected cells. Cells stably expressing the 
GFP-tagged 8b were also shown to down-regulate E and reduce virus replication by 
approximately 10-folds. In addition, it was demonstrated that the mechanism of down-
regulation of E by 8b is via an ubiquitin-independent proteasome pathway. An 
oligonucleotide microarray analysis also revealed that 8b alters the mRNA levels of 
several host proteins, suggesting that they may be involved in virus replication. In 
summary, we have identified an important viral-viral interaction that could have evolved 
in the human epidemic strains. 
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CHAPTER 1: INTRODUCTION 
 
1.1 An Overview of SARS-CoV 
In November 2002, the emergence of an unknown virus that causes atypical 
pneumonia sends a shock wave around the world, causing major social disruption and 
having an extensive impact on the healthcare systems and the world economies (Bell, 
2004; Caulford, 2003; Lee et al., 2003). The virus spreads from Guangdong province in 
China to 29 countries world-wide, resulting in 8,098 infections with 774 deaths (Peiris et 
al., 2004; WHO, 2004; Zhong et al., 2003). The aetiological agent for the pneumonia 
disorder was identified to be a novel coronavirus termed as severe acute respiratory 
syndrome coronavirus (SARS-CoV) (Drosten et al., 2003; Fouchier et al., 2003; Ksiazek 
et al., 2003; Kuiken et al., 2003; Peiris et al., 2003b). SARS-CoV belongs to the 
Coronaviruses genus, in the Coronaviridae family of the Nidovirales order, in the virus 
taxonomy. Coronaviruses are divided into 3 subgroups, with group 1 and 2 comprising of 
mammalian coronaviruses and group 3 comprising of avian coronaviruses (Bradburne, 
1970; McIntosh et al., 1969; Woo et al., 2009). Based on sequence comparisons and 
similarity of the ORF1a region of SARS-CoV to group 2 coronaviruses, it is suggested 
that SARS-CoV belongs to the group 2b of the genus Coronaviruses but was later 
assigned in a novel group 2c of the same genus (Snijder et al., 2003; Woo et al., 2006). 
SARS-CoV is an enveloped, positive-sense, single-stranded RNA virus with a 
genome size of 29.7 kilobases (kb) encoding for sixteen non-structural proteins (NSPs), 
four structural proteins and eight accessory proteins (Marra et al., 2003; Rota et al., 2003; 
Ruan et al., 2003) (Fig. 1.1). SARS-CoV replicates in the cytoplasm of the infected cells. 
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Using electron microscopy techniques, it was shown that SARS-CoV establishes its 
replication complexes at the endoplasmic reticulum (ER)-derived membranes (Stertz et 
al., 2007). Recently, the SARS-CoV replication complexes were found to be supported 
by a reticulovesicular network of modified reticulum and are membrane-protected, 
possibly having a role in hiding the viral complexes from the host anti-viral defense 
mechanism (Knoops et al., 2008; van Hemert et al., 2008). Viral RNA synthesis begins 
with the transcription of a minus-strand RNA template from the viral genome, followed 
by the transcription of a genomic messenger ribonucleotide acid (mRNA) and eight sub-
genomic mRNAs, and subsequently leading to the expression of the NSPs, the structural 
proteins and the accessory proteins (Sawicki and Sawicki, 2005a; Sawicki et al., 2007; 












Fig. 1.1: SARS-CoV Genome Organization.  
Figure adapted from Plant and Dinman, Front Biosci, 2008. 
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1.1.1 Non-structural proteins (NSPs) 
The expression of the genome of SARS-CoV begins with the translation of gene 1 
at the 5’ end to two replicase polyproteins, pp1a and pp1ab (Baranov et al., 2005; Dos 
Ramos et al., 2004). Pp1a is encoded by ORF1a and translation stops at the stop codon 
resulting in a 490 kilo-Dalton (kDa) polyprotein. A programmed -1 ribosomal frame shift 
prior to the stop codon of the open reading frame (ORF) 1a directs a fraction of the 
elongating ribosomes into an alternative reading frame that is -1 relative to the initiating 
ORF1a for the expression of a 790 kDa polyprotein, pp1ab (Dos Ramos et al., 2004; 
Plant and Dinman, 2008; Thiel et al., 2003). A slippery site composed of a heptameric 
sequence and a stimulatory structure such as the mRNA pseudoknot in SARS-CoV is 
required for the frame shifting event (Brierley et al., 1989; Dos Ramos et al., 2004). 
Polyproteins pp1a and pp1ab are immediately processed by proteinase activities in the 
nascent polyproteins into intermediate and mature NSPs and therefore, are not detected 
during infection (Harcourt et al., 2004). Virally encoded proteinases, the papain-like 
proteinase (PLP) encoded in NSP3 and the 3C-like proteinase (3CLpro) encoded in 
NSP5, process pp1a and pp1ab into 16 NSPs (Prentice et al., 2004; Thiel et al., 2003). 
NSP1 to NSP11 are encoded within pp1a and pp1ab while NSP12 to NSP16 are only 
encoded within pp1ab (Fig. 1.1). The SARS-CoV NSPs have critical roles in the 
transcription and replication of the viral genome and extensive studies were carried out to 




Table 1.1 – Functional characteristics of SARS-CoV NSPs 
Protein 
 
Protein properties and effect(s) on viral and/or host replication Other host cellular effect(s) 
NSP1 - Suppression of the host protein synthesis via the inactivation of the 
translational functions of the 40S ribosomal subunit and by inducing the 
modification of the 5’ region of capped mRNA template to render it 
translationally incompetent (Connor and Roper, 2007; Kamitani et al., 2009; 
Kamitani et al., 2006; Narayanan et al., 2008a). 
- NSP1 mutant that loses its ability to degrade host mRNA induces a large 
amount of IFN-β during infection, suggesting that the suppression of the host 
gene expression is vital for the blocking of the host anti-viral response in 
infected cells (Narayanan et al., 2008a) 
 
- Inhibits the IFN-dependent signaling by decreasing STAT1 
phosphorylation, and attenuating NSP1 results in a reduced ability 
of the virus to replicate in cells with an intact IFN response 
(Wathelet et al., 2007). 
- Over-expression of NSP1 dysregulates CCL5, CXCL10 and CCL3 
cytokine expression in A549 cells, and CCL5 and CXCL10 
cytokine expression in HepG2 cells (Law et al., 2007). 
 
NSP2 - Non-essential for viral replication but its deletion attenuates viral growth and 
RNA synthesis (Graham et al., 2005). 
- Interacts with two host protein complex (prohibitin 1 and 
prohibitin 2) involved in mitochondrial biogenesis and intracellular 
signaling, suggesting a role of NSP2 in the disruption of 
intracellular host signaling during SARS-CoV infections (Cornillez-
Ty et al., 2009). 
 
NSP3 - Possesses a papain-like protease (PLP2) domain that carries out the main 3C-
like protease activity and was shown to be sufficient to cleave the nsp1/nsp2, 
nsp2/nsp3 and nsp3/nsp4 sites (Harcourt et al., 2004). 
- Shares consensus motif LXGG with cellular deubiquitinating (DUB) enzymes 
and exhibits DUB and deISGylation activities in vitro (Barretto et al., 2005; 
Lindner et al., 2005; Sulea et al., 2005). Crystal structure of PLP2 domain 
resembles that of cellular DUB enzymes, USP14 and HAUSP (Ratia et al., 
2006). 
- Contains a predicted N-terminal acidic domain that is rich in glutamate 
(Serrano et al., 2007). 
- Has an X domain that was predicted to be an ADP-ribose-1” monophosphate 
(Appr-1”-p) processing enzyme and specifically dephosphorylate Appr-1”-p to 
ADP-ribose (Putics et al., 2005; Saikatendu et al., 2005). 
- Has a papain-like non-canonical (PLnc) domain that functions as a 
replication/transcription scaffolding protein (Imbert et al., 2008). 
- Over-expression of NSP3 antagonizes the host interferon response 
via the inhibition of the NF-κB pathway (Wathelet et al., 2007).  
- PLP2 domain is a potent IFN antagonist, acting via the blocking 
of the phosphorylation and activation of IRF3 (Devaraj et al., 2007). 
- PLP2 domain blocks the NF-κB pathway via the stabilization of 
the NF-κB inhibitor, IκBα, and ubiquitin-like (UBL) domain is 
necessary but not sufficient for antagonism of IRF3 function 
(Frieman et al., 2009). 
- Novel nuclei acid binding (NAB) domain and SARS-unique 
domain (SUD) were identified using proteomic analysis (Neuman et 
al., 2008). 
- SUD binds RNA G quadruplexes and the G-stretches found on 3’-
non-translated regions of host cells mRNA coding for proteins 
involved in apoptosis and signal transduction (Tan et al., 2007c; 
Tan et al., 2009). 
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Table 1.1 - Continued 
Protein 
 
Protein properties and effect(s) on viral and/or host replication Other host cellular effect(s) 
NSP4 - Involved in the early secretory pathway, which is important for the formation of replication 
complexes (Oostra et al., 2007b).  
 
- Not known 
NSP5 - Functions similar to a 3C-like protease (Anand et al., 2003). 
- Shares a high degree of structural similarity with other coronavirus 3CLpro and plays a critical 
role in processing pp1a and pp1ab polyproteins to start the virus replication cycle (Thiel et al., 
2003; Ziebuhr et al., 2000).  
- Exists in equilibrium between the monomeric and dimeric forms but only the dimeric form is 
active (Fan et al., 2004; Graziano et al., 2006).  
- Only one active protomer in the dimer is sufficient for the catalytic properties (Chen et al., 
2006).  
- Long-range cooperative interactions also modulate the dimerization of SARS-CoV 3CLpro 
(Barrila et al., 2006).  
- Disruption of the dimer interface, using peptides that represent the N-terminus of the protein, 
results in the inactivation of the 3CLpro (Ding et al., 2005; Wei et al., 2006).  
- N-terminal residue 1 to 7 (N-finger) is critical for the SARS-CoV 3CLpro dimerization and 
essential for the formation of an enzymatically active dimer (Chen et al., 2005b; Zheng et al., 
2007; Zhong et al., 2008). 
- Asn28 of SARS-CoV 3CLpro have a critical role in maintaining the structural integrity of the 
protein’s active site and in orientating key residues involved in binding at the dimer interface and 
substrate catalysis (Barrila et al., 2010).  
- Arg4, Glu290 and Arg298 were key components in maintaining the dimer form (Chou et al., 
2004; Shi et al., 2008a).  
- Arg4, Ser10, Glu14 and Phe140 on the dimer interface were critical for both the dimer stability 
and its enzymatic activity (Chen et al., 2008). 
 
- Induces mitochondrial-mediated apoptosis, 
suggesting that it may contribute to the 
pathogenesis observed in SARS-CoV infection 
(Lai et al., 2007). 
NSP6 - Not known 
 
- Not known 
NSP7 - Possesses a novel and unique sequence and structure to the Coronaviridae but the function 
remains unknown (Peti et al., 2005). 
- Interacts with NSP8 to forms a hexadecamer structure, which may function as a second, non-
canonical RNA-dependent RNA polymerase (RDRP) in SARS-CoV (Imbert et al., 2006; Zhai et 
al., 2005). 
- Not known 
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Table 1.1 - Continued 
Protein 
 
Protein properties and effect(s) on viral and/or host replication Other host cellular effect(s) 
NSP8 - Co-localized with NSP2 and NSP3 (Prentice et al., 2004). 
- Interacts with an accessory protein, ORF6, in a yeast-two hybrid assay (Kumar et al., 2007). 
 
- Not known 
NSP9 - Crystal structure revealed that it is a single-stranded RNA-binding protein and possesses a unique RNA-binding 
subunit (Egloff et al., 2004). 
- An RNA-binding, dimeric protein that interacts with NSP8 (Sutton et al., 2004). 
- Disruption of the dimerization of NSP9 by reverse genetics approach demonstrated the non-critical role of NSP9 
dimerization for its RNA binding function but was shown to be lethal to the virus (Miknis et al., 2009). 
 
- Not known 
NSP10 - Interacts with the two subunits of the cellular RNA polymerase complex, BTF3 and ATF5 (Li et al., 2005c). 
- Has a novel fold with two zinc-binding motifs and has nuclei acid binding ability, suggesting its possible 
function as a transcription factor during replication (Joseph et al., 2006; Su et al., 2006). 
- Has low affinity binding to single and double-stranded RNA and DNA without obvious sequence specificity 
(Joseph et al., 2006). 
- Specifically interacts with NSP14 and NSP16 in mammalian-two hybrid system, yeast-two hybrid system and 
GST pull-down assay (Imbert et al., 2008; Pan et al., 2008).  
- Is an essential factor to trigger full NSP16 2’-O-MTase activity (Bouvet et al., 2010). 
 
- Interacts specifically with 
NADH 4L subunit and 
cytochrome oxidase II that may 
contribute to the extensive 
cytopathic effect observed in 
SARS-CoV infection (Li et al., 
2005c). 
NSP11 - Not known 
 
- Not known 
NSP12 - Full-length NSP12 first detected by immuno-blotting using an antibody targeting a fragment of SARS-CoV 
RdRp, with an observed mass of 106 kDa (Prentice et al., 2004).  
- Molecular models were developed to predict the critical residues responsible for the RdRp functions (Azzi and 
Lin, 2004; Xu et al., 2003).  
- siRNA targeting the SARS-CoV RdRp knock down SARS viral genes in FRhk4 cells, specifically inhibit 
expression of RDRP in 293 and HeLa cells and significantly reduced the plaque formation of SARS-CoV in Vero 
E6 cells (He et al., 2003b; Lu et al., 2004). 
- In vitro RdRp activity of NSP12 with primer-dependent activity on poly(A) templates was observed in filter 
binding polymerase assay (Cheng et al., 2005).  
- Primer-dependent on both homo- and heteropolymeric templates and its functions were postulated to have a 
close dependency on the NSP8 primase activity (Imbert et al., 2006; te Velthuis et al., 2010). 
- Not known 
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Table 1.1 - Continued 
Protein 
 
Protein properties and effect(s) on viral and/or host replication Other host cellular effect(s) 
NSP13 - First predicted as an mRNA cap 1 methyl-transferase by 3D jury system but was later reported to possess a 
distinct 5’ to 3’ helicase activity (Tanner et al., 2003; von Grotthuss et al., 2003) . 
- Possesses both the RNA 5’-triphosphate activity, involved in the formation of the 5’ cap structure of viral RNA, 
and the helicase activity (Ivanov et al., 2004b). 
- Interacts with a multi-functional cellular protein, DDX5, in a mammalian cell two-hybrid system. siRNA 
specific for DDX5 that knocked down its expression in FRhK4 cells significantly inhibited SARS-CoV 
replication, suggesting an important role of DDX5 in the SARS-CoV genome transcription (Chen et al., 2009a).  
 
- Not known 
NSP14 - Predicted based on the identification of motifs belonging to the DEDD superfamily of 3’ to 5’ exonuclease, 
which includes DNA proof-reading enzymes (Moser et al., 1997; Snijder et al., 2003). 
- Functional and genetic analysis performed on MHV temperature sensitive mutants mapping to N7-MTase 
domain of NSP14 and in the (nucleoside-2’-O)-methyltransferase (2’-O-MTase) of NSP16 indicated that both 
NSP14 and NSP16 are involved in the positive-strand RNA synthesis by forming replicase-transcriptase 
complexes (Sawicki et al., 2005b). 
- Has in vitro 3’ to 5’ exoribonuclease but not exodeoxyribonuclease activity and alanine substitution of the 
DEDD residues blocks its activity (Minskaia et al., 2006).  
- Exoribonuclease activity shown to require binding to Mg
2+
 to induce a structural change that is proposed by the 
authors to be a pre-requisite for NSP14 catalytic activity (Chen et al., 2007c). 
- Identified as a novel S-adenosyl-L-methionine (Ado-Met)-dependent (guanine-N7)-methyltransferase (N7-
MTase), which was proposed to play a role in the formation of CoV mRNA caps (Chen et al., 2009c).  
- Analysis of viable SARS-CoV mutant viruses containing inactivating substitutions in the NSP14 ExoN DEDD 
motif I (AADD) showed that the inactivation of ExoN resulted in a 21-fold decrease in replication fidelity 
compared to wild-type SARS-CoV, suggesting that ExoN is not required for SARS-CoV replication in culture but 
is required for high-fidelity replication (Eckerle et al., 2010). 





Table 1.1 - Continued 
Protein 
 
Protein properties and effect(s) on viral and/or host replication Other host cellular effect(s) 
NSP15 - Predicted to contain a domain called nidoviral uridylate-specific endoribonuclease (NendoU) that is conserved 
in nidoviruses (Snijder et al., 2003). 
- Has a preference for cleavage at the 3’ end of uridylates of double-stranded RNA (dsRNA) at GU or GUU 
sequences to produce 2’-3’ phosphate ends (Bhardwaj et al., 2006; Ivanov et al., 2004a). 
- Endoribonuclease activity was found to be dependent on Mn
2+
 but not other divalent metal ions (Bhardwaj et al., 
2004; Ivanov et al., 2004a). 
- Structure analysis using circular dichroism spectroscopy determined NSP15 to exist in solution as monomers 
and hexamers in equilibrium (Guarino et al., 2005).  
- Only the hexameric form of this enzyme is active, and the active site is destructed in the monomeric form due to 
the displacement of two loops in the catalytic domain (Guarino et al., 2005; Joseph et al., 2007). 
- Crystal structure revealed that the catalytic centre of NSP15 resembles the active site of a nuclease, RNase A 
(Ricagno et al., 2006).  
- Similar to RNase A in employing two histidine and one lysine residues for its catalytic action (Bhardwaj et al., 
2008).   
 
- Not known 
NSP16 - Based on comparative sequence analysis, NSP16 was predicted to encode an AdoMet-dependent mRNA cap 2’-
O-MTase and is essential for efficient viral replication (Decroly et al., 2008; Snijder et al., 2003; Wang et al., 
2008a). 
- RNA 2’-O-MT activity of NSP16 blocks the dsRNA cleavage function of NSP15, indicating a functional 
interplay between the two NSPs and both the NendoU and 2’-O-MT enzymes are shown to be essential for 
efficient coronavirus RNA synthesis (Almazan et al., 2006). 
- Not known 
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1.1.2 Structural proteins of SARS-CoV 
Similar to other coronaviruses, SARS-CoV genome encodes for structural 
proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N). Nal et al showed 
the differential maturation and sub-cellular localization of SARS-CoV S, M and E in 
Baby Hamster Kidney 21 cells that were infected by recombinant Semliki Forest virus 
expressing the respective proteins (Nal et al., 2005). Highly mannosylated S and M was 
found to assemble into trimers in the ER prior to acquisition of complex N-glycans in the 
Golgi while E was not glycosylated and localized to the ER only. S was also detected 
along the secretory pathway from the ER to the plasma membrane while M 
predominantly accumulates in the Golgi and partially in ER-Golgi intermediate 
compartments (ERGIC) trafficking vesicles (Nal et al., 2005). Contrary to the report, 
Chen et al. demonstrated the glycosylation of recombinant myc-tagged E expressed in 
Vero E6 cells (Chen et al., 2009b). In addition, the authors reported that E is a double-
spanning membrane protein and the two trans-membrane domains are involved in the 
insertion of the cytoplasmic protein into the ER membrane. These two transmembrane 
domains also co-localize with M and are required for the interaction of E with M via one 
of the hydrophilic regions (amino acids (aa) 1 to 10 and aa 60-76).  
It was shown that the M and E proteins were sufficient for the efficient formation 
of virus-like particles (VLPs) using co-infection of recombinant baculoviruses, 
expressing each of the proteins, in insect cells (Ho et al., 2004; Mortola and Roy, 2004). 
Contrasting to these reports, Huang et al. described the formation of VLPs using co-
expression of M and N in transfected 293 cells (Huang et al., 2004b). The region on N 
required for interaction with M was found to be between aa 101 to 115, and a minimal 
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portion of N, aa 301 to 422, is required for pseudoparticle formation when co-expressed 
with M in human embryonic kidney (HEK)-293 cells (Hatakeyama et al., 2008). It was 
recently demonstrated that both E and N are required to be co-expressed with M for the 
efficient production and release of VLPs in transfected Vero E6 cells (Siu et al., 2008). In 
addition, the authors showed that the native trimeric S glycoprotein can be incorporated 
into the VLPs when co-expressed with M, N and E. The properties and functional roles of 
the E, M and N proteins are summarized in Table 1.2. The glycoprotein S will be 
reviewed in more details in the later paragraphs. 
The S protein is a 1255 aa precursor polypeptide that is composed of 23 potential 
N-linked glycosylation sites (Marra et al., 2003; Rota et al., 2003; Xiao et al., 2003). It 
was demonstrated that the treatment of Vero E6 with glucosidase inhibitor N-butyl-
deoxynojirimycin inhibits the N-glycans processing of SARS-CoV S and protects the 
cells from the cytopathic effect of the virus (Ritchie et al., 2010). The S protein assembles 
as trimers on the surface of the coronaviruses to form the characteristic “crown-like” 
structures (Tripet et al., 2004). S is important for the viral attachment and entry into the 
host cells (Simmons et al., 2004). The SARS-CoV S is a type-I glycoprotein that consists 
of the amino-terminal S1 and a carboxyl-terminal S2 subunits. A novel di-basic motif (-
KxHxx-COOH) is identified in the cytoplasmic tail of S and it is shown to retain the 
protein in the ERGIC, contributing to the localization of S near the virus assembly site 
(Lontok et al., 2004). Further work demonstrated that the KxHxx motif binds to coatomer 
complex I and plays an important role in the co-localization of S and M in the Golgi 
compartment, suggesting that KxHxx re-cycles S through the ER-Golgi system for 
efficient assembly of virions in the ERGIC (McBride et al., 2007). 
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Li et al. identified a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), 
as a functional receptor for SARS-CoV (Li et al., 2003b). Further studies by the authors 
demonstrated that the SARS-CoV binding to rats and murine ACE2 were not as efficient 
as that to human ACE2, indicating the adaptation of the virus to human receptor (Li et al., 
2004a). The receptor binding domain (RBD) has been mapped to amino acid (aa) 
residues 318 to 510 on the S1 subunit (Babcock et al., 2004; Wong et al., 2004). The 
RBD binds to ACE2 to trigger a conformational change that allows the heptad repeats 1 
(HR1) and heptad repeats 2 (HR2) regions on the S2 subunit to form a six helix bundle to 
facilitate the insertion of the fusion peptide into the cellular membrane for viral-cell 
membrane fusion to occur (Liu et al., 2004). A point mutation at residue D454 was 
shown to abolish the association of the RBD with ACE2 (Wong et al., 2004). In addition, 
Yi et al. demonstrated that the alanine mutation at residues R441 and R453 abolished 
entry of pseudovirus carrying the mutant S (Yi et al., 2005). A study using alanine 
scanning mutagenesis identified ten residues (K390, R426, D429, T431, I455, N473, 
F483, Q492, Y494 and R495) that significantly reduces binding to ACE2 when mutated 
(Chakraborti et al., 2005). Further analysis of these mutations with the crystal structure of 
RBD complexed to ACE2 suggest two hotspots, R426 and N473, which likely contribute 
to the binding energy (Li et al., 2005a). 
It was shown that the infection of the primary human airway epithelia by SARS-
CoV positively correlates with the expression and localization of ACE2 and the 
differentiation state of the cells (Jia et al., 2005). In another study, it was demonstrated 
that the SARS-CoV infection and the S protein both reduce the expression of ACE2 
which resulted in worsened acute lung failure in mice and this induced lung injury can be 
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attenuated by blocking the rennin-angiotensin pathway, indicating a crucial role of ACE2 
in SARS-CoV pathogenesis (Kuba et al., 2005). Further studies revealed that the RBD on 
S could induce ACE2 internalization in the SARS-CoV susceptible cells (Wang et al., 
2008b). More recently, it was demonstrated that the SARS-CoV S induces tumor necrosis 
factor (TNF)-α-converting enzyme-dependent shedding of the ACE2 ectodomain to 
facilitate viral entry but also causes tissue damage through TNF-α production (Black et 
al., 1997; Haga et al., 2008).  
Another receptor, CD209L (also known as L-SIGN), has also been identified as a 
receptor for SARS-CoV  by studying the binding of soluble SARS-CoV S with Chinese 
hamster ovary (CHO) cells that were transduced with a human lung complementary 
deoxyribonucleotide acids (cDNA) library in vesicular stomatitis virus G pseudovirus 
(Jeffers et al., 2004). In addition, several groups also identified dendritic cell-specific 
ICAM-3 grabbing non-integrin (DC-SIGN) as SARS-CoV cellular receptor (Marzi et al., 
2004; Yang et al., 2004a). Further studies revealed that the minimal DC-SIGN binding 
domain on S is residues 324 to 386 and S mutants with N330Q and N357Q mutations 
showed diminished DC-SIGN-binding capacity (Shih et al., 2006). By using pseudovirus 
packaged with S, it was shown that an N-linked glycosylation site, N330, is critical for 
the interaction of S with mannose binding lectin (MBL), which resulted in the blocking 
of the virus binding to DC-SIGN (Zhou et al., 2010). It was also shown that another 
lectin, LSECtin, enhances infection driven by the SARS-CoV S, suggesting that LSECtin 
could be an attachment factor that could function in conjunction with DC-SIGN 
(Gramberg et al., 2005).  Besides identifying the host receptors for SARS-CoV, a close 
examination of the cysteine residues in the S1 domain of SARS-CoV S also reveal a 
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significant redox insensitivity, which may contribute to the wide host range of the virus 
(Lavillette et al., 2006). 
By studying various soluble fragments of S expressed from 293T cells for their 
oligomerization ability, it was demonstrated that the S ectodomain contains the 
dimerization domain while the trimerization domain may exist in the transmembrane 
domain in its pre-fusion state (Xiao et al., 2004). Further studies showed that the 
truncation of the cytoplasmic tail containing the transmembrane domain resulted in a 
mutant S that is secreted into the medium and has much lower efficiency of trimer 
formations, suggesting that the transmembrane domain plays an important role in forming 
and anchoring the S trimers to the virion lipid envelope (Song et al., 2004). A study on 
the conformational states of the SARS-CoV S ectodomain revealed that low pH induces 
an irreversible trimerization of S and renders the cleaved S2 insensitive to trypsin 
digestion (Li et al., 2006). Furthermore, exposure of these S2 trimers to 1 M urea causes 
most of the protein to form rosettes that possess the final post-fusion conformation. 
Interestingly, it was found by Arbely et al. that a novel GxxxG motif in the 
transmembrane domain of SARS-CoV S contributes to the trimerization of the entire 
spike protein (Arbely et al., 2006). However, a later study demonstrated that the removal 
of the GxxxG motif does not prevent the trimerization of the mutant S and only 
moderately affected the entry of the pseudovirus bearing the mutant S (Corver et al., 
2007). 
Early studies showed that S expressed on the surface of insect cells could be 
cleaved by exogenous trypsin but not by co-expressed furin, suggesting that the protein is 
not normally cleaved during infection (Yao et al., 2004). Several other studies supported 
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this finding showing that the SARS-CoV S was not cleaved (Song et al., 2004; Xiao et 
al., 2003). However, a later study showed that the cleavage products of S was observed in 
SARS-CoV infected Vero E6 cells, indicating the presence of proteolytic processing of 
the S protein in the host cells (Wu et al., 2004a). It was also demonstrated that the S1/S2 
cleavage can be enhanced by expression of furin family enzymes (Bergeron et al., 2005). 
Initial study showed that the introduction of a furin cleavage site at R667, replacing the 
trysin cleavage site, enhances cell-cell fusion but does not have any effect on the virion 
entry (Follis et al., 2006). Consistent with this result, Watanabe et al demonstrated that 
the introduction of a furin-like cleavage sequence in S at aa 798 to 801 resulted in 
cleavage of the mutant S without trypsin treatment and also induces cell fusion when 
expressed on cell surfaces (Watanabe et al., 2008). In addition, it was found that the 
pseudoviruses carrying the cleaved form of mutant S infected cells in the presence of 
lysosomotropic agents and protease inhibitors but was blocked by heptad repeat peptides, 
indicating that SARS-CoV with a cleaved form of S is able to enter the cells directly from 
the cell surface (Watanabe et al., 2008).  
Significantly, a study demonstrated that the SARS-CoV could employ two 
distinct pathways for cell entry, the protease-mediated entry and the endosomal pathway 
(Matsuyama et al., 2005). The protease-mediated entry, using trypsin, thermolysine and 
elastase, was shown to be 100 to 1000 fold more efficient than the endosomal pathway. 
Simmons et al. confirm this finding and in addition, the authors found that the proteolysis 
mediated by cathepsin L within the endosome was sufficient to activate membrane fusion 
by SARS-CoV (Simmons et al., 2005). It was also shown that the inhibitors of cathepsin 
L was found to block the infection of ACE-expressing 293T cells by SARS-CoV and the 
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expression of exogenously expressed cathepsin L substantially enhanced infection 
mediated by the SARS-CoV S protein (Huang et al., 2006c; Simmons et al., 2005). 
Another study confirmed that cathepsin L proteolysis indeed activates the membrane 
fusion function of the SARS-CoV S protein and mapped the cleavage site to aa residue 
T678 (Bosch et al., 2008b). The site of trypsin cleavage on SARS-CoV S was identified 
on residue R667 (Li et al., 2006). It was later shown that the heptad repeat derived 
peptides block the SARS-CoV entry via the protease-mediated pathway but does not 
affect entry using the endosomal pathway (Ujike et al., 2008). Interestingly, it was shown 
that the mutation of R667 and K672 blocked the cleavage of the S protein at the S1/S2 
boundary but failed to have any effect on the trypsin-primed membrane fusion, 
suggesting the presence of a different site for the proteolytic processing of S to activate 
the virus infectivity (Belouzard et al., 2009). The authors further reported a critical 
proteolytic cleavage at aa residue R797, which acts in concert with the R667 cleavage to 
mediate membrane fusion and virus infectivity.  
Several other protease were shown to have an effect on the fusion activity and 
infectivity mediated by the cleaved S. Du et al. reported that the protease factor Xa 
cleaved the SARS-CoV S and is associated with the viral infectivity (Du et al., 2007). It 
was recently reported that the aa residue T795 is critical for the elastase-mediated 
cleavage of SARS-CoV S and altering this site affects both the proteolytic cleavage and 
fusion activation of the S protein (Belouzard et al., 2010). In addition, it was 
demonstrated that low pH is not required for triggering membrane fusion mediated by the 
SARS-CoV S protein (Xiao et al., 2003). 
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Using bioengineering techniques, it was shown that HR1 and HR2 of SARS-CoV 
S bind to each other to form a six-helix bundle, also known as the fusion core that is 
essential for the fusion mechanism of the coronavirus (Zhu et al., 2004). The crystal 
structures of the pre-fusion core and the fusion core have been solved (Beniac et al., 
2006; Deng et al., 2006; Supekar et al., 2004; Xu et al., 2004a). Further biochemical 
studies revealed that the HR1 and HR2 of SARS-CoV associate in an anti-parallel 
manner in the very stable α-helical six-bundle structure, and the HR1 can form a stable α-
helical coiled coil in the absence of HR2 while the HR2 in isolation formed a weakly 
stable trimeric coiled coil (Bosch et al., 2004; Ingallinella et al., 2004; Tripet et al., 2004; 
Xu et al., 2004c). The solution structure of the HR2 domain in the pre-fusion state 
confirmed that HR2 forms a coiled coil symmetric trimer in the absence of HR1 
(Hakansson-McReynolds et al., 2006). In addition, biophysical characterization of the 
HR2 peptide analogs interaction with the HR regions of the SARS-CoV S reveals the 
importance of the α-helical structure in the formation of the six-helix bundle (Yan et al., 
2006b). It was also shown that the conserved asparagine and glutamine residues on HR1 
propagates from two central chloride ions to provide hydrogen-bonding zippers that 
strongly constrain the HR2 main chain to force it to adopt an extended conformation at 
either end of the short HR2 α-helix (Duquerroy et al., 2005). The residues that were 
essential for the interaction was narrowed to residues 902 to 950 on HR1 and residues 
1151 to 1184 on HR2 of SARS-CoV S (Tripet et al., 2004; Xu et al., 2004c).  
A novel transition state of the fusion complex, represented by an ensemble of 
unstructured monomers, was also reported to be a required passage from the pre-fusion 
state to the post-fusion state (McReynolds et al., 2008). The unstructured monomoers 
 17 
were also shown to be in a dynamic equilibrium with the structured trimer in the pre-
fusion state. Further studies of the dynamics of the pre-fusion and transition states of the 
SARS-CoV S complex reveals that the transition state enables the conformational change 
of the envelope necessary for the SARS-CoV entry by the efficient sampling of a large 
area of conformational space (McReynolds et al., 2009). 
A hydrophobic stretch of 19 aa residues corresponding to aa 770 to 778 was 
proposed to function as a fusion peptide of the SARS-CoV S (Sainz et al., 2005a). It was 
further demonstrated that the putative fusion peptide strongly partitions into membranes 
containing negatively charged phospholipids to increase the water penetration depth and 
displayed membrane activity that are modulated by the lipid composition of the 
membrane, suggesting its involvement in the merging of the viral and target cell 
membrane by perturbing the membrane phospholipids (Guillen et al., 2008a). 
Biophysical studies also help to identify a second fusion peptide corresponding to aa 873 
to 888 (Guillen et al., 2005, 2008b). Three main membrane-active regions from the S2 
subunit were identified to be involved in the SARS-CoV S-mediated membrane fusion 
process and were shown to participate in the fusion process by acting in a synergistic way 
(Guillen et al., 2008c; Guillen et al., 2005). The three regions comprise of the two 
identified fusion peptide domains and a pre-transmembrane domain (aa 1185 to 1202) 
that is shown to be essential for the enhancement of the viral and cell fusion process 
(Guillen et al., 2007). In addition, a peptide corresponding to a region in the loop domain 
of the S2 (aa 1073 to 1095) was also found to play a role in the SARS-CoV S-mediated 
membrane fusion, suggesting the involvement of this region in the merging of the viral 
and cell membranes (Guillen et al., 2009).  
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In another study, residues L803, L804 and F805 were identified to be critical for 
membrane fusion by functioning as a novel internal fusion peptide for SARS-CoV S after 
proteolytic cleavage within the S2 domain (Madu et al., 2009a). It was also shown that 
the conserved domain flanked by cysteines 822 and 833 on the SARS-CoV S is critical 
for the membrane fusion by forming a loop structure that control the activation of the 
membrane fusion via its interaction with the other components of the S trimers (Madu et 
al., 2009b). 
Serine-scanning mutagenesis of the C-terminal heptad repeat regions showed that 
the hydrophobic side-chains within the short helical segment (I1161, I1165, L1168, 
A1172 and L1175) are critical for cell-cell fusion, suggesting the important role of α-
helical packing in promoting S glycoprotein-mediated membrane fusion (Follis et al., 
2005). Another mutagenesis study revealed that the amino acid L927, L941, I955 on HR1 
domain and I1165 on HR2 domain are important to mediate the membrane fusion while 
L1179 on the HR2 domain is important for a post-fusion process (Chan et al., 2006b). In 
addition, alanine substitution were carried out on the tryptophan residues to investigate 
the importance of the trpytophan-rich region at the pre-transmembrane region, and the 
results showed that individual substituted mutants have substantial decrease in infectivity 
of more than 90 percent while global substituted mutants aborogate infectivity suggesting 
that this region is essential for SARS-CoV infectivity (Lu et al., 2008). A similar study 
supported this finding, demonstrating that the replacement of all the tryptophan residues 
in this region with alanines abolish S-mediated entry in a pseudovirus assay (Corver et 
al., 2009). In addition, the authors showed that the aromatic domain was also crucial for 
the S-mediated pseudovirus entry and that the positioning of the aromatic domain with 
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the hydrophobic domain relative to each other is an essential characteristic of the 
membrane fusion process (Corver et al., 2009).  
By circular dichroism analysis, it is shown that the aromatic amino acid rich 
region within the S2 subunit did not have a propensity for a defined secondary structure 
and it was shown to strongly partitioned into lipid membrane as well as induced lipid 
vesicle permeabilization in leakage assays, suggesting that it may function to perturb the 
target cell membrane during the membrane fusion process (Sainz et al., 2005b). This 
result is confirmed in another study that demonstrated that the entry of retrovirus 
pseudoviruses, expressing the aromatic amino acid deletions or substitution, into the 
human ACE2 (hACE2) expressing HEK-293 cells were greatly reduced (Howard et al., 
2008). In addition, S mediated cell-cell fusion were also reduced by 60 to 70 percent in 
all alanine substituted mutants, suggesting the importance of this conserved 
juxtamembrane domain in SARS-CoV infection (Howard et al., 2008). By using 
pseudovirus and cell-cell fusion assay, the transmembrane domain of the SARS-CoV S 
was also demonstrated to be important for both the fusogenicity and infectivity of the 
virus (Broer et al., 2006). The authors showed that the replacement of the SARS-CoV S 
transmembrane domain with that of the VSV-G, that was less stable, resulted in lower 
fusogenicity and infectivity of the pseudovirus carrying the chimeric S.  
A study of the proximal cysteine-rich motif at the carboxyl terminal of S revealed 
that this region plays an important role in cell-surface expression of S and S-mediated 
cell-cell fusion (Petit et al., 2005). Further studies showed that the palmitoylation of two 
of the four clusters of cysteine residues in the cytoplasmic domain are important for the 
S-mediated cell fusion (Petit et al., 2007). In addition, palmitoylation of SARS-CoV S 
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was also shown to be required for partitioning into detergent-resistant membranes and for 
cell-cell fusion (McBride and Machamer, 2010b). Taken together, the data presented 
demonstrate that the S2 subunit of SARS-CoV S contains multiple essential regions that 
play important roles for different stage of the viral-cell membrane fusion process. 
Several studies were carried out to delineate the effects of S on the host response 
during SARS-CoV infection. It is found that S specifically modulates the unfolded 
protein response (UPR) via inducing the transcriptional activation of UPR effectors, 
GRP78, GRP94 and C/EBP, to facilitate viral replication (Chan et al., 2006a). It was also 
reported that the first 422 aa of SARS-CoV S is crucial for the induction of 
cyclooxygenase-2 expression as well as the correct localization of the S protein (Liu et 
al., 2006a). In addition, it was demonstrated that the over-expression of the S2 domain 
was shown to induce apoptosis in Vero E6 cells in a time- and dose-dependent manner 
(Chow et al., 2005). Recently, the SARS-CoV S was shown to trigger ACE2 signaling 
and upregulates the fibrosis-associated chemokine ligand 2 expressions through the Ras-
ERK-AP1 pathway (Chen et al., 2010). 
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Table 1.2 – Functional characteristics of SARS-CoV structural proteins 
Protein 
 
Characterization Functional role(s) 
E - Well conserved sequence within each coronavirus group (Godet et al., 1992). 
- Contains a hydrophilic amino and carboxy terminus, with a hydrophobic region 
in between the two ends (Torres et al., 2007; Wilson et al., 2004). N- and C-
terminal ends were commonly found to be exposed to the cytoplasmic side of the 
membrane but a minor proportion of the protein that were modified by N-linked 
glycosylation inserted into the membrane only once, exposing only the C-
terminus to the luminal side (Yuan et al., 2006c). 
- Structure study using bioinformatics analysis and circular dichroism (CD) 
technique reveal that E forms a single transmembrane domain helix and a short 
β-sheet segment that can form a hydrogen bond with the lipid bilayer (Shen et al., 
2003). 
- Fourier transformed infra-red (FITR) spectroscopy, X-ray reflectivity and 
molecular modeling showed that E forms an unusual palindromic transmembrane 
helical hairpin structure that is orientated perpendicular to the dimyristolylated 
phosphatidylchoine (DMPC) bilayer (Arbely et al., 2004; Khattari et al., 2006). 
- Contains at least one α-helical transmembrane domain that spans approximately 
25 aa residues and the transmembrane domain forms dimer, trimer and two forms 
of pentamers (Torres et al., 2006). 
- Site-directed mutagenesis studies revealed the importance of two cysteine 
residues for the oligomerization of E, and biochemical characterization 
demonstrated that all the cysteine residues on E is post-translationally modified 
by palmitoylation (Liao et al., 2006). 
- Co-localized with NSP3 in infected cells and binds to NSP3 in these cells as 
well as in cell-free systems via the N-terminal acidic domain on NSP3 (Alvarez 
et al., 2010). 
- Forms ion channel that are more permeable to monovalent 
cations than to monovalent anions (Wilson et al., 2004). 
- Oligomerization was shown to have an enhancement effect on the 
membrane permeability in both bacterial and mammalian cells 
(Liao et al., 2004; Liao et al., 2006). 
- Transmembrane domain have improved solubility when flanked 
with two lysine residues on each end and these terminal lysines 
induce a kink at the centre of the transmembrane α-helix structure 
that do not interfere with the ion channel activity, suggesting the 
presence of inherent conformational plasticity in the 
transmembrane domain that may be necessary for the ion channel 
function (Parthasarathy et al., 2008; Torres et al., 2007). 
- Ion channel activity can be inhibited by amantadine and 
hexamethylene amiloride (HMA) and viral replication was 
inhibited by HMA as well (Pervushin et al., 2009; Torres et al., 
2007). 
- Induces apoptosis in transfected Jurkat T cells via its interaction 
with an anti-apoptotic protein, Bcl-xL, to reduce its anti-apoptotic 
activity (Yang et al., 2005b). 
- Mutant virus with the E gene deleted by reverse genetics was able 
to replicate, although the virus titer was reduced by 20 to 200 fold 
when compared to the wild-type virus and was attenuated in 
hACE2 transgenic mouse model and in hamsters (DeDiego et al., 





Table 1.2 - Continued 
Protein 
 
Characterization Functional role(s) 
M - A triple-spanning protein that is N-glycosylated at asparagine 4 and is retained 
in the ERGIC with a steady state accumulation in the Golgi complex (Nal et al., 
2005; Oostra et al., 2006; Voss et al., 2006). 
- Co-localized with S, E and N when co-expressed in cells and the C-terminal is 
responsible for the binding to N while multiple regions on M interacts with S and 
E (Hsieh et al., 2008). 
- Binding domain of M to N is in the region between aa 194 to 205 in the C-
terminal region of M (Fang et al., 2005). 
- Interacts with the S cytoplasmic tail and the M cytoplasmic tail is necessary for 
retaining S at the Golgi region when the proteins were co-expressed in cells 
(McBride et al., 2007). 
- An essential tyrosine residue, Y195, on the M cytoplasmic tail is important for its 
interaction with S to retain the protein at the Golgi region (McBride and 
Machamer, 2010a). 
- Consists of an N-terminal ectodomain, three transmembrane domains and a 
long cytosolic C-terminus. The N-terminal 134 aa is sufficient for the 
accumulation of M in the Golgi, recruitment of S to the sites of the virus 
assembly and budding in the ERGIC. (Voss et al., 2009). 
- The N-terminal 50 aa are sufficient for the membrane binding, multimerization 
and Golgi rentention of M in transfected cells and multiple regions on M were 
involved in the self-assembly and subcellular localization (Tseng et al., 2010). 
- Expression of M triggered an accelerated apoptosis in insect cells 
but did not induce apoptosis in mammalian cells (Lai et al., 2006). 
- Expression of the cytoplasmic tail of M is sufficient to suppress 
the expression of NF-kB, TNFα and Cox-2 and M interacts with 
IKKβ in a co-immunoprecipitation assay, suggesting that M 
suppresses NF-kB through the direct interaction with IKKβ, 
resulting in a lower Cox-2 expression. (Fang et al., 2007). 
- Induces apoptosis in HEK293T cells and transgenic Drosophila 
via the modulation of the cellular Akt pro-survival pathway and 
mitochondrial cytochrome c release (Chan et al., 2007). 
- Associates with RIG-1, TBK1, IKKε and TRAF3, sequestering 
them in the membrane-associated cytoplasmic compartments to 
prevent the formation of TRAF3-TANK-TBK1/IKKε complex, 
resulting in the inhibition of TBK1/IKKε-dependent activation of 
IRF3/IRF7 transcription factors and subsequently inhibiting gene 
transcription of type I interferons (Siu et al., 2009). 
- Inhibits interferon synthesis via the inhibition of IRF3 and NFkB 






Table 1.2 - Continued 
Protein 
 
Characterization Functional role(s) 
N - Detected in the alveolar epithelium and macrophages in lung atopsies of SARS 
patients (Nicholls et al., 2006). 
- Distributed in the cytoplasm in both transfected and infected cells (Rowland et 
al., 2005; Surjit et al., 2005; You et al., 2005).  
- Nucleolar localization was observed in some infected cells and N was shown to 
have the Pat4, Pat7 and the bi-partite type nuclear localization signal (NLS) and 
predicted a CRM-1 dependent nuclear export signal (You et al., 2005). 
- N-terminal contains NLS1 (aa 38 to 44) that localizes to the nucleus while the 
C-terminal contains NLS2 (aa 257 to 265) and NLS3 (aa 369 to 390) that 
localizes to the cytoplasm and nucleolus, indicating that N may function as a 
shuttle protein between the cytoplasm, nucleolous and the nucleus (Timani et al., 
2005). 
- Efficiently phosphorylated by cyclin-CDK complex, active only in the nucleus, 
and associates with 14-3-3 protein in a phospho-specific manner, indicating the 
presence of N in the nucleus (Surjit and Lal, 2008). 
- Molecular modeling and comparison of coronavirus nucleolar retention signals 
suggest that N may interact with cellular proteins to traffic them to and from the 
nucleolus and cytoplasm (Reed et al., 2006). 
- Modified by acetylation and sumoylation (Krokhin et al., 2003; Li et al., 
2005b). 
- Interacts with a ubiquitin conjugating enzyme of the sumoylation system, 
Hubc9 (Fan et al., 2006).  
- Sumoylation played a key role in the modulation of the homo-oligomerization, 
nucleolar translocation and cell-cycle de-regulatory property of the N protein (Li 
et al., 2005b). 
- Phosphorylation observed when 293T cells were infected with adenovirus that 
expresses SARS-CoV N (Zakhartchouk et al., 2005).  
- Phosphorylated by mitogen activated protein kinase (MAPK), cyclin-dependent 
kinase (CDK), glycogen synthase kinase 3 (GSK3) and casein kinase 2 (CK2) 
(Surjit et al., 2005). 
- A mutant N lacking the sumoylation motif induces cell cycle 
arrest (Li et al., 2005b). 
- Inhibits S phase progression via the down-regulation of cyclin E 
and CDK2 in cells (Surjit et al., 2006). 
- Interacts with elongation factor 1-alpha (eIF1- ) to induce its 
aggregation, leading to inhibition of protein translation and 
cytokinesis by blocking F-actin bundling (Zhou et al., 2008). 
- Binding activity of several transcription factors involved in the 
signal transduction pathway of activated protein-1 (AP-1), such as 
c-fos, ATF-2, CREB-1 and fos B, was found to be enhanced by 
exogenously expressed N protein using ELISA, thus suggesting the 
involvement of N in a number of cellular processes (He et al., 
2003c). 
- Activates NF-kB in VeroE6 cells (Liao et al., 2005). 
- Activates interleukin 6 (IL6) expressions via direct binding to the 
NF-kB binding element and trans-locating NF-kB from cytosol to 
nucleus (Zhang et al., 2007b).  
- Binds directly to the NFkB response element present in the pro-
inflammatory factor, cyclo-oxygenase 2 protein (COX2), via aa 
136 to 204 to up-regulate the transcriptional level of COX2 protein 
(Yan et al., 2006a). 
- Possesses a high affinity for the human cellular heterogenous 
nuclear ribonucleoprotein A1 (hnRNPA1), with the interaction 
domain on N mapped to aa 161 to 210, suggesting an involvement 
in the regulation of the viral RNA synthesis (Luo et al., 2004a; Luo 
et al., 2004b).  
- Strongly associates with human cyclophilin A, a protein 
previously shown to associate with HIV-1 gag and is crucial for 
HIV-1 infection (Gamble et al., 1996; Luo et al., 2004a). 
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Table 1.2 - Continued 
Protein 
 
Characterization Functional role(s) 
N - Structural analysis showed two independent domains that are connected by a linker region in N 
(Chang et al., 2006). 
- Linker region was predicted to undergo phosphorylation and has been reported to interact with 
M and a human cellular protein, hnRNPA1 (Luo et al., 2005b; Luo et al., 2006; Luo et al., 
2005a). 
- N-terminal associates with several viral 3’ un-translated RNA sequence, indicating the RNA 
binding property of the protein (Huang et al., 2004a). 
- RNA binding motif on N was mapped to aa 363 to 382 (Luo et al., 2006).  
- Another RNA binding domain that has a stronger RNA interaction was identified in the C-
terminal region (aa 248 to 365) of N and it is suggested that the genomic RNA is packaged in a 
helical manner by the N protein (Chen et al., 2007a). 
- Essential for RNA packaging in a SARS-CoV VLPs system and there are two independent 
RNA binding domains on the protein; aa 1 to 235 at the N terminal and aa 236 to 384 at the C 
terminal (Hsieh et al., 2005). 
- Possesses RNA chaperone activity (Zuniga et al., 2007). 
- Self-associates via the interactions at its C-terminal (Surjit et al., 2004a) as well as via a domain 
(aa 184 to 196), encompassing a SR-rich motif, to form an oligomer (He et al., 2004a). 
- SR-rich motif has binding affinity that is specific for only the central region of another N 
protein, while the C-terminal (aa 283 to 422) binds to the same region on another N protein to 
form dimer, trimer, tetramer and hexamer and the essential region for oligomerization, that also 
encompasses the RNA binding motif, was mapped to aa 343 to 402 (Luo et al., 2005b; Luo et al., 
2006; Luo et al., 2005a; Yu et al., 2005; Yu et al., 2006). 
- Confirmed by structural studies that the ribonucleocapsid formation of SARS-CoV is mediated 
by the molecular actions of the N-terminal domain of N (Saikatendu et al., 2007). 
- Interacts with a transmembrane molecule, 
HAb18G/CD147, to facilitate the invasion of host 
cells by SARS-CoV (Chen et al., 2005d). 
- Induces apoptosis in Cos-1 monkey kidney cells 
via the down-regulation of pro-survival factors, 
Akt and Bcl2, and the up-regulation of pro-
apoptotic factors, caspase-3 and caspase-7 (Surjit 
et al., 2006; Surjit et al., 2004b). 
- Activates the mitochondrial death pathway to 
induce apoptosis (Zhang et al., 2007a). 
- Blocks apoptosis of SARS-CoV-infected cells via 
its interaction with Smad3 to impair the Smad3-
Smad4 hetero-complex formation (Zhao et al., 
2008). 
- Promotes the transforming growth factor-beta 
(TGF- )-induced expression of plasminogen 
activator inhibitor-1 (PAI-1), a protein that plays a 
critical role in tissue fibrosis (Zhao et al., 2008). 
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1.1.3 Accessory proteins of SARS-CoV 
All the coronaviruses encode a group of accessory proteins that are shown to be 
non-essential for virus growth in vitro (Curtis et al., 2002; de Haan et al., 2002; Haijema 
et al., 2004; Yount et al., 2005). These accessory proteins are virus-specific and have low 
levels of homology between the different coronaviruses (Lai and Cavanagh, 1997). 
SARS-CoV genome encodes eight putative accessory proteins that do not show any 
significant similarity to proteins of known coronaviruses (Snijder et al., 2003). Intensive 
studies were performed to understand the specific function(s) of each of these proteins. 
The characterization and functional roles of the proteins encoded by ORF3a, 3b, 6, 7a, 7b 
and 9b are summarized in Table 1.3. The studies performed on the proteins encoded by 
ORF8 will be reviewed in more details in the later paragraphs. 
Epidemiological studies revealed that the ORF8 of the SARS-CoV isolated from 
the middle and late phase SARS patients contain a 29-nucleotide deletion that is present 
in the virus isolated from the animal and the early phase SARS patients (Guan et al., 
2003). As a result, the ORF8 of the virus circulating in the middle and late phase patients 
encodes for a 39 and 84 aa proteins, 8a and 8b, respectively, instead of a single 122 aa 
protein, 8ab. It was found in a study by Wu et al. that the infection of civets with SARS-
CoV without the 29-nucleotide deletion (BJ01) induces a higher average temperature and 
slightly stronger antibody response than civets infected with SARS-CoV bearing the 29-
nucleotide deletion (GZ01), suggesting a role of ORF8 proteins in SARS-CoV 
pathogenesis (Wu et al., 2005). 
Over-expression studies showed that the 8b-EGFP protein is localized to both the 
nucleus and the cytoplasm of Vero E6 and CHO cells (Law et al., 2006). In SARS-CoV 
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infected Vero E6 cells, Oostra et al. reported no detection of 8b expression after 8h post-
infection (Oostra et al., 2007a). A characterization study of the ORF8 proteins showed 
that 8b binds to monoubiquitin and polyubiquitin and was degraded rapidly by 
proteasomes when expressed in mammalian cells (Le et al., 2007). Interestingly, the over-
expression of 8b was also shown to induce DNA synthesis (Law et al., 2006). The over-
expression of 8a-EGFP in HEK-293T cells showed that the protein is localized to the 
mitochondrial and perturb the mitochondrial membrane potential to induce apoptosis via 
a caspase-3 dependent pathway (Chen et al., 2007b). Using stable cell clones expressing 
8a for siRNA transfection, the authors also demonstrated that 8a enhances virus 
replication and cytopathic effect.  
In another study, it was demonstrated that 8ab was modified and stabilized by N-
linked glycosylation on the N81 residue and the protein can be further modified by 
ubiquitination (Le et al., 2007). Subsequent studies showed that 8ab possessed a 
cleavable signal peptide which directs the precursor protein to the ER and mediates its 
translocation into the lumen, after which the cleaved protein becomes N-glycosylated for 
assembly of di-sulfide-linked homo-multimeric complexes, which remained stable in the 
ER (Oostra et al., 2007a; Sung et al., 2009). In addition, 8ab was found to be capable of 
inducing the proteolysis of activating transcription factor 6, leading to the up-regulation 
of endogenous ER-resident chaperones expression that are involved in protein folding 
(Sung et al., 2009). This suggests that 8ab could play a role in SARS-CoV pathogenicity 
by modulating the UPR. 
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Table 1.3 – Functional characteristics of SARS-CoV accessory proteins. 
Protein Characterization of protein Functional role(s) of protein 
3a - Localized to the plasma membrane and peri-nuclear region of infected and 
transfected cells (Tan et al., 2004a).  
- An 0-glycosylated protein containing three trans-membrane domains as 
well as an N-terminal ecto-domain and a C-terminal endo-domain (Ito et 
al., 2005; Oostra et al., 2006; Tan et al., 2004a; Yuan et al., 2005a). 
- Possesses tyrosine-sorting (Yxx ) and di-acidic motifs, which are 
important for the protein sorting and trafficking of 3a to the cell surface, 
where it eventually undergoes endocytosis (Tan et al., 2004a).  
- Contains binding motifs for caveolin-1, a protein that is important in cell 
signaling (Cai et al., 2003; Padhan et al., 2007). 
- Does not share any homology with any known RNA binding protein but 
specifically interact with the 5’-UTR of its genomic RNA using a 75 aa 
interaction domain (Sharma et al., 2007). 
- Associates with structural proteins S, M and E as well as an accessory 
protein, 7a and was incorporated into the virus particle through its 
association with S (Tan et al., 2004a; Zeng et al., 2004).  
- A novel structural protein that assembles into virus-like particles (VLPs) 
when co-expressed with S, E, M and N (Huang et al., 2006b; Ito et al., 
2005; Khan et al., 2007; Shen et al., 2005; Zeng et al., 2004). 
- Production of VLPs in the absence of 3a expression as well as the ability 
to generate viable SARS-CoV in deletion mutants lacking 3a suggest that 
3a is not essential for SARS-CoV particle assembly in cell culture (Hsieh et 
al., 2005; Huang et al., 2006a; Mortola and Roy, 2004; Yount et al., 2005).  
- Some viruses isolated from SARS patients encode only the truncated 
form(s) of 3a and not the full-length 3a, indicating that the protein is 
dispensible for virus replication (Tan et al., 2005c).   
- 3a deletion mutant of SARS-CoV and the silencing of 3a and 3b using 
siRNA yields a lower progeny of viruses (Akerstrom et al., 2007; Yount et 
al., 2005). 
- Induces apoptosis in VeroE6 cells (Law et al., 2005b).  
- Activates the mitochondrial death pathway via the p38 MAP kinase 
activation (Padhan et al., 2008).  
- Promotes cell death and membrane re-arrangement (Freundt et al., 
2010).  
- Induces G1 phase cell-cycle arrest by reducing cyclin-D3 expression 
and inhibiting retinoblastoma protein phosphorylation in in vitro 
expression studies (Yuan et al., 2007). 
- Functions as a potassium ion channel to modulate virus release by 
forming a homo-tetramer complex via intermolecular disulfide bridges 
(Lu et al., 2006) and the ion channel activity is required for its pro-
apoptotic function (Chan et al., 2009). 
- Up-regulates the expression and secretion of fibrinogen in human lung 
epithelial cells, A549 (Tan et al., 2005b).  
- Expression of 3a in A549 cells activates nuclear factor kappa B (NF-
kB) and enhances the activation of NF-kB responsive chemokines, 
interleukin 8 (IL8) and RANTES (CCL5) (Kanzawa et al., 2006; Law et 
al., 2005a).  
- A significant induction of NF-kB dependent promoter activity in 
SARS-CoV infected 293/ACE2 cells was shown by Narayanan et al. but 
Frieman et al. and Spiegel et al. reported no significant induction of NF-
kB promoter-driven gene expression in 293 cells (Frieman et al., 2008; 
Narayanan et al., 2008b; Spiegel et al., 2005).  
- Expression of 3a in murine macrophage cell-line, RAW264.7, 
enhanced NF-kB activity and differentiation into osteoclast-like cells in 
the presence of receptor activator of NF-kB ligand (RANKL) and its 
expression in A549 cells expressing ACE2 up-regulates TNF-alpha, 
which is known to accelerate osteoclastogenesis (Obitsu et al., 2009). . 
- Induces down-regulation of type-I interferon alpha receptor (IFNAR1) 
by increasing its ubiquitination via inducing serine phosphorylation 
within the subunit 1 degradation motif (Minakshi et al., 2009).  
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Table 1.3 - Continued  
Protein Characterization of protein Functional role(s) of protein 
3b - Expressed via an internal ribosomal entry 
mechanism (Snijder et al., 2003). 
- Detected in SARS-CoV infected cells and the 
anti-3b antibody was detected in SARS patient’s 
serum (Chan, 2005; Guo, 2004). 
- Localize to both the nucleolus and mitochondria 
in expression studies (Yuan, 2005, 2006).  
- GFP-tagged 3b localize only to nucleolus without 
evidence of mitochondrial localization (Kopecky-
Bromberg et al., 2007). 
- Induces growth arrest in G1/G0 phase (Yuan et al., 2005b). 
- Over-expression of 3b induces both necrosis and apoptosis in VeroE6 cells (Khan et al., 2006).  
- Inhibits both interferon production and signaling in SARS-CoV infection, via the inhibition of 
IRF3 (Kopecky-Bromberg et al., 2007). 
 
6 - Bears a minimal transcription regulatory 
sequence upstream of its gene and its mRNA was 
detected in SARS-CoV infected Vero cells 
(Snijder et al., 2003; Thiel et al., 2003). 
- Expressed in lung and intestinal tissues of SARS 
patients and in SARS-CoV infected cells (Geng et 
al., 2005). 
- HA-tagged ORF6 protein localizes to ER and 
Golgi apparatus while EGFP-tagged ORF6 protein 
localizes to the perinuclear region and ER of the 
transfected cells (Geng et al., 2005; Law et al., 
2006; Pewe et al., 2005). 
- Localize to the ER and Golgi compartments in 
SARS-CoV infected cells (Frieman et al., 2007) 
- Co-localizes with LAMP-1, a lysosomal marker, 
in SARS-CoV infected Vero E6 cells (Kumar et 
al., 2007). 
- A virion-associated protein that can be 
incorporated into the VLPs and is secreted by 
transfected cells expressing the protein (Huang et 
al., 2007). 
- Stimulates DNA synthesis in CHO and VeroE6 cells (Law et al., 2006). 
- Converts a sub-lethal infection of rodents by an attenuated murine coronavirus to lethal 
encephalitis, and enhances virus growth in cell culture (Pewe et al., 2005).  
- Viral RNA in virus-infected cultures using recombinant MHV expressing ORF6 protein were five 
to eight times higher compared to wild-type MHV. Co-immunoprecipitate with viral RNA and co-
localized with cytoplasmic vesicles with replicating viral RNAs (Tangudu et al., 2007).  
- Interacts with SARS-CoV RdRp, NSP8, in a yeast-two-hybrid screen and co-localization were 
observed in SARS-CoV infected cells (Kumar et al., 2007).  
- Mutation of the N-terminal hydrophobic region affects ORF6 protein ability to enhance virus 
growth (Netland et al., 2007).  
- The hydrophilic C-terminal region containing the YSEL, a sorting motif for endosome/lysosome 
internalization interacts with cellular importins (Frieman et al., 2007).  
- Deletion of this C-terminal region does not interfere with the nuclear import processes but the 
ORF6 protein can still augment MHV infections and siRNA directed against importin-beta mRNAs 
did prime cells for enhanced MHV infections (Hussain et al., 2008). 
- Required for optimal replication of SARS-CoV when cells were infected at low MOI and 
accelerated disease in transgenic mice expressing the human ACE2 (Zhao et al., 2009). 
- Over-expression of the ORF6 protein induces apoptosis via a caspase-3 mediated ER stress and 
JNK-dependent pathway (Ye et al., 2008).  
- Inhibits both the promoter-binding and activation of IRF3 and nuclear translocation of STAT1 
(Kopecky-Bromberg et al., 2007). C-terminal tether karyopherin alpha 2 to the ER/Golgi membrane 
to disrupt STAT1 nuclear import, thus blocking the expression of STAT1-activated genes required 
to establish an anti-viral response (Frieman et al., 2007). 
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Table 1.3 - Continued 
Protein Characterization of protein Functional role(s) of protein 
7a - Localize to the perinuclear region and the ER and intermediate compartments 
of SARS-CoV infected and transfected Vero E6 cells, and possesses an N-
terminal signal peptide, an ER retrivel motif (KRKTE) and a transmembrane 
helix in the C-terminal tail (Fielding et al., 2004). 
- Nuclear magnetic resonance (NMR) spectroscopy and the crystal structure of 
7a revealed a compact seven-stranded β sandwich fold in the N-terminal 
ectodomain, similar to the topology found in members of the immunoglobulin 
(IgG) superfamily (Hanel et al., 2006; Nelson et al., 2005).  
- High structural similarity to the D1 domains of integrin ligands, ICAM-1 and 
ICAM-2, suggesting that it can binds to the αL integrin I domain of LFA-1 
(Hanel et al., 2006).  
- Short cytoplasmic tail and transmembrane domain mediate the trafficking of 
7a within the ER and Golgi network (Nelson et al., 2005).  
- Expression of 7a was detected in SARS-CoV infected Vero E6 cells and lung 
tissues of SARS patients (Chen et al., 2005c). 
- A novel structural protein that associates with purified SARS-CoV particles 
and was incorporated into VLPs by co-expression with S, M, N and E (Huang et 
al., 2006a).  
- Interacts with 3a, S, M and E (Fielding et al., 2006; Huang et al., 2006a; Tan 
et al., 2004a).  
- Interaction with S and 3a were dispensable for its assembly into the VLPs 
(Huang et al., 2006a).  
- Interacts with small glutamine-rich tetratricopeptide repeat-containing protein 
(SGT) in a yeast-two hybrid screen (Fielding et al., 2006).  
- Function as an RNA silencing suppressor by reducing the levels of siRNA to 
suppress both the transgene and virus-induced gene silencing, and has the 
ability to enhance heterologous replicon activity. (Karjee et al., 2010). 
- Treatment with and over-expression of 7a inhibited the growth of 
Balb/C 3T3 cells (Chen et al., 2005c).  
- Expression of 7a in HEK293 cells correlates with reduction of 
mRNA transcription and expression of cyclin D3 level as well as 
the phosphorylation of retinoblastoma (Rb), thus preventing the 
progression of the cell cycle at the G0/G1 phase, explaining the 
ability of 7a to inhibit cell growth. (Yuan et al., 2006b).  
- Over-expression of 7a induces apoptosis via a caspase-dependent 
pathway in cell-lines from different organs (Tan et al., 2004b).  
- Extensive apoptosis observed in the pathological tissues of SARS-
CoV patients (Chau et al., 2004; Zhang et al., 2003a).  
- Induction of apoptosis by 7a may be related to its ability to inhibit 
cellular translation and activate p38 mitogen-activated protein 
kinase (Kopecky-Bromberg et al., 2006).  
- Interacts with different members of the Bcl-2 family of pro-
survival proteins and is found to co-localize with Bcl-XL at the ER 
and mitochondria (Tan et al., 2007b).  
- Deletion of gene 7 from SARS-CoV reduces the efficiency of the 
virus to induce DNA fragmentation, suggesting the contribution of 
gene 7 products to the virus-induced apoptosis (Schaecher et al., 
2007a).  
- Gene 7 deleted SARS-CoV did not induce early apoptosis markers 
or activate caspase 3, and it has no effect on virus replication in in 
vitro and in vivo models, suggesting that 7a and/or 7b contribute to 
but are not solely responsible for the apoptosis observed in SARS-
CoV infected cells (Schaecher et al., 2008a; Schaecher et al., 
2007a). 
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Table 1.3 - Continued 
Protein Characterization of protein Functional role(s) of protein 
7b - Transcribed via a non-canonical leaky scanning mechanism from the ORF7b initiation codon that 
overlaps the ORF7a stop codon in a -1 shifted ORF (Schaecher et al., 2007b; Snijder et al., 2003).  
- A type III integral membrane protein with a Golgi localization signal and complex retention signal within 
the transmembrane domain and 7b co-localized with both cis- and trans-Golgi markers (Schaecher et al., 
2008b). 
- Specific antibodies targeting 7b were detected in the convalescent serum of SARS patients (Guo et al., 
2004).  
- Proposed to be a structural component of the SARS-CoV virion as 7b can associate with intracellular 
virus particle and is detected in purified virus particles (Schaecher et al., 2007b).  
- SARS-CoV lacking the ORF7 proteins replicated as well as the wild-type virus in cell lines and mice, 
indicating that 7a and 7b are not essential for SARS-CoV replication in vitro (DeDiego et al., 2008; Sims 
et al., 2005; Yount et al., 2005).  
- A 45-nucleotide deletion within the ORF7b acquired by serial passaging of the virus did not affect the 
virus replication as well (Thiel et al., 2003).  
- Using CaCO2 and Huh7 cells as well as in golden Syrian hamster models, SARS-CoV carrying an 
ORF7b deletion had a replicative advantage, increasing the virus titer by 4 to 6 fold and 23 fold, 
respectively, and the viral RNA in the lungs of the hamsters increases by 94.8 fold. (Pfefferle et al., 
2009a).  
 
- Not known 
9b - Translated from a bi-cistronic mRNA9 via a leaky ribosome scanning mechanism (Xu et al., 2009).  
- Antibodies against the protein have been detected in patients, and its expression was shown in diseased 
organs and SARS-CoV infected cells (Chan et al., 2005; Moshynskyy et al., 2007; Qiu et al., 2005).  
- Crystal structure reveals a novel fold that comprise of a dimeric tent-like  structure with an amphipathic 
surface and a central hydrophobic cavity that binds lipid molecules (Meier et al., 2006).  
- Exported outside the cell nucleus and localizes to the ER (Moshynskyy et al., 2007).  
- Amino acid residues 46 to 54 on 9b function as a nuclear export signal and the protein is incorporated 
into both the VLPs and purified SARS-CoV virions (Xu et al., 2009). 
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1.2 Zoonotic origins of SARS-CoV 
1.2.1 Cross-species transmission of SARS-CoV 
It was postulated that SARS-CoV was spread to humans via zoonotic 
transmission after several studies showed that more animal food handlers and traders 
were found to be infected and having a higher prevalence of IgG antibodies against 
SARS-CoV than individuals from other trades in Guangdong Province, China (Xu et al., 
2004d; Yu et al., 2003; Zhong et al., 2003). Majority of these individuals also have 
asymptomatic infection (He et al., 2003a; Xu et al., 2004d; Yu et al., 2003). 
The first investigation into the origin of the SARS-CoV in animals was carried 
out in Dongmen market located within Shenzhen in Guangdong province (Guan et al., 
2003). In this study, eight different species comprising of 6 masked palm civets, 1 
raccoon dog, 2 ferret badgers, 3 hog-badgers, 3 beavers, 4 domestic cats, 3 Chinese hares 
and 2 Chinese muntjac were tested for SARS-CoV nuclei acid of the N gene of the 
human SARS-CoV using reverse transcription-polymerase chain reaction (RT-PCR) and 
all the swabs were inoculated into rhesus monkey embryonic kidney cells, FRhK4, for 
virus isolation. All the masked palm civets and raccoon dogs were tested positive by 
either RT-PCR or virus isolation and neutralizing antibody to a SARS-CoV isolated from 
a masked palm civet (SZ16) were found in 3 of the masked palm civets, a raccoon dog 
and a Chinese ferret badgers. Two more surveillance studies carried out on masked palm 
civets also showed positive results for the detection of antibodies to SARS-CoV (Hu et 
al., 2005; Tu et al., 2004). Another 3 research teams showed that the sequences of SARS-
CoV S genes in samples of masked palm civets and 4 patients from a sporadic outbreak 
in December 2003, who have direct or indirect contact with the masked palm civets, were 
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almost identical (Kan et al., 2005; Liang et al., 2004; Song et al., 2005; Wang et al., 
2005a). These studies suggest that SARS-CoV could have spread to the human 
population via the palm civets in the live market. Experimental studies also showed that 
palm civets were sensitive to infection by human SARS-CoV and in vivo amplification 
and secretion of the infected palm civets were significantly more efficient than other 
animal models such as African green monkeys, cynomolgus macaques, ferrets, cats, 
mouse and golden Syrian hamsters (Buchholz et al., 2004; Bukreyev et al., 2004; Kuiken 
et al., 2003; Martina et al., 2003; Roberts et al., 2005; Rowe et al., 2004; Subbarao et al., 
2004; Wu et al., 2005).  
Although SARS-CoV could be detected in some of the masked palm civets, it was 
shown that majority of the farmed palm civets in China were tested negative for SARS-
CoV (Kan et al., 2005). An independent study in the live animal market in Guangzhou 
also showed negative results for SARS-CoV or SARS-like coronavirus (SL-CoV) 
infection in the civets (Wang et al., 2005b). In addition, civet SARS-CoV exhibits a 
limited genetic diversity and was highly identical to the human SARS-CoV (Lam et al., 
2008; Song et al., 2005). This suggests that the although it is possible that SARS-CoV 
could be transmitted from the masked palm civets to the human population, the palm 
civets may not be the reservoir for SARS-CoV.  
Interestingly, the attention were turned to the bats in 2005 when SL-CoV RNA 
sequences and anti-SARS nucleocapsid antibodies were reported to be detected in 
Rhinolophus Chinese horseshoe bats without any clinical signs of infection (Lau et al., 
2005b; Li et al., 2005d). Bats are long known to serve as reservoirs for a variety of 
viruses, and all human coronaviruses are postulated to originate from the bats 
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coronaviruses (Sulkin and Allen, 1974; Vijaykrishna et al., 2007). More studies to search 
for coronaviruses in bats revealed that these flying mammals harbor a diverse array of 
SL-CoV and novel coronaviruses that could be related to the existing human 
coronaviruses (Chu et al., 2008a; Dominguez et al., 2007; Pfefferle et al., 2009b; Poon et 
al., 2005; Tang et al., 2006; Woo et al., 2006). Sequence analysis revealed that the bats 
SL-CoV has the 29 nucleotide region in the ORF8 that are present in palm civets and 
early human phase SARS-CoV strains but absent in the late human phase SARS-CoV 
strain, indicating a close evolutionary relationship to the viruses that cause the SARS 
outbreak in 2002 (CSMEC, 2004; Ren et al., 2006). Phylogenetic analysis based on the 
full sequence of bats SL-CoV revealed a close relationship with the human and civet 
SARS-CoV but not other coronaviruses in the group 2 (Shi and Hu, 2008b). However, 
based on the relative distant relationship in the phylogenetic tree, it was suggested that 
none of the currently sampled SL-CoV in bats are the direct ancestor of the SARS-CoV 
in humans and civets (Hon et al., 2008). The direct ancestor of the SARS-CoV might be 
still at large in the bats population. Interestingly, a recent study demonstrated that the 
civet SARS-CoV SZ3 strain may likely be a recombinant virus arising from the bats SL-
CoV Rp3 strain and the bats SL-CoV Rf1 strain (Lau et al., 2010). 
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1.2.2 Molecular evolution and genomic differences of SARS-CoV 
Several laboratories had carried out intensive studies on the genomic differences 
and molecular evolution to understand the evolutionary path and identify the source of 
the highly infectious virus. Early studies showed that most human SARS-CoV strain 
during the epidemic carries a 29-nucleotide (nt) deletion upstream of the N gene domain, 
when compared to viral strains from SARS patients during the early outbreak and animal 
sources (CSMEC, 2004; Guan et al., 2003). This deletion resulted in the two proteins, 8a 
and 8b, instead of a single 8ab protein to be encoded by ORF8. The significance of the 
ORF8 proteins in viral virulence and pathogenesis remained to be investigated. In 
addition, SARS-CoV strains carrying 82-nt deletion within the ORF8 region were also 
isolated from several SARS patients (CSMEC, 2004). Sequence comparison reveals that 
a similar SARS-like CoV strain carrying the 82-nt deletion was previously isolated from 
farmed civets in Hubei Province, suggesting that this strain could have originated from 
the animals (Hu et al., 2003). Interestingly, co-infection of the two virus genotypes, with 
the 29-nt and 82-nt deletions, was found in the lung biopsy of a patient from the epidemic 
phase (CSMEC, 2004). In addition, another virus genotype with a 415-nt deletion 
resulting in the loss of the whole ORF8 region was also isolated from two patients during 
the late phase of the epidemic (CSMEC, 2004). This is not the only report that shows 
large genomic deletions in the SARS-CoV strains from the late phase epidemic; SARS-
CoV strains with a 386-nt deletion flanking the previously identified 29-nt deletion site 
were also identified (Chiu et al., 2005). Anti-parallel reverse symmetrical sequences that 
result in hairpin structures were readily predicted around the deletion sites, which may 
explain for the high occurrence of deletions within this region (CSMEC, 2004). 
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RNA viruses were known to have high mutation rates, giving them a survival 
edge either by increasing viral virulence, escaping host defenses or switching tissue 
tropism (Brown et al., 2001; Rasschaert et al., 1990; Seo et al., 2002). A high number of 
single nucleotide variations were identified from sequence comparison of 63 SARS-CoV 
sequences, resulting in either synonymous or non-synonymous mutations (CSMEC, 
2004). The ratio of the rates of non-synonymous to synonymous changes (Ka/Ks) for the 
S gene showed that positive selection pressure was greatest during the early epidemic and 
progressively slowed down as the epidemic progress to the late phase (CSMEC, 2004). 
Genomic sequences analysis showed that the mutation rate for the strains obtained from 
different regions of the world during the 2003 epidemic was 2.2 to 6.7 x 10
-6
 nt 
substitution per site per day (Zhao et al., 2004). Analysis on the Singapore strains from 
the epidemic yields similar results at 5.7 x 10
-6
 nucleotide substitution per site per day 
(Vega et al., 2004). 
It was shown that the putative S1 domain of the bats SL-CoV, containing the 
RBD, has a low sequence similarity compared to the human and civet SARS-CoV S1 
domain (Wong et al., 2004). In addition, Li et al. identified one insertion and three 
deletion sites in the S1 domain of the bats SL-CoV (Li et al., 2005a). These results 
suggest that the bats SL-CoV use a different receptor molecule for virus entry. However, 
the S2 domain of all the SL-CoV has a high sequence identity of 96% to that of SARS-
CoV, suggesting a similar fusion mechanism employed by the SL-CoV (Wong et al., 
2004). Mutational analysis between the bats SL-CoV, the civets and human SARS-CoV 
revealed some key mutational hotspots in the NSP3, ORF1a, S, ORF3 and ORF8 region 
(CSMEC, 2004). The host receptor for coronaviruses has previously been shown to be an 
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important determinant of host range expansion. For SARS-CoV, ACE2 has been shown 
to be the functional receptor for infection of the human host, and CD209L is shown to 
function as a co-receptor (Jeffers et al., 2004; Li et al., 2003b) . Comparison of the S 
RBD in the civets, early and late-phase human SARS-CoV showed that positive selection 
was taking place in the civet and early-phase SARS-CoV strains while negative selection 
was taking place in the late-phase SARS-CoV strains (CSMEC, 2004; Hu et al., 2003). 
Taken together, the results suggest that there is a high genomic similarity between SARS-
CoV and the SL-CoV identified in the civets and bats, thus SARS-CoV most likely is an 
evolved strain from an ancestor SL-CoV strain that is residing in the bats population. 
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1.3 Goals of the project 
The interactions between viruses and their host cells are complex and multi-
faceted. Over the years, much effort had been put into understanding the roles of viral-
viral and viral-host interactions in infection. SARS-CoV entry into the cell is driven by 
the S glycoprotein, which is a class I fusion protein (Bosch et al., 2003). The S protein of 
coronaviruses is known to be responsible for the induction of host immune responses and 
virus neutralization by antibodies and therefore, it is one of the major targets for the 
development of vaccine candidates (Buchholz et al., 2004; Castilla et al., 1997).  
In this study, our aim is to identify neutralizing epitopes on S that can be used for 
the development of a vaccine or a therapeutic agent. Control of potential neutralization 
escape mutants is also an important area of concern in prophylactic and therapeutic 
treatment. For the development of an effective immune prophylaxis, a better 
understanding of the dynamics and evolution of the SARS-CoV is crucial.  Thus in the 
current study, we aimed to develop neutralizing monoclonal antibodies for the generation 
of escape SARS-CoV that can help us to identify critical residues for the inhibitory 
activity of the mAbs, which may then allow us to identify novel domains necessary for 
viral entry as well as to gain a better understanding of the roles of the identified critical 
residues in the mechanism of coronavirus entry into the host cells. In addition, it was 
previously shown that nitric oxide (NO) can inhibit the replication cycle of SARS-CoV 
via the production of inducible NO synthase (iNOS) (Akerstrom et al., 2005). In this 
project, we aim to investigate the mechanism of inhibition of SARS-CoV replication by 
NO and to explore the potential application of NO as a therapeutic drug in the treatment 
of coronavirus infection. 
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For SARS-CoV, there are eight accessory proteins with no significance sequence 
homology to viral proteins of other coronaviruses. Although most of these accessory 
proteins have been shown to be expressed during SARS-CoV infection, it has not yet 
been established which of them are essential for viral replication and/or pathogenesis.  
Interestingly, a 29 nucleotide deletion has occurred in ORF8 after the transmission of 
SARS-CoV from animal to human and as a result, the 8ab protein became two separate 
proteins (8a and 8b) in the human isolates. The approach adopted by our laboratory is to 
study the interactions between the structural proteins and the ORF8 proteins and to 
identify cellular proteins that can contribute to the functions of these viral proteins. Our 
goal for this project is to provide a better understanding on the contribution of the 
mutation in ORF8 region to the replication and pathogenesis of SARS-CoV. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Mammalian cell lines used in the study  
The monkey kidney cell lines Cos7 and Vero E6, Chinese hamster ovary CHO 
and human embryonic kidney 293T used in this study were purchased from the American 
Type Culture Collection (ATCC; Manassas, Va.). Cos7 and Vero E6 cells were cultured 
at 37 °C in a 5 % CO2 incubator in Dulbecco modified Eagle medium (DMEM; Sigma-
Aldrich Inc.) containing 0.1 mg/ml of streptomycin, 100 U/ml of penicillin, and 10 % 
fetal bovine serum (FBS; HyClone, Logan, Utah). A CHO cell line (CHO-ACE2) stably 
expressing the receptor, ACE2, for SARS-CoV S was established using the methods 
described previously (Chou et al., 2006) and grown in complete DMEM containing 0.1 
mM ZnSO4. 
2.2 Viruses 
The strain Sin2774 of SARS-CoV (GenBank accession number AY283798) was 
isolated from a SARS patient in Singapore General Hospital and was adapted to grow in 
Vero E6 cells. The strain HK39849 of SARS-CoV (GenBank accession number 
AY278491) was provided and used in experiments done in the University of Hong Kong. 
The strain Frankfurt 1 of SARS-CoV (AY291315) was provided and used in experiments 
in Swedish Institute for Infectious Disease Control. Recombinant vaccinia/T7 virus 
(vTF7-3) was grown and titrated on Vero E6 cells. Recombinant vaccinia viruses, rVV-
L-SP and rVV-L-NP, expressing the S and N proteins of SARS-CoV, respectively, were 
obtained from Baxter Vaccines and grown in CV-1 cells. 
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2.3 Construction of plasmids.  
2.3.1 Plasmids for expression of viral proteins in mammalian cells. 
Viral RNA was extracted from a virus isolate from a Singapore patient (strain 
SIN2774, GenBank accession number AY283798) was extracted and used for 
amplification of the S gene by reverse transcription-PCR (RT-PCR) with specific 
primers. For expression of S under the control of a T7 promoter, the full-length S PCR 
products were digested with BamHI and StuI and ligated into BamHI/EcoRV-cut pKT0 
to construct plasmid pKT-S. pKT0 is a modified form of pING14, in which a T7 RNA 
polymerase promoter sequence was inserted (Liu et al., 1991). pING14 is modified from 
pSP64T (Addgene). For characterization of the polyclonal antibodies, specific primers 
were designed to amplify S from nucleotide positions 21476 to 25171, 25066, 24934, 
24415, 24157, and 23866 (Appendix 1). The six RT-PCR products were digested with 
BamHI and StuI and ligated to BamHI/EcoRV-cut pKT0, giving rise to plasmids pKT-
SΔ11, pKT-SΔ12, pKT-SΔ13, pKT-SΔ14, pKT-SΔ15 and pKT-SΔ16, respectively.  
For screening of monoclonal antibodies binding sites, specific primers were 
designed for two-round PCR to amplify S fragments with internal deletions of the S gene 
from nucleotide positions 3084 to 3150, 3151 to 3210, 3211 to 3270, 3271 to 3330, 3331 
to 3390, 3391 to 3450, 3451 to 3510, and 3511 to 3576, respectively (Appendix 1). The 
eight PCR products were digested with EcoRV and SacI and ligated to EcoRV/SacI-cut 
pKT-S under the control of a T7 promoter, giving rise to plasmids pKT-SΔ50, pKT-
SΔ51, pKT-SΔ52, pKT-SΔ53, pKT-SΔ54, pKT-SΔ55, pKT-SΔ56, and pKT-SΔ57, 
respectively.  
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For the construction of pXJ-8a, pXJ-8a-myc, pXJ-8b and pXJ-8b-myc, the ORF 
8a and 8b were amplified by PCR using cDNA prepared from SARS-CoV infected cells 
as templates as previously described (Tan et al., 2004a). In order to construct a plasmid 
for expressing the 8ab protein found in animal SARS-CoVs, we used the cDNA template 
described above and sequential PCR to insert the 29-nt. Primers were designed based on 
the early phase human SARS-CoV isolate, GZ02, which has the 29-nt insertion in ORF8 
(GenBank accession number AY390556). All sequences were confirmed by sequencing 
performed by the core facilities at the Institute of Molecular and Cell Biology, Singapore. 
The PCR amplicons containing ORF8a, ORF8b and ORF8ab were cloned into the 
mammalian expression vector pXJ3′HA as previously described (Tan et al., 2004a). In 
order to create a C terminus myc-tag, PCR methods were used to insert a myc-tag 
(AEEQKLISEEDLLRKH) into the 3′ of the ORFs. These proteins were tagged at their C 
termini to avoid interference with their post-translational processing as both 8a and 8ab 
are predicted to contain one signal peptide at their N termini 
(http://www.cbs.dtu.dk/services/SignalP). The C-terminal HA tag present in the 
pXJ3′HAvector is not expressed, as a stop codon was added before the HA tag coding 
sequences. The PCR amplicons containing E gene or E mutants were cloned into the 
mammalian expression vector pXJ3′HA as previously described (Tan et al., 2004a) and 
using specific primers (Appendix 3). All primers used in this study were purchased from 
Research Biolabs or Proligo, Singapore, and are listed in Appendix 1, 2 and 3. 
2.3.2 Plasmids for expression of viral proteins in Escherichia coli 
Five PCR fragments encoding the SΔ1, SΔ2, SΔ3, SΔ9, and SΔ10 fragments (Fig. 
3.1) were obtained with the primers listed in Appendix 1. The PCR products were 
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digested by BamHI/XhoI and ligated into the BamHI/XhoI-cut pGEX4T1 vector 
(Amersham Pharmacia Biotech, Uppsala, Sweden) to obtain plasmids pGEX-SΔ1, 
pGEX-SΔ2, pGEX-SΔ3, pGEX-SΔ9, and pGEX-SΔ10 for the expression of glutathione 
S-transferase (GST) fusion proteins. The GST tag was located at the N terminus of the 
fusion protein. The cDNA encoding 8a (16–39aa) and 8b (27–84aa) were obtained by 
PCR methods (see Appendix 2 for primer sequences) and were cloned into pGEX-4T1 
vector (Amersham Biosciences) to obtain plasmid pGEX-8aΔN15 and pGEX-8bΔN26 
for the expression of GST-8aΔN15 and GST-8bΔN26 proteins. 
2.4 Expression and purification of GST-fusion proteins 
Plasmids pGEX-SΔ1, pGEX-SΔ2, pGEX-SΔ3, pGEX-SΔ9, pGEX-SΔ10, pGEX-
8aΔN15 and pGEX-8bΔN26 were separately transformed into BL21 (DE3) cells 
(Stratagene, La Jolla, CA). A single colony from each plate was grown at 37 °C 
overnight in Luria-Bertani (LB) medium containing 100 μg per milliliters (ml) of 
ampicillin. Five ml of the resulting cultures was inoculated into 2 liters of LB medium 
containing 100 μg/ml ampicillin and the cultures were incubated in a shaker at 37 °C 
until the optical density at 600 nm reached 0.6. Expression of proteins was induced with 
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). Cells were harvested 2 h after 
induction by centrifugation at 5,000 x g for 10 min at 4 °C. The cell pellets obtained were 
re-suspended in phosphate-buffered saline (PBS) containing 1 mM phenylmethylsulfonyl 
fluoride (PMSF) and 20 μg/ml of DNaseI and lysed by two passages through a French 
press. Lysates were centrifuged at 22,000 x g for 30 min. For GST fusion proteins SΔ1, 
SΔ2, SΔ3, SΔ9, and SΔ10, the insoluble proteins in the pellet were washed three times 
and re-suspended in PBS containing 1 % Triton X-100.  
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Proteins were separated in 10 % sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gels. Gel strips containing GST fusion proteins were cut, 
and the proteins were eluted with a Mini Trans-Blot cell (Bio-Rad, Hercules, Calif.). The 
resulting fusion proteins were detected by western blotting with mouse anti-GST 
antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif.), and their concentrations were 
estimated by comparison with bovine serum albumin (BSA) standards in a Coomassie 
brilliant blue R-250 (Bio-Rad)-stained SDS-PAGE gel. For GST-8aΔN15 and GST-
8bΔN26, 10% glycerol was added to the purified proteins to prevent aggregation. As for 
GST-8bΔN26, 2 mM DTT and 1.5% sarkosyl were included in the lysis buffer and after 
sonication; Triton X-100 was added to a final concentration of 2 % before the protein was 
purified using GSH-sepharose beads. 
2.5 Generation of rabbit polyclonal antibodies 
One milligram of each of the purified GST fusion proteins SΔ1, SΔ2, SΔ3, SΔ9, 
SΔ10, 8aΔN15, 8bΔN26 and E was mixed with an equal volume of complete Freund’s 
adjuvant (Sigma, St. Louis, Mo.) and used for the immunization of New Zealand White 
rabbits. Two rabbits were used to raise antibodies against each respective antigen. Three 
weeks after the initial immunization, the rabbits were given booster injections at 2-week 
intervals. Incomplete Freund’s adjuvant (Sigma) was used for subsequent booster 
injections. Ten milliliters of blood was harvested from the rabbits each time after the 4th, 
6th, 8th, 12th, 14th, and 16th injections. All procedures for the use of laboratory animals 
were done in accordance with the regulations and guidelines of Animal Research Ethics 
Committee. 
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2.6 Transient expression of SARS-CoV proteins in mammalian cells 
Cells were plated on to 60 mm or 100 mm dish for transient transfection for 
immunoprecipitation, immunoblotting or radio-labeling experiments. For virus-infected 
cells, transient transfection was carried out at 1 h post-infection with Effectene 
transfection reagents (Qiagen, Valencia, Calif.) according to the manufacturer’s protocol. 
For other cells, transient transfection was performed using Lipofectamine 2000 reagent 
(Invitrogen, Carlsbad, CA) according to manufacturer’s protocol. Transient transfection 
was carried out in DMEM without FBS or penicillin, and the medium was replaced 6 h 
post-transfection with DMEM containing 10 % FBS, 0.1 mg/ml of streptomycin and 100 
U/ml of penicillin. 
2.7 SDS-PAGE 
SDS-PAGE was performed according to Laemmli’s method (Laemmli, 1970). 
Discontinuous SDS-PAGE with a stacking gel (pH 6.8, 0.125 M Tris-HCl, 0.1 % SDS 
and 3 % acrylamide) and separating gel (pH 8.8, 0.375 M Tris-HCl, 0.1 % SDS and 10-
15 % acrylamide) were conducted in 1X SDS running buffer (25 mM Trizma Base, 250 
mM glycine, 0.1 % SDS) at 20 milli-Amperes per gel. 
2.8 Coomassie blue staining 
Gel were stained in 0.25 % Coomassie Brilliant Blue R-250 (Biorad) staining 
solution containing 20 % methanol and 10 % acetic acid for 30 min, followed by a few 
washes using de-staining solution (20 % methanol, 10 % acetic acid) until the 
background of the gel is fully de-stained. 
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2.9 Immunoprecipitation (IP) 
The cells were harvested at 16 h post-transfection and washed with PBS. Then, 
the cells were re-suspended in 150 μl of IP buffer (50 mM Tris pH 8, 150 mM NaCl, 0.5 
% NP40, 0.5 % deoxycholic acid, 0.005 % SDS) supplemented with 0.5 % Triton X-114 
and subjected to sonication for 45 min using an ultrasonic processor (Sonics, Newtown, 
CT, USA), followed by freeze–thawing for six times. 100 μl of the lysates were diluted 
with 100 μl of IP buffer and 5 μl of rabbit anti-myc polyclonal antibody (Santa Cruz 
Biotechnology) were added and the mixture was subjected to end-over-end mixing at 4 
°C for 2 h. Protein A-agarose beads (Roche) were then added and the mixing continued 
for at least 4 h at 4 °C. Beads were washed three times with cold IP buffer and then 20 μl 
of Laemmli's SDS buffer were added and the samples boiled at 100 °C for 5 min to 
release the immuno-complexes. Samples were separated on SDS–PAGE and subjected to 
western blot analysis. In some cases, tricine gels (Biorad) were used instead for better 
resolution of low molecular weight proteins. Co-immunoprecipitation experiments with 
SARS-CoV-infected cells were performed in a similar manner. 
2.10 Western blot analysis 
Cell lysates were prepared with SDS loading buffer under reducing conditions (60 
mM Tris-HCl (pH 6.8), 1 % SDS, 20 mM dithiothreitol, 10 % glycerol and 0.02 % 
bromophenol blue). Proteins were separated in 7.5%, 10 %, 12% or 15% SDS-PAGE gel 
and transferred to a nitrocellulose membrane. The membranes were blocked in 5 % non-
fat milk in PBS with 0.05 % Tween-20 and probed with primary antibodies at 4 °C 
overnight. The membranes were incubated with horseradish peroxidase-conjugated 
secondary antibodies (Pierce, Rockford, Ill.) at a dilution of 1:2,000 for 2 h at room 
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temperature and developed with enhanced chemiluminescence reagent (Pierce). For 
loading control, membranes were stripped with stripping buffer [2 % SDS, 100 mM β-
mercaptoethanol, 62.5 mM Tris-HCl (pH 6.8)] for 30 min at 65 °C and washed 
extensively with PBS containing Tween-20 before being re-probed with a mouse anti-
actin antibody (Sigma) at a dilution of 1:3,000. 
2.11 Indirect immunofluorescence microscopy 
Vero E6, 293T and Cos7 cells grown on Permanox slide (Nalge Nunc 
International, Naperville, Ill.) were infected and/or transfected as described above. At 8 h 
post-transfection, cells were fixed with 4 % paraformaldehyde for 10 min at room 
temperature and blocked with PBS containing 1 % bovine serum albumin for 30 min. The 
cells were then incubated with primary antibody for 1.5 h and washed three times before 
incubated with fluorescein isothiocyanate-conjugated (FITC) secondary antibody (1:200; 
Santa Cruz Biotechnology) for 1 h. All incubations and washes were performed at room 
temperature. Slides were mounted with fluorescence mounting medium (Dako 
Cytomation) and analyzed on an Axio-Vision fluorescence light microscope (Carl Zeiss 
Vision GmbH, Hallbergmoss, Germany).  
2.12 Radioactive pulse-chase protein labeling 
Cos7 cells were infected with vaccinia virus vTF7-3 and transfected with pKT-S 
or plasmids expressing the S C-terminal deletion mutant proteins (pKT-SΔ11, pKT-
SΔ12, pKT-SΔ13, pKT-SΔ14, pKTSΔ15, and pKT-SΔ16) as described above. Cells were 
mock transfected with pKT0 as controls. At 3 h post-transfection, the cells were starved 
for 30 min with methionine-cysteine (Met-Cys)-free medium before being labeled with 
[
35
S]Met-Cys for 1 h and chased with 4 mM cold Met-Cys for 2 h. For the time course 
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experiment, the chase periods before harvesting the cells were 0, 1/2, 1, 2, 4, and 6 h. For 
virus-infected Vero E6 cells, cells were infected at a MOI of 5, radiolabeled at 5 h post-
infection for 1 h, and chased for 3 h. Cells were lysed with lysis buffer containing 150 
mM NaCl, 20 mM Tris (pH 7.5), 1 % NP-40, 5 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride and centrifuged at 16,000 x g for 10 min.  
A portion of the supernatant (300 μl) was incubated for 1/2 h with 5 μl of 
antiserum, followed by a 1 h incubation with protein A-Sepharose beads (Roche). The 
beads were washed three times with lysis buffer. Twenty microliters (µl) of 1X SDS 
loading buffer was added to the beads and boiled for 5 min at 100 °C. For the EndoH 
treatment, the beads were re-suspended in EndoH buffer provided by the manufacturer 
and the immunoprecipitated proteins were eluted by boiling for 5 min. Samples were 
treated with EndoH enzyme (Roche Diagnostics) at 37 °C for 2 h. For the control, 
samples were treated in the same manner except no enzyme was added. All the samples 
were separated in a 7.5 % SDS-PAGE gel and visualized by autoradiography. 
Vero E6 cells grown in 60 mm dishes were infected with recombinant vaccinia 
virus carrying the S gene (rVV-L-S), at a MOI of 0.1. For mock-infected cells, a 
recombinant vaccinia virus carrying the N gene (rVV-L-N) was used. At 1 h post-
infection, the cells were treated with 400 µM of SNAP (Sigma, St. Louis, Mo.), 400 µM 
N-acetyl-penicillamine (NAP; Sigma), 400 µM of SIN-1 (Sigma, St. Louis, Mo) or 400 
µM of SIN-1 and 400 µM of MnTBAP (Calbiochem). Treatments were repeated 4 times 
with 2-h intervals. At 24 h post-infection, cells were labeled with 400 µCi of [
3
H]-
palmitic acid (Perkin Elmer, USA) for 2 h or starved with methionine-cysteine (Met-




cysteine for 2 h. The labeled cells were washed 3 times with cold PBS and lysed in 1 ml 
TES lysis buffer [20 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 % Triton X-
100 and 2 mM PMSF]. Cell debris was removed from the lysates by centrifugation at 
13,000 rpm for 10 min.  
Immunoprecipitation was carried out by adding rabbit anti-SΔ10 antibody to the 
lysates and rotating at 4 °C for 1 h, followed by overnight incubation with protein-A 
Sepharose beads (Roche Diagnostics). The beads were washed 3 times with lysis buffer 
and boiled in 20 μl of 2X Laemmli's SDS loading buffer. Samples were separated in a 7.5 
% SDS-PAGE gel, fixed for 30 min using fixing solution (10 % acetic acid, 45 % 
methanol), and treated with Amplify Fluorographic Reagent (Amersham Biosciences) 
according to protocol. Visualization was done by autoradiography. 
2.13 Virus neutralization assay  
To determine the neutralizing activities of the rabbit anti-sera, we performed a 
neutralization assay using a 96-well plate. Vero E6 cells (2 x 10
4) were grown in 200 μl 
of medium in each well of the 96-well plates and incubated at 37 °C. Serial dilutions of 
rabbit sera with the medium in ratios of 1:10 to 1:1,280 were prepared. Diluted rabbit 
anti-sera (0.1 ml) were mixed with 0.1 ml of SARS-CoV at 200 (or 1,000) 50 % tissue 
culture infective doses (TCID50) for 1 h at 37 °C before being added into the respective 
wells. At each dilution, antiserum and virus mixtures were added to eight wells. The 96-
well plate was incubated in a CO2 incubator for 4 days to observe the cytopathic effect. 
The ratios of infected wells to uninfected wells were determined under microscopy.  
The titers of the neutralizing antibodies were calculated by the Reed-Muench 
method (Reed and Muench, 1938) and expressed as TCID50 per 0.1 ml. All experiments 
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were carried out in duplicate. Neutralization assays for monoclonal antibodies were 
performed in a 96-well plate format. Complement proteins in ascitic fluids were 
inactivated at 56 °C for 30 min before use. Monoclonal antibodies (mAb) were first 
diluted 10 times, and then serial two-fold dilutions were prepared in maintenance 
medium. One set of antibody dilutions was added to cells to detect the toxicity of the 
ascitic fluids. The diluted antibodies were incubated with 10 TCID50 of SARS-CoV in an 
equal volume of medium for 1 h at 37 °C before being added into the respective wells 
containing 5 x 10
4
 Vero E6 cells per well. At each dilution, the mixtures of antibody and 
virus were added to four wells and incubated with Vero E6 cells. After 3 days, cytopathic 
effect (CPE) developed in all the negative controls and the back titration wells. The titers 
of the neutralizing antibodies were determined by applying the Ka¨rber formula: 
Negative log of the lowest dilution - [(sum of percentage positive/100) - 0.5] x log 
interval. All experiments were carried out in triplicate, and the neutralizing titers were 
expressed as the reciprocal of the highest antibody dilution where the viral CPE in 50 % 
of the wells was neutralized. 
2.14 Generation of monoclonal antibodies  
GST-tagged and His-tagged fusion proteins, GST-SΔ10 and SΔ10-His, were 
expressed in E. coli and purified as described above. They were used for immunization of 
mice and screening of hybridomas secreting S-specific mAbs, respectively. Each of the 6-
week-old female BALB/c mice was given primary injection (intra-peritoneal) with 100 
µg of the protein GST-SΔ10 emulsified in complete Freund’s adjuvant (Sigma-Aldrich 
Inc.). Two weeks later, each mouse was given one secondary booster injection using the 
 50 
same amount of antigen mixed with incomplete Freund’s adjuvant (Sigma-Aldrich Inc.). 
Booster injections were administered to each mouse at 1-week intervals three more times.  
S-specific antibodies in the serum of immunized mice were tested by Western blot 
assays prior to hybridoma fusion. The spleen was excised, and hybridoma fusion was 
performed using the Clonal Cell-HY Complete kit (StemCell Technologies, Canada) 
according to the manufacturer’s instructions. All procedures on the use of laboratory 
animals were done in accordance with the regulations and guidelines of the National 
Advisory Committee for Laboratory Animal Research, Singapore. MAbs in supernatants 
of hybridoma cultures were screened in an enzyme-linked immuno-sorbent assay 
(ELISA). Briefly, 96-well ELISA plates were coated with the protein SΔ10-His or bovine 
serum albumin (50 ng/well) in 0.1 M sodium carbonate buffer (pH 9.6) overnight at 4 °C. 
The plates were blocked with PBS containing 5 % FBS and 0.05 % Tween-20 for 1 h at 
37 °C and washed three times with PBS containing 0.05 % Tween-20 and three times 
with PBS. Supernatants of hybridoma cultures (50 μl/well) were incubated for 1 h at 37 
°C. After washing, goat anti-mouse immunoglobulin G (IgG)-horse radish peroxidase 
(HRP) antibodies (200 µg/ml, Santa Cruz, Calif.) at a dilution of 1:2,500 were added to 
the ELISA plates, which were then incubated for 1 h at 37 °C. After washing three times 
with PBS, substrate TMB (Pierce Biotechnology) was added and the reaction was 
stopped 15 min later by adding an equal volume of 1 M H2SO4. Optical density was read 
at 450 nm. Mouse immune and pre-immune sera were used as positive and negative 
controls. Samples giving a value of optical density that is equal or greater than 3 standard 
deviations above the mean value of bovine serum albumin controls were considered 
positive. 
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2.15 Purification of monoclonal antibodies  
A 1ml HiTrap Protein G HP beads column (GE Healthcare) is pre-washed using 
10-20 ml of 20 mM sodium phosphate buffer, pH 7.0 at a constant flow-rate of 1 ml/min 
using a peristaltic pump. Five milliliters of ascites fluids is mixed with equal volume of 
40 mM sodium phosphate buffer and passed through a 0.45 µm filter. The filtered ascites 
fluids were ran at the same flow-rate through the column. Three washes were performed 
using the 20mM sodium phosphate buffer. Elution buffer (0.1 M glycine-HCl, pH 2.7) 
was run through the column at a flow-rate of 1 ml/min and the flow-through was 
collected in 1.5ml eppendorf tubes containing 20µl of neutralization buffer (1 M Tris-
HCl, pH 9.0). The protein concentration in each tube was determined against BSA 
standards at 0.595 nm using a spectrophotometer.  
2.16 Fluorescence activated cell sorting (FACS) analysis.  
293T cells infected with rVV-L-SP expressing the S proteins (293T-SP) and 
stable cell line CHO-ACE2 were first detached with 0.04 % EDTA, washed once with 
PBS, and incubated with rabbit anti-SΔ10 serum diluted 1:40, mAbs or goat anti-ACE2 
IgG primary antibodies (100 µg/ml; Santa Cruz) diluted 1:20 in PBS containing 1 % fetal 
bovine serum and 0.1 % sodium azide for 1 h at 4 °C. Cells in tubes were placed on a 
roller to ensure constant mixing under non-permeabilizing conditions. The cells were 
washed and subsequently incubated with FITC-labeled goat anti-rabbit IgG (200 µg/ml; 
Santa Cruz), rabbit anti-goat IgG secondary antibodies (200 µg/ml; Santa Cruz), or goat 
anti-mouse IgG secondary antibodies (200 µg/ml; Santa Cruz) at a 1:20 dilution for 1 h at 
4 °C and placed on a roller to ensure constant mixing. Immediately after washing, cells 
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were measured for FITC fluorescence using a Becton Dickinson FACScan flow 
cytometer and results were analyzed using Cell-quest Pro software. 
2.17 Cell-cell membrane fusion assay.  
The 293T cells were transfected with plasmid pEGFP-N1 (Clontech Laboratories 
Inc, Pala Alto, Calif.), which encodes GFP, using Effectene transfection reagent (Qiagen) 
according to the manufacturer’s instructions. After 24 h, medium was removed and the 
cells (293T-GFP) were washed twice with room temperature PBS before the infection 
medium was added. 293T-GFP cells were infected with recombinant vaccinia virus 
expressing the SARS-CoV spike protein (rVV-L-SP) at an MOI of 0.1. After 1 h of 
adsorption, the infection medium was removed and subsequently replaced with complete 
DMEM for 24 h for S expression. Infected 293T-GFP (293T-SP) and CHO-ACE2 were 
first detached with 0.04 % EDTA, washed once with PBS, and re-suspended in DMEM 
containing 0.25 mg/ml porcine trypsin (JRH Biosciences Inc.) and 5.6% fetal bovine 
serum. 293T-SP and CHO-ACE2 cells were mixed at a 1:1 ratio per well (up to 1 X 10
6
 
cells) in a 12-well plate (Nunc). Syncytium formation was observed 6 h after mixing of 
cells. Serially diluted rabbit anti-SΔ10 serum (at a dilution factor of 1:40, 1:80, 1:160), 
pre-immune serum (at a dilution factor of 1:40), or serially diluted mAbs (at dilution 
factor of 1:40, 1:80, 1:160) were pre-incubated with 293T-SP cells at 37 °C for 10 min. 
Inhibition of syncytium formation could be observed from 6 h onwards.  
Five micrographs were taken randomly in a 10X magnified field of view on an 
Olympus UV microscope CKX41 equipped with an Olympus Camedia C-5060 digital 
camera. Syncytium with a size equal to or greater than 10 cells was considered a true 
fusion, and the average numbers of syncytia were scored. The total number (T) of 
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possible syncytia without cell-cell membrane fusion inhibition was derived from fusion 
experiment with non-SARS-CoV-related mouse ascitic fluid (anti-dengue mAb serotype I 
6F8-3) or rabbit pre-immune serum. The number (I) of syncytia with inhibition effect was 
derived from fusion experiments in the presence of specific antibodies of interest. 
Percentage inhibition of cell-cell membrane fusion was expressed as (T-I)/T. 
2.18 Generation of escape SARS-CoV 
Using 100 TCID50 of SARS-CoV for infection in the presence of different 
concentrations of mAbs, we tested the supernatant of the infected cells for the extent of 
reduction of virus titers in a 96-well plate. The concentration of mAbs that can reduce the 
virus titers by about 4 logarithms (log) is ideal as the selective pressure for the generation 
of virus escape mutants. Quadriplicate experiments were performed. The concentration 
for the selection of virus escape mutants for mAb1A9 and mAb1G10 is determined at 





CoV strain HKU-39849 were incubated in the presence of a constant amount of mAb1A9 
(0.25mg/ml) and mAb1G10 (0.1mg/ml), for 1 h at 37 °C and 5 % CO2. The virus-mAb 
mixture is then incubated with Vero E6 cells in a 96-well plate for 1 h at 37 °C and 5 % 
CO2, then the virus-mAb mixture was removed and the cells were washed twice with 
medium. Finally, the cells were incubated for 2 days in the presence of the above 
concentration of the respective mAb in 0.5 ml medium. The highest dilution, at which the 
cells exhibit cytopathic effect, will have the supernatant harvested for further selection. 
The supernatant, containing potential escape viruses, will be passaged three times in Vero 
E6 cells at the above mAb selection concentration.  
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The final virus sample will be added to Vero E6 cells in a 6-well plate and 
incubated for 1 h at 37 °C and 5 % CO2, before the wells are overlaid with agarose 
containing the above mAb selection concentration and incubated for 3-5 days at 37 °C 
and 5 % CO2. Individual escape virus plaques were picked using a Pasteur pipette and 
freeze-thawed once, and amplified in Vero E6 cells. Neutralization test were then 
performed on all the virus clones to confirm that they can escape the mAb inhibition at 
the previous neutralizing concentration. 
2.19 TOPO cloning and sequencing 
Viral RNA of all escape virus clones was isolated using the Viral RNeasy kit 
(Qiagen) and converted into cDNA by standard RT-PCR. Subsequently, the cDNA was 
amplified by PCR using specific primers targeting the S gene to generate a long fragment 
(aa 1 to 1003) and a short fragment (aa 969 to 1255). These gene fragments were cloned 
into TOPO vectors (Invitrogen) and used for sequencing. 
2.20 Pseudovirus luciferase assay  
To produce HIV pseudovirus bearing the SARS-CoV S protein, 9 μg of HIV-1 
luciferase reporter vector pNL4.3.Luc.R-E- (HIV-luc) and 4.5 μg of SARS-CoV S 
protein expression plasmid (pXJ3′-S-HA) were co-transfected into 293T cells in a 100-
mm dish using Lipofectamine2000 reagent (Invitrogen) following manufacturer's 
instructions. For the negative control, the cells were transfected with pNL4-3.Luc.R-E-
alone. The construction of the plasmids has been described previously (Connor et al., 
1995; He et al., 1995; Tan et al., 2004a). The virus-containing medium was harvested 
after 72 h of incubation, and centrifuged at 2000 rpm for 5 min to remove any cell debris.  
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Virus in the supernatant was subsequently concentrated through a 20% sucrose 
cushion for 3 h at 30,000 rpm and 4 °C by using an SW41 rotor, and subsequently re-
suspended in DMEM. In order to normalize the amount of pseudovirus used, 10 μl of 
each sample was used to measure p24 content using a p24 ELISA kit (Perkin Elmer Life 
Sciences, Boston, MA), according to the manufacturer's protocol. Absorbance readings 
were made at 492 nm in a plate reader (Tecan) and sample concentrations were 
determined from a standard graph. Appropriate volumes corresponding to 16 ng of 
pseudovirus were then used to infect GFP, GFP-8b or CHO-ACE2 stable cell lines (Chou 
et al., 2006). At 24 hpi, the cells were washed once with PBS. Cells were harvested using 
0.5ml trypsin and washed twice using PBS. Cell pellet was lysed using the Promega lysis 
buffer and luciferase activity was determined using a luciferase assay kit, following 
manufacturer's instructions (Promega, Madison, WI). Luciferase readings were measured 
using a Veritus microplate luminometer (Turner Biosystems, CA). 
2.21 P24 ELISA assay  
HIV pseudovirus bearing the SARS-S protein was produced as described in the 
pseudovirus entry assay (see above). Virus containing medium was harvested after 24 h 
of incubation and centrifuged at 3000 rpm for 5 min to remove any cell debris. 10 μl of 
the medium were diluted 20X using DMEM and used to measure virus concentration 
using a P24 ELISA kit (Perkin Elmer), according to the manufacturer's protocol. Virus 
concentration was determined from a standard graph, and 80 ng of virus was used for 
infection of CHO-ACE2 cells. CHO-ACE2 cells were pre-incubated in DMEM with 1 % 
BSA at 4 °C for 1 h prior to infection at 4 °C for 2 h. After infection, the cells were 
washed 4X using PBS with 1 % BSA and harvested in DMEM, freeze-thawed six times 
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and sonicated for 2 min with 20 sec intervals. Samples were centrifuged at 13,000 rpm to 
remove any cell debris and 200 μl of supernatant was used to determine P24 content 
using the P24 ELISA kit. The concentration of bound virus was then determined using 
the standard graph. 
2.22 Culturing of stable cell lines  
Vero E6 cells were transfected with 10 μg of pEGFP-8b by electroporation and 
plated onto a 100 mm dish. Medium containing 2 mg/ml G418 (Invitrogen) was added 24 
h post-transfection and cells were cultured for 3 to 5 days. Colonies of cells were picked 
and transferred into individual wells in a flat-bottomed 96-well plate and cultured for 5 
days before transferring into a 24-well plate. After 3 to 5 days, cells were split into two 
60 mm dishes for screening and freezing down. Positive clones were re-thawed and 
grown in a T75 flask for experiments. 
2.23 SARS-CoV infection and titration 
Vero E6 cells, stably expressing GFP-8b and GFP, grown in 24-well plates were 
infected with SARS-CoV (Frankfurt strain 1) at M.O.I. of 0.1. At 1 hpi, the cells were 
washed twice and fresh medium was added. After 24 hpi, the virus supernatant was 
harvested and titration of progeny virus was carried out on a 96-well plate containing 
fresh Vero E6 cells as described previously (Akerstrom et al., 2005). At 48 hpi, the 
amount of virus, determined as the 50 % tissue culture infectious dose (TCID50), was 
calculated from the cytopathic effect induced in cell culture by serial ten-fold dilutions of 
the harvested virus. 
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2.24 Northern blot analysis  
Total RNA from 293T cells transfected as described above was extracted using 
the RNeasy mini kit (Qiagen) by following the protocol supplied by the manufacturer. 
The final RNA pellet was re-suspended in diethyl pyrocarbonate-treated water and 
quantified by measuring absorbance at 260 nm. 15 μg of total RNA was separated on 1.2 
% denaturing agarose-formaldehyde gel (containing ethidium bromide), transferred 
overnight in 1X saline-sodium citrate (SSC) buffer to nylon membranes Hybond N+ 
(Amersham Biosciences). The blot was dried at room temperature for 30 min and baked 
at 80 °C for 30 min. The blot was then pre-hybridized with salmon testes DNA (Sigma) 
in hybridization buffer containing 6X SSC, 2X Denhardt's Reagent and 0.1 % SDS for 2 
h. The E gene cDNA fragment was cloned into the TA cloning vector pCRII-TOPO 
(Invitrogen) and linearized with Hind III restriction enzyme. Probes were generated from 
the linearized plasmid using T7 polymerase from the DIG RNA labeling kit (Roche). 
Hybridization was performed overnight at 68 °C with the DIG-labeled probe in the 
hybridization buffer.  
After hybridization, the blot was washed once for 20 min in 1X SSC buffer with 
0.1 % SDS followed by 3 washes, each 30 min, in 0.2× SSC with 0.1 % SDS. All washes 
were performed at room temperature. The blot was then probed with alkaline 
phosphatase-conjugated anti-digoxigenin antibody and developed using 
chemiluminescence substrate CSPD (DIG luminescent detection kit; Roche). This was 
performed according to the manufacturer's protocol and the results were obtained by 
autoradiography. RNA ladders from Fermentas Life Sciences (Ontario, Canada) were 
used for size determination of mRNA. 
 58 
2.25 Reverse transcription reaction  
Total RNA were extracted from cells harvested from 60 mm dishes using the 
RNAeasy Mini Kit (Qiangen) using the manufacturer’s protocol. The concentrations of 
the RNAs were measured at 260 nm using a Nanodrop spectrophotometer. 5 µg of total 
RNAs were mixed with 10 µM oligo-dTs or specific primers and 1 μl of RNase inhibitor 
(40 U/ml), followed by incubation at 65 °C for 10 min. For synthesizing cDNAs, 1 μl of 
dNTPs (New England Biolabs) and Reverse Transcriptase (Invitrogen) were added to the 
above mixture and incubated at 42 °C for 1 h. 
2.26 Microarray analysis 
Human genome-wide gene expression was examined with the GeneChip Human 
Genome U133 Plus 2.0 Array (Affymetrix Inc., Santa Clara, CA), which is composed of 
more than 54,000 oligonucleotide probe sets interrogating approximately 47,000 unique 
transcripts, including 38,500 well-characterized human genes. GeneChip hybridization, 
data acquisition and analysis were performed according to the standard protocols 
available from Affymetrix. In brief, total RNAs of the stable cell lines (GFP-8b, GFP-8b* 
and GFP) were extracted using the RNeasy mini kit (Qiagen, Valencia, CA). Single 
stranded cDNA was synthesized from 10 µg of total RNA with the SuperScript II 
Reverse Transciptase (Invitrogen). By using the Affymetrix-defined comparison 
mathematical algorithms, the difference in mRNA levels between the GFP-8b stable cell 
line and another GFP-8b stable clone, named as GFP-8b*, was calculated. For genes that 
showed at least 2-fold higher or lower expression in GFP-8b cells than GFP-8b* cells, 
real-time quantitative PCR was performed. 
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2.27 Real-time quantitative PCR 
Real-Time PCR was performed from reverse-transcribed cDNA samples of GFP-
8b, GFP-8b* and GFP cells. Probes and primers for the 16 genes that were identified to 
be up-regulated or down-regulated by GFP-8b (Table 1) were obtained from Applied 
Biosystems. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe and primers 
were obtained from Applied Biosystems to be used as loading control. Real-time PCR 
was performed with the ABI 7500 Fast Real-Time PCR system. Quantification of the 
PCR signals was performed by normalizing the cycle threshold value of each sample in 
triplicate with the cycle threshold values of the GAPDH reference gene. 
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CHAPTER 3: NEUTRALIZING ANTIBODIES AGAINST SARS-CoV 
 
3.1 Characterization of rabbit polyclonal antibodies against SARS-CoV S 
3.1.1 Generation of rabbit polyclonal antibodies against different regions of S 
To determine the regions on SARS-CoV S that can elicit strong neutralizing 
antibodies, we expressed five fragments of S (SΔ1, SΔ2, SΔ3, SΔ9, and SΔ10) 
encompassing the entire S ecto-domain in Escherichia coli and used the purified antigens 
to generate polyclonal antibodies (Fig. 3.1). Enzyme cleavage studies have shown that 
SARS-CoV S is cleaved by trypsin into the S1 and S2 domains at residue R667 while 
cathepsin L cleaves the S1-S2 junction at residue T678 (Bosch et al., 2008b; Li et al., 
2006) (Fig. 3.1).  
Of the five fragments of S that we have designed, two fragments spanned the S1 
domain (SΔ1 and SΔ3), two fragments spanned the S2 domain (SΔ9 and SΔ10), and one 
fragment contained a portion of both S1 and S2 domains (SΔ2) (Fig. 3.1). Of note, SΔ3 
contains the RBD while SΔ9 and SΔ10 include the HR1 and HR2 regions, respectively. 
The RBD has been shown to be essential for virus attachment to host cells via its 
interaction with the ACE2 receptor while the highly conserved HR1 and HR2 domains 




Fig. 3.1: Schematic diagram showing the different regions of S encoded by the plasmids 
used in this study. Full-length S with the RBD, heptad repeat regions HR1 (aa 891 to 975), HR2 
(aa 1148 to 1193) and several important sites are shown. Regions representing the five bacterial-
expressed proteins (SΔ1, SΔ2, SΔ3, SΔ9, and SΔ10) used to generate the antibodies are indicated 
by the arrows on top. The numbers at each end of the arrows represent the positions of the amino 
acid residues in the S. 
 
3.1.2 Detection of denatured form of SARS-CoV S by Western blotting.  
Western blot analysis was used to determine the sensitivity and specificity of the 
antibodies for full-length S that was expressed in mammalian Cos7 cells. As predicted, 
anti-S antibodies in the serum of a patient (P6) who has recovered from SARS-CoV 
infection could detect both the 140 kDa unglycosylated form and the 200 kDa 
glycosylated form of full-length S expressed in transfected Cos7 cells (Fig. 3.2, lane 1). 
These are specific bands for S, as they were not detected in mock-transfected cells (Fig. 
3.2, lane 2) or when probed using serum from a healthy donor (Fig. 3.2, lanes 13 and 14). 
We observed similar results with the antibodies that we raised against the five S fusion 
proteins (Fig. 3.2, lanes 3, 5, 7, 9, and 11). No specific bands were detected in mock-
transfected cells (Fig. 3.2, lanes 4, 6, 8, 10, and 12) and by pre-immune sera from the 
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generated against the five S fragments could bind specifically to the linearized full-length 
S under denaturing conditions. 
 
 
Fig. 3.2: Western blot analysis for the detection of SARS-CoV S. Cos7 cells were transfected 
with plasmid pKT-S (lanes 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23) or empty vector as a 
negative control (lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). Cell lysates were separated in 
10% SDS-PAGE gel. Western blotting was performed with the anti-sera, pre-immune sera, and 
control serum indicated at the top of each gel. Arrowheads (left) indicate molecular masses (in 
kilodaltons) of specific S proteins. Membranes were re-probed with mouse anti-actin to be used 
as the loading control. High-range Rainbow molecular weight markers (right; Amersham) were 
used. α, anti. 
 
3.1.3 Detection of the recombinant form of S in transfected cells  
Immuno-precipitation experiments were carried out using the various antibodies 
to determine the specificity of the antibodies for their respective target regions in the S 
protein. Lysates of Cos7 cells infected with vTF7-3 vaccinia virus and transfected with 
plasmids encoding S or S mutant proteins with C-terminal deletions (pKT-SΔ11, pKT-
SΔ12, pKT-SΔ13, pKT-SΔ14, pKTSΔ15, and pKT-SΔ16) (Fig. 3.3) were immuno-
precipitated with P6 serum and the five generated polyclonal antibodies (Rabbit α-SΔ1, 
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α-SΔ2, α-SΔ3, α-SΔ9, and α-SΔ10). The SARS-CoV full-length S protein and all the 
recombinant S proteins with C-terminal deletions were immunoprecipitated by the P6 
serum, rabbit α-SΔ1, α-SΔ2 and α-SΔ3 (Fig. 3.3A-C, F). Antibodies targeting SΔ9 only 
detected full-length S and SΔ11 to SΔ15 proteins but not SΔ16 as it does not comprise of 
the SΔ9 region (Fig. 3.3D). Antibodies targeting SΔ10 only detected the proteins 
expressed by pKT-S and pKT-SΔ11 to pKT-SΔ13 (Fig. 3.3E). The regions expressed by 
pKT-SΔ14 to pKT-SΔ16 do not contain the SΔ10 region and thus, rabbit α-SΔ10 did not 
detect any bands in these lanes, indicating that these antibodies are highly specific to their 
target regions. 
As expected, the sizes of the S mutants decreased from SΔ11 to SΔ16, as more 
amino acid residues were removed from the C terminus. Two forms of S (~200 and ~210 
kDa) were detected in the lysates of cells transfected with the full-length S construct (Fig. 
3.3A-F, lane 1), representing the Endoglycosidase H (EndoH)-sensitive form and the 
matured EndoH-resistant form of the full-length glycosylated S, respectively (See Fig. 
3.4B, lanes 9 and 10). The 140 kDa unglycosylated form of S (Fig. 3.2, lanes 1, 3, 5, 7, 9 
and 11) was not detected by immunoprecipitation with any of the antibodies used. The 
results suggest that either the 140 kDa unglycosylated S protein was not recognized by 
these antibodies under non-denaturing conditions or it did not accumulate in the pulse-
chase experiments. Taken together, the immunoprecipitation results suggest that the 
protein possesses an epitope(s) which was retained in the non-denaturing conditions that 




Fig. 3.3: Radio-labeled immunoprecipitation. Cos7 cells were transfected with plasmids 
expressing full-length S and the C-terminal truncated S proteins, SΔ11, SΔ12, SΔ13, SΔ14, 
SΔ15, and SΔ16 (lanes 1, 2, 3, 4, 5, 6, and 7) or with a plasmid without an insert as a negative 
control (lanes 8). 
35
S-labeled S proteins were immunoprecipitated with the antibodies indicated 
(top of each autoradiograph) and then separated in 7.5% SDS-PAGE gels. Arrowheads (left), 
molecular masses (in kilodaltons) of specific S proteins. High range Rainbow molecular weight 
markers (right; Amersham) were used. α, anti. 
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3.1.4 Detection of the native S protein in virus-infected cells and cultured media 
Using immunoprecipitation, these polyclonal antibodies were further analyzed for 
their ability to bind native S synthesized in SARS-CoV infected cells that were released 
as components of the virions into the cultured medium. As shown in Fig. 3.4A, all 
generated rabbit α-S antibodies can detect S in both cell lysates (top, lanes 2, 6, and 10; 
bottom, lanes 2 and 6) and media (top, lanes 4, 8, and 12; bottom, lanes 4 and 8). S was 
not detected in lysates and media of mock-infected cells (lanes 1, 3, 5, 7, 9, and 11) or in 
infected cells and medium when probed with rabbit pre-immune serum for detection (lane 
9-12). S detected in the media had a slightly larger size than S detected in cell lysates, 
suggesting that the glycosylated S protein had undergone maturation from the 200 kDa to 
the 210 kDa forms in the cells and that only the fully matured form of S (210 kDa) was 
assembled into the virion. These results confirmed that all the generated antibodies are 
specific for the native S in virus-infected cells and virus particles. 
3.1.5 Maturation of S from EndoH-sensitive to EndoH-resistant form  
Two bands specific for S were observed in the immunoprecipitation experiments 
(Fig. 3.3A-F, lanes 1). It is hypothesized that the 210 kDa band represents the mature 
glycosylated S protein while the 200 kDa band is the immature glycosylated S protein. 
To investigate the maturation of S, we carried out a pulse-chase labeling experiment. 
Cos7 cells infected with vaccinia virus vTF7-3 and transfected with pKT-S were radio-
labeled with [
35
S] Met-Cys and chased with cold Met-Cys for 0.5, 1, 2, 4, and 6 h, 
followed by immunoprecipitation with rabbit anti-SΔ10.  
The results showed a gradual increase in the amount of 210 kDa protein 
accompanied by a gradual decrease in the amount of 200 kDa protein (Fig. 3.4B, lanes 1 
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to 8). The yield of 200 and 210 kDa proteins decreased after chasing for 4 h due to cell 
death caused by vTF7.3 infection but the ratio of 210 to 200 kDa protein increased. 
Immunoprecipitation was performed with all the other anti-sera (rabbit α-SΔ1, α-SΔ2, α-
SΔ3, and α-SΔ9), and the same results were obtained (data not shown). To provide more 
evidence to support our findings, an EndoH treatment experiment was carried out to 
determine whether the bands were sensitive to EndoH. The radio-labeled cell lysates 
described above were immunoprecipitated with rabbit α-SΔ10 and treated (or mock 
treated) with EndoH enzyme. Results showed that the 210 kDa protein was EndoH-
resistant while the 200 kDa protein was EndoH-sensitive (Fig. 3.4B, lanes 9 and 10). 
Hence, the results demonstrated the maturation of S from the 200 kDa EndoH-sensitive to 
the 210 kDa EndoH-resistant forms. Other antibodies (rabbit α-SΔ1, α-SΔ2, α-SΔ3, and 
α-SΔ9) could also recognize both the immature and mature forms of the S glycoprotein 
(data not shown). 
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Fig. 3.4: Detection of the different forms of S in virus-infected cells and virions. (A) 
Immunoprecipitation of S in cell lysate and media of virus-infected Vero E6 cells. Vero E6 cells 
in 60 mm dishes were infected (lanes 2, 4, 6, 8, 10, and 12) with SARS-CoV at a MOI of 5 or 
mock infected (lanes 1, 3, 5, 7, 9, and 11). Cells were radio-labeled 5 h post-infection with 
[
35
S]Met-Cys for 1 h and chased with medium containing 4 mM Met-Cys for 3 h. Cells (lanes 1, 
2, 5, 6, 9, and 10) and media (lanes 3, 4, 7, 8, 11, and 12) were harvested with 1X or 1/5 volume 
of 5X lysis buffer, respectively. Samples were immunoprecipitated with anti-sera and pre-
immune serum as indicated and then separated in 7.5% SDS-PAGE gels. The S-specific bands are 
indicated on the right. (B) Time-course of S maturation. Cos7 cells transfected with pKT-S were 
radio-labeled and chased for 0, 0.5, 1, 2, 4, and 6 h (lanes 1, 2, 3, 4, 5, 6, and 7). Cos7 cells 
transfected with a plasmid without an insert were harvested at 6 h as a negative control (lane 8). 
All the cell lysates were immunoprecipitated with rabbit α-SΔ10 antibodies and then separated in 
7.5% SDS-PAGE gels. In a separate experiment, the immunoprecipitated proteins (6 h post-
transfection) were treated (+) with EndoH (lane 10) or untreated (-) as a control (lane 9). The S-
specific bands and their molecular masses (in kilodaltons) are indicated on the right. High-range 
rainbow molecular weight markers (left; Amersham) were used. α, anti. 
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3.1.6 Detection of SARS-CoV S on surfaces of Cos7 cells  
 To provide further evidence that the antibodies raised against the five fusion 
proteins were able to recognize S, we performed indirect immunofluorescence 
experiments under non-permeabilized conditions. After infection with vTF7-3 vaccinia 
virus and transfection with pKT-S, sufficient time (8 h post-transfection) was allowed for 
S to be expressed and transported to the cell surface. Mature S can exist in trimeric or 
oligomeric forms on the cell surface, and these were clearly detected by any of the 
antibodies generated against the various S fragments (Fig. 3.5, top row). The results 
showed that all the antibodies bound to S on the cell surface, suggesting that these 









Fig. 3.5: S expressed on the surfaces of transiently transfected Cos7 cells. (Top row) Cos7 
cells were transfected with full-length S and visualized under UV light. The green fluorescence 
represents the S protein expressed on the surfaces of Cos7 cells probed with primary antibodies 
rabbit anti-SΔ1 (α-SΔ1), α-SΔ2, α-SΔ3, α-SΔ9, and α-SΔ10, followed by fluorescein 
isothiocyanate-conjugated (FITC) secondary antibodies. (Bottom row) Cos7 cells were mock 
transfected with the empty vector and probed with the antibodies indicated on the left, as control 
experiments, and visualized under UV light. 








3.2 A region in S2 can elicit neutralizing activity 
After confirming that all the antibodies could recognize the native SARS CoV S, 
we further investigated their neutralizing activities. All anti-sera from rabbits injected 
with the various bacterial-expressed S protein fragments were tested for their neutralizing 
activities after each bleed. The bacterial expression system was chosen as it offers a 
cheap and fast way for large production of vaccines. Results for serum obtained from 
rabbits injected with bacterial-expressed SΔ1, SΔ2, SΔ3, and SΔ9 were negative. Sera 
from rabbits injected with SΔ10 but not the pre-immune sera from the same rabbits 
showed neutralizing activities after the fourth injection. Initial tests using SARS-CoV at 
200 TCID50/well showed high titers (1:364) of neutralizing antibodies in all the α-SΔ10 
sera, beginning with serum bled after the 8
th
 injection (Table 3.1). The 16
th
 injection was 
the last booster injection and the rabbits were sacrificed at this stage. The neutralizing 
titer was comparable to, if not higher than, the titers detected in SARS patients. The 
antibody response in SARS patients at 100 TCID50/well ranged between 1:150 to 1:475 
over a period of 210 days (Shi et al., 2004).  
To ascertain the results above, serum samples taken after the 4th, 6th, 8th, 12th, 
14th, and 16th injections of SΔ10 were tested for neutralizing activity using SARS-CoV 
at 1,000 TCID50/well (Table 3.2). Neutralizing activities were found to be as high as 
1:189.2 at l,000 TCID50/well. This result showed that the SΔ10 fragment expressed in E. 
coli covering amino acid residues 1055 to 1192 can stimulate neutralizing antibodies but 
not the other fragments covering all other regions of the ecto-domain of S.  
It was interesting that SΔ10 (aa 1055 to 1192), which contained the HR2 domain, 
could elicit a strong neutralizing response but not SΔ9 (aa 798 to 1055), which covered 
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the HR1 domain. SΔ1, SΔ2, SΔ3, and SΔ9 could possess neutralizing epitopes that are 
conformation or glycosylation dependent and these epitopes could have been impaired in 
the bacterial expression system, which explains the lack of neutralizing activity in 
antibodies raised against these regions. 
 
 
Table 3.1: Neutralizing test at 200 TCID50 per well 
a 
No. of injections before 
bleeding 
Neutralizing titers  in TCID50/ 0.1ml 
b 
(Average of 2 experiments)
 











 Neutralizing tests were done in a 96 well plate at 200 TCID50 per well.  
b




Table 3.2: Neutralizing test at 1000 TCID50 per well 
a
 
No. of injections before 
bleeding 
Neutralizing titers in TCID50/ 0.1ml
 b
 
(Average of 2 experiments) 















 Neutralizing tests were done in a 96 well plate at 1000 TCID50 per well.  
b




3.3 Generation of monoclonal antibodies (mAbs) against SΔ10 region 
To identify linear neutralizing epitopes and characterize functional domains in S 
bearing the residues 1029 to 1192, mAbs were generated against this region. By using 
bacterially-expressed S fragment GST-SΔ10 as an antigen, BALB/c mice were 
immunized and boosted up to four times. Sera were collected one week after each booster 
injection and tested for the presence of specific antibodies by Western blot analysis. An 
antibody response was observed after the first booster injection (at a serum dilution of 
1:1,000) (data not shown), indicating that the GST-SΔ10 fragment was highly 
immunogenic in terms of inducing antibodies in mice.  
After hybridoma fusion and hypoxyanthine-aminopterin-thymidine selection, 
culture supernatants of individual clones were screened by ELISA using a C-terminal 
His-tagged S protein fragment (SΔ10-His) covering the same region of S. This eliminated 
clones that reacted to GST antigenic determinants. Out of the 125 ELISA-positive 
hybridomas, 94 were positive in Western blot screening using the full-length S protein 
prepared in a vaccinia-T7 expression system in Cos7 cells as previously described. These 
hybridomas were passaged twice and the supernatants were re-tested in Western blot 
assays. The results showed that 48 out of 94 hybridomas were stably secreting specific 
monoclonal antibodies. Among them, eight hybridomas which produced a higher 
concentration of mAbs in their supernatants were sub-cloned and used to generate ascitic 




3.4 Characterization of monoclonal antibodies 
3.4.1 Detection of S by mAbs in SARS-CoV infected cells  
To confirm the binding specificity of mAbs to the S protein, all the monoclonal 
antibodies generated were used to detect S in virus-infected Vero E6 cells. As shown in 
Fig. 3.6A, the mAbs could detect the 210 kDa S in infected (lanes 2, 4, 6, and 8) but not 
mock-infected (lanes 1, 3, 5, and 7) cells. The results demonstrated that the mAbs were 
specifically binding to S in SARS-CoV infected cells. The mAbs against the SΔ10 region 
could recognize the full-length S protein synthesized in virus-infected Vero E6 cells 
which is consistent with previous results obtained using rabbit anti-SΔ10 polyclonal 
antibodies. 
3.4.2 Mapping of binding sites of monoclonal antibodies  
To determine the binding sites of the mAbs, eight internal deletion mutant 
plasmids were constructed, expressed in Cos7 cells, and used to determine the linear 
binding sites of mAbs by Western blot analysis. Each of these constructs encodes a S 
mutant protein with a 20 or 22 residue deletion (20 to 22 residues shorter than the full-
length S). The positions of the deleted amino acid residues are indicated in Table 3.3. The 
binding sites of the eight mAbs were mapped, and the results are shown by representative 
gels in Fig. 3.6B. Both the glycosylated and unglycosylated forms (bottom gel, lanes 1 to 
8) of each mutant protein (SΔ50 to SΔ57) were detected using rabbit α-SΔ10 serum. 
These were S-specific bands, as no bands were detected in mock-transfected cells (lane 
9). In contrast, S encoded by one or two mutant constructs were not detected by each of 
the four types of mAbs. Therefore, these mAbs bound to residues that were deleted in the 
corresponding internal-deletion mutants.  
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In summary, we classified the antibodies according to their binding sites as the 
type I, II, III, and IV mAbs that bound to residues 1091 to 1130, 1111 to 1130, 1151 to 
1170, and 1151 to 1192, respectively (Table 3.4). The results showed that residues 1091 
to 1192 of the SΔ10 fragment harbor the major antigenic epitopes, but not the residues 
1029 to 1090. Antigenic site I (1091 to 1130) overlapped with site II (1111 to 1130), 
while antigenic site III (1151 to 1170) overlapped with site IV (1151 to 1192) (Fig. 3.7). 
Despite the overlap, each site may represent an epitope that is distinct from the other. It 
seems that these antigenic sites were immuno-dominant within the SΔ10 region (residues 
1029 to 1192). 
 
 
Fig. 3.6: Detection of S by mAbs in virus-infected cells and mapping the binding sites of the 
mAbs (A) Vero E6 cells were infected with SARS-CoV at an MOI of 1 (lanes 2, 4, 6, and 8) or 
mock infected (lanes 1, 3, 5, and 7) for 24 h. Cell lysates were separated on 10% SDS-PAGE gels 
and analyzed in Western blots using mAbs 2B2, 1A9, 4B12, and 1G10. Molecular weight 
markers are indicated to the left. Position of S is indicated by an arrowhead. (B) The S mutants 
(lanes 1 to 8, SΔ50 to SΔ57) with an internal 20- or 22-residue deletion were synthesized in a 
vaccinia-T7 expression system in Cos-7 cells. Cell lysates were separated on 10% SDS-PAGE 
gels and analyzed in Western blots using type I, II, III, and IV mAbs and polyclonal antibody 
rabbit α-SΔ10 as indicated to the right of the gels. Mock-transfected cell lysate (lane 9) was used 
as a negative control (Cont.). Molecular weight markers are indicated to the left. 
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  deleted 
      
SΔ50  1029-1050 
SΔ51  1050-1070 
SΔ52  1071-1090 
SΔ53  1091-1110 
SΔ54  1111-1130 
SΔ55  1131-1150 
SΔ56  1151-1170 
SΔ57  1171-1190 
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3.4.3 In vitro neutralization of virus infectivity by mAbs 
Ascitic fluids of the eight mAbs, all of which are of the immunoglobulin isotype 1 
(IgG1), were prepared and antibody concentrations of the crude preparations were 
determined (Table 3.4). The ascitic fluids were diluted 10 times and then two-fold serial 
dilutions were prepared. Neutralization assays were performed in 96-well plates by 
incubating equal volumes of diluted antibodies and virus suspension containing 10 
TCID50/well for 1 h at 37 °C before adding the mixture to confluent Vero E6 cells in the 
wells. After 3 days, complete cytopathic effect (CPE) was observed in all control wells 
containing the virus suspension in the absence of antibodies and in wells containing anti-
dengue mAb (non-SARS-CoV related) or a non-neutralizing mAb, 7G12-6, which targets 
amino acid residues 281 to 300 of S. All the ascitic fluids were not toxic to the cells at the 
starting concentration used. The neutralizing titers were expressed as reciprocal of the 
final dilution of antibodies required to completely protect cells in 50% of the wells (no 
CPE observed) from virus infection. As shown in Table 3.4, all four types of mAbs 
showed neutralizing activity with titers ranging from 24 to 75 at mAb concentrations 
ranging from 13 to 100 μg/ml. 
Table 3.4: In vitro neutralizing activities of mAbs 
mAb        mAb type  Isotype Titers       IgG (μg/ml) 
 
2B2  I  IgG1  40  50 
2G2  I  IgG1  47  85 
1A9  II  IgG1  28  35 
1C6  III  IgG1  24  83 
1H1  III  IgG1  40           100 
6B9  III  IgG1  24  42 
4B12  III  IgG1  47  42 
1G10  IV  IgG1  75  13 
7G12  -  IgG1  0  50 
Anti-dengue -  IgG1  0  50
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3.5 Understanding the mechanism of neutralization by mAbs 
3.5.1 Neutralizing mAbs bind to regions upstream of and within the HR2 domain  
The amino acid sequence of the region (residues 1091 to 1192), which the four 
types of mAbs target, were aligned with corresponding S regions of other coronaviruses 
(Fig. 3.7). The HR2 domain of the SARS-CoV S has been predicted to be located within 
residues 1125 to 1193 or 1144 to 1191 (Bosch et al., 2004; Xu et al., 2004b). Therefore, 
the upstream region from residues 1091 to 1124 or 1143 is considered to be a part of the 
spacer region between HR1 and HR2. As shown in Fig. 3.7, type I and II mAbs bound to 
the spacer region immediately upstream of HR2, residues 1091 to 1131 and 1111 to 1131 
respectively. Type III and IV mAbs bind directly to the HR2 domain (residues 1151 to 
1192). These results suggest that the HR2 domain and the spacer region immediately 















Fig. 3.7: Clustal W multiple sequence alignment of coronavirus S proteins. The S region 
corresponding to the binding sites of mAbs to SARS-CoV (Singapore strain 2774) is aligned with 
the group 1 coronaviruses feline infectious peritonitis virus (FIPV) and human coronavirus 229E 
(HCoV-229E), the group 2 coronaviruses HCoV-OC43 and MHV-59A (mouse hepatitis virus), 
and the group 3 coronavirus infectious bronchitis virus (IBV) (GenBank accession numbers 
AY283798, VGIH79, VGIHHC, CAA83661, VGIH59, and M95169, respectively). The shading 
indicates sequence identity and similarity. The predicted HR2 region and upstream spacer region 
and binding sequences of type I, II, III, and IV mAbs are shown by arrows and lines. 
FIPV      1274 
HCoV-229E  997 
HCoV-OC43 1204 
MHV-A59   1160 
IBV        992 
SARS-CoV  1091 
FIPV      1335 
HCoV-229E 1057 
HCoV-OC43 1265 
MHV-A59   1221 
IBV       1054 







Part of spacer region between HR1 and HR2 
Type I MAb (1091-1130) 
Type II MAb (1111-1130) 
Type III MAb (1051-1170) 









3.5.2 Inhibition of S-induced cell-cell membrane fusion by mAbs  
During virus entry into cells, the HR1 and HR2 domains interact with each other 
and a subsequent conformational change triggers virus-cell membrane fusion. To test if 
the antibodies targeting this functional region could interfere with HR1 and HR2 
interaction and block membrane fusion, a cell-cell membrane fusion assay was 
developed. 293T cells infected with recombinant vaccinia virus, rVV-L-SP, expressing S 
proteins (293T-SP), and CHO-ACE2 cells stably expressing receptor ACE2 were used in 
this assay.  
First, FACS analysis was performed to verify that S and ACE2 were expressed on 
the cell surface of 293T-SP and CHO-ACE2 cells respectively, under non-permeabilizing 
conditions. 293T-SP cells were incubated with rabbit α-SΔ10 primary antibodies, and 
CHO-ACE2 cells were incubated with goat α-ACE2 primary antibodies. The cells were 
subsequently incubated with FITC-conjugated goat anti-rabbit or rabbit anti-goat IgG 
secondary antibodies. As shown in Fig. 3.8A (left), FITC fluorescence intensity measured 
for CHO-ACE2 was higher than that for control cells CHO, indicating expression of 
ACE2 proteins on the surface of CHO-ACE2 cells. As shown in Fig. 3.8A (right), FITC 
fluorescence measured for 293T-SP was higher than that for control cells (293T-NP) 
expressing the N (nucleocapsid) protein of SARS-CoV, indicating expression of S on 
293T-SP cells.  
To investigate if the epitopes upstream of HR2 (types I and II) and within HR2 
(types III and IV) are exposed and accessible to specific antibodies, eight mAbs of 
interest (1:20) or an unrelated anti-dengue mAb was incubated with 293T-SP cells. The 
cells were subsequently incubated with FITC-conjugated goat anti-mouse IgG secondary 
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antibodies, and the interaction between the mAbs and S was measured by FACS analysis. 
In Fig. 3.8B, a representative histogram for each type of mAb (type I mAb, 2B2; type II 
mAb, 1A9; type III mAb, 4B12; type IV mAb, 1G10) is shown. Generally, FITC 
fluorescence intensity measured for each mAb was significantly higher than that for 
control anti-dengue mAb, suggesting that the four target epitopes on S were exposed and 
accessible to their specific antibodies.  
Next, a cell-cell membrane fusion assay was set up to observe syncytium 
formation. 293T-SP or 293T-NP cells transfected with pEGFP-N1 (expressing green 
fluorescent protein [GFP]) was incubated with either target CHO-ACE2 or normal CHO 
cells. A representation of the morphology of normal cells and cells that have undergone 
cell-cell fusion is shown in Fig. 3.8C. Syncytium formation (10 or more cells fused 
together) as a result of the interaction between S and ACE2, expressed on the surfaces of 
293T-SP and CHO-ACE2 cells, was displayed in bright field (top row, left), dark field 
under UV excitation (top row, right), and a combined view (top row, center). In contrast, 
no syncytium was observed when control cells, 293T-NP, were incubated with CHO-
ACE2 (Fig. 3.8C, bottom micrographs). In Fig. 3.8C (bottom micrographs), individual 
cells were distinguishable with a clear cell boundary in the bright field view (left) and as 
single spots of green fluorescence in the dark field view (right), in contrast to the lack of 
cell boundaries and massive bodies of green fluorescence as shown in Fig. 3.8C (top 
micrographs). 293T-SP cells incubated with normal CHO cells did not yield any syncytia 
in the fusion experiments (data not shown). Only fusion experiments consisting of 293T-
SP cells and CHO-ACE2 cells could form syncytia. These results confirmed that the cell-
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cell membrane fusion was induced by S and was dependent on the receptor ACE2 (Li et 
al., 2003b; Simmons et al., 2004; Sui et al., 2004).  
In order to investigate the inhibition of syncytium formation by specific 
antibodies, all the antibodies were incubated in the cell-cell membrane fusion assay at 
different dilutions of 1:40, 1:80, and 1:160. Rabbit α-SΔ10 serum and goat α-ACE2 
antibody were included as positive controls and rabbit pre-immune serum and anti-
dengue mAb were included as negative controls. As shown in Fig. 3.9A, syncytium 
formation was not observed in the presence of 1:40 diluted rabbit α-SΔ10 serum (top 
right) or mAb1A9 (bottom right). No syncytium formation was also observed in the 
presence of goat anti-ACE2 antibody (data not shown). In contrast, as shown in the left 
panels of Fig. 3.9A, large syncytia were observed in the presence of 1:40 non-inhibiting 
rabbit pre-immune serum (top left) or anti-dengue mAb (bottom left).  
Next, the distribution of the number of nuclei per syncytium was scored. It was 
found that syncytia formed from 10 or more cells accounted for at least 90 % of all 
potential syncytia scored (data not shown). Only syncytia with 10 nuclei or more were 
counted in order to eliminate artifacts scored as a result of cell division or abnormal cell 
clumping and to avoid difficulty in identifying syncytia of small sizes. The number of 
syncytia was then scored and the percentage of syncytium formation inhibition at 
different antibody dilutions is summarized in Fig. 3.9B. At a 1:40 dilution, all the mAbs 
inhibited more than 50% of syncytia formation. However, syncytia inhibition decreased 
significantly when each mAb was serially diluted from 1:40 to 1:80 and 1:160. The 
formation of syncytia was inhibited in a dose-dependent manner, indicating that the 

















Fig 3.8: FACS analysis of the surface expression of the S and ACE2 and syncytium 
formation assay. (A) Left, ACE2 surface expression on CHO-ACE2 stable cells (solid line) and 
negative control CHO cells (dotted line) was probed with goat anti-ACE2 primary and FITC-
conjugated anti-goat IgG secondary antibodies. Right, S surface expression (solid line) and N 
expression (dotted line; negative control) on 293T cells were probed with rabbit α-SΔ10 primary 
and FITC-conjugated anti-rabbit IgG secondary antibodies. (B) 293T-SP were probed with four 
representative mAbs of interest and an unrelated anti-dengue MAb, followed by FITC-conjugated 
anti-mouse IgG secondary antibodies. Top left panel, S was probed with type I mAb 2B2 (solid 
line) and anti-dengue mAb (dotted line). Top right panel, S was probed with type II mAb 1A9 
(solid line) and anti-dengue mAb (dotted line). Bottom left panel, S was probed with type III mAb 
4B12 (solid line) and anti-dengue mAb (dotted line). Bottom right panel, S was probed with type 
IV mAb 1G10 (solid line) and anti-dengue mAb (dotted line). (C) Assay is captured in bright 
field (left panel), dark field (right panel), and a combination of both (center panel). Top panel, 
293T cells expressing S and GFP were mixed with CHO-ACE2 cells expressing ACE2. Bottom 
panel, 293T cells expressing N and GFP were mixed with CHO-ACE2 cells expressing ACE2 as 


































Fig 3.9: Dose-dependent inhibition of syncytium formation between 293T-SP and CHO-
ACE2 cells. (A) Top panel, incubation with rabbit pre-immune serum (left) and rabbit α-S10 
polyclonal antibody (right) at 1:40 dilution. Bottom panel, incubation with mouse α-dengue 
ascitic fluid (left) and mouse mAb 1A9 (right) at a 1:40 dilution. Micrographs were taken at a 
10X magnification. (B) Percentage of inhibition of syncytium formation between 293T-SP cells 
and CHO-ACE2 cells, in the presence of antibodies at 1:40 (blue), 1:80 (white), and 1:160 



































The coronavirus S is a major determinant of tissue tropism by mediating binding 
to cellular receptors and virus-cell membrane fusion. For SARS-CoV, various studies 
have shown that antibodies targeting S can provide immunity against the virus (Bisht et 
al., 2004; Buchholz et al., 2004; Bukreyev et al., 2004; Hofmann et al., 2004a; Sui et al., 
2004). In this study, we generated rabbit polyclonal antibodies against five S fragments 
expressed in Escherichia coli in order to identify linear neutralizing epitope(s) on S. 
Interestingly, it was shown that the antibodies can recognize the denatured and 
recombinant form of S, as well as the native S expressed in SARS-CoV infected cells that 
was later incorporated into virions detected in the medium (Fig 3.2, 3.3 and 3.4A, 
respectively). It is likely that the proteins used for immunization maintained a certain 
degree of conformation or that the antibodies recognize linear and exposed epitope(s) in 
the native conformation of S. It was also shown that the antibodies could bind to both the 
EndoH-sensitive (200kDa) and EndoH-resistant (210kDa) forms of S (Fig. 3.4B). 
Immuno-fluorescence experiment results further confirmed that all the antibodies could 
recognize the glycosylated mature S expressed on the cell surface (Fig. 3.5).  
Neutralization assays showed that antibodies targeting GST-S 10 were capable of 
neutralizing SARS-CoV replication in Vero E6 cells at a titer of 1:364 at 200 TCID50 
(Table 3.1), which is comparable to the level obtained from convalescent patients (Shi et 
al., 2004). As shown in Tables 3.1 and 3.2, rabbit α-S 10 antibodies showed a steady 
increase in neutralizing titers with more booster immunizations but none of the antibodies 
targeting the other four fragments showed neutralizing activity. While it has been shown 
that the antibodies targeting the RBD have potent neutralizing activity, our antibodies 
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against the GST-S 3 fragment (bearing the RBD) showed no neutralizing activity (Sui et 
al., 2004). It is possible that the RBD is heavily glycosylated and/or contains rigid tertiary 
structure under native conditions that is not recognized by the α-S 3 antibodies. Hence, 
our results showed that the region from residues 1055 to 1192, but not residues 48 to 
1055, is suitable for the development of vaccines that are peptide-based or based on non-
mammalian systems that do not mimic the protein glycosylation and folding processes 
that occur in mammalian cells. 
Interestingly, S 10 encompasses the loop region between HR1 and HR2 domain, 
as well as the N-terminal of the HR2 domain. HR1 (residues 891 to 975) and HR2 
(residues 1195 to 1223) have been shown to play crucial roles in forming a six-helix 
bundle that is essential for the virus-cell membrane fusion process (Gallagher and 
Buchmeier, 2001). Our results are consistent with several studies that showed that 
peptides mimicking the HR2 region could block SARS-CoV infection (Bosch et al., 
2004; Yuan et al., 2004; Zhu et al., 2004). 
To investigate the mechanism of neutralization of SARS-CoV infection by α-
S 10 antibodies, we generated eight mAbs against this region and mapped their binding 
sites using S deletion mutants (Fig. 3.6B). The results showed that the antigenic sites 
recognized by the mAbs could be narrowed down to residues 1091 to 1130 and 1151 to 
1192, suggesting that these regions may be immuno-dominant in the humoral immunity 
against S 10. The results also demonstrated the neutralizing activity of the eight mAbs 
(Table 3.4). However, the titers of the eight mAbs targeting the S2 region were lower 
than the mAbs that target the RBD of SARS S (Chou et al., 2005; Sui et al., 2004). The 
results are consistent with previous findings on murine hepatitis virus (MHV) showing 
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that the neutralizing concentrations of mAbs targeting the S2 region were 3 to 4 orders 
magnitude lower than those targeting the receptor-binding S1 region (Kubo et al., 1993; 
Taguchi and Shimazaki, 2000). Nevertheless, α-S 10 polyclonal antibodies targeting 
multiple epitopes do neutralize SARS-CoV infection more efficiently than each of the 
mAbs, suggesting that the mAbs may act cooperatively or synergistically (ter Meulen et 
al., 2004; Zwick et al., 2005). 
Using a syncytium formation inhibition assay, we showed that all the eight mAbs 
that could neutralize SARS-CoV infection in vitro, could also block syncytium formation 
in a dose-dependent manner (Fig. 3.9B). The structure of the SARS-CoV S protein was 
determined and aa 1150-1184 in HR2 were demonstrated to interact with aa 902-947 for 
the formation of the six-helix bundle, a fusion-competent structure that is observed in all 
type-I viral fusion proteins (Supekar et al., 2004; Xu et al., 2004b). Interestingly, the type 
III and IV mAbs which bind to residues 1151-1170 and 1151-1192 respectively on the 
HR2 domain displayed neutralizing and cell-cell fusion inhibition properties. It is 
possible that the binding of antibodies to the HR2 domain interfere with the interaction 
between HR1 and HR2, disrupting the conformational change and hence abolishing the 
fusion activity. Our results are consistent with other studies demonstrating that peptides 
mimicking aa 1161-1187 (HR2-18), aa 1153-1189 (CP1), aa 1126-1193 (sHR2-8) and aa 
1130-1189 (sHR2-2) of the HR2 domain inhibit the propagation of SARS-CoV (Bosch et 
al., 2004; Liu et al., 2004; Yuan et al., 2004). 
Type I and II mAbs bind to the loop region between the HR1 and HR2 domains 
and their mechanism of neutralization of SARS-CoV remains unknown. One possible 
explanation is that the occupancy of the loop region between the HR1 and HR2 domains 
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interferes with their interaction via steric hindrance, thus abolishing fusion activity. The 
SARS-CoV S possesses a longer loop region (140 to 170 residues) compared to the 
fusion proteins of other enveloped viruses (5 to 26 residues) (Bosch et al., 2003). It is 
postulated that the absence of a spacer region or the very short spacer region between the 
HR2 and trans-membrane domain is compensated by the presence of a longer loop region 
between the HR1 and HR2 domains (Ingallinella et al., 2004). This longer loop region 
may be important in providing the flexibility needed for the trimeric HR1 coiled coil to 
pack together with the three helices of the HR2 in an anti-parallel manner during the six-
helix bundle formation. The loop region that the type I and II mAbs bind is a novel 
neutralizing domain that may facilitate the development of new entry inhibitors. The 
identification of novel neutralizing sites may also provide new targets for the 
development of efficacious vaccines based on peptides mimicking the linear epitope(s). 
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CHAPTER 4: FURTHER CHARACTERIZATION OF THE SARS-CoV 
NEUTRALIZING MONOCLONAL ANTIBODIES 
 
4.1 Sequence comparisons of human and animal SARS-CoV S 
In recent years, co-ordinated efforts were put into determining the parental strain 
of SARS-CoV in the animal reservoirs. After much concerted effort, it was reported by 
Lau et al. that bat SARS-like coronavirus (SL-CoV) Rf1 and Rp3 strains could have 
undergone a recombination event to achieve the civet SARS-CoV SZ3 strain, which in 
turn was transferred to humans during the SARS epidemic (Lau et al., 2010). A 
comparison of the S1 and S2 domains of the three strains (SZ3, Rp3 and Rf1) with the 
human SARS-CoV strain indicates that the S1 domain is less conserved than the S2 
domain (Table 4.1). The S1 domain of the bats Rp3 and Rf1 strains have low sequence 
identity of only 64.3% and 63.6% when compared to the S1 domain of the human 
HK39849 strain while the S2 domains have a high sequence identity of 95.8% and 
92.7%, respectively. 
As mentioned in the previous chapter, the neutralizing mAbs that we have 
generated target the S2 domain. To investigate the cross-neutralizing ability of the mAbs 
against the civet and bat strains, we selected two mAbs (mAb 1A9 and 1G10) that target 
different regions on S. As mentioned earlier, mAb 1A9 targets the loop region between 
the HR1 and HR2 domains while mAb 1G10 targets the N-terminus of the HR2 domain 
(Fig. 3.7). Sequence alignment analysis indicates that the binding site of mAb 1A9 is 
100% conserved while there are two aa differences in the binding region of mAb 1G10 
among the four strains (Fig. 4.1). 
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Table 4.1: Percentage identity of the S protein sequence 
  Protein              Amino acid identity to HK39849 
 
   SZ3  Rp3  Rf1 
 
     S1   98.4%  64.3%  63.6% 











Fig. 4.1: Protein sequence alignment for binding domain of mAbs to S of Human HK39849, 
Civet SZ3, Bats Rp3 and Rf1 coronaviruses. The differences in the protein sequences are 
highlighted in red, while the binding sites for mAbs 1A9 (top) and 1G10 (below) are underlined. 
The number above the amino acid represents the position of the amino acid in the S protein 
sequence. 
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4.2 Cross-neutralization ability of both mAb 1A9 and 1G10 in animal strain S-
mediated cellular entry 
In this study, the receptor-binding domain of S in the bats SL-CoV Rp3 and Rf1 
strains and civet SARS-CoV SZ3 strain were replaced with the RBD of S in the human 
SARS-CoV strain for further investigation using a pseudovirus entry assay. It had been 
demonstrated by Ren et al. that the bat SL-CoV uses a different receptor for entry and 
thus, could not infect cells expressing ACE2 receptors. However, the replacement of the 
receptor binding region on S of these bat SL-CoV can restored their infectivity to cells 
expressing the human ACE2 receptor in a pseudovirus assay (Ren et al., 2008). Using 
Western blot analysis, it was shown that receptor-modified S from all three strains were 
expressed in the transfected 293T cells and could be detected as efficiently as the human 










Fig. 4.2: Detection of receptor-modified S of civet and bat strains. 293T cells were transfected 
with expression plasmid for S(HK39849), S(SZ3), S(Rp3) and S(Rf1) and harvested 24 h post-
transfection. The proteins were detected in Western blot using the mAbs indicated at the top of 
the gel. 
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 To study the efficiency of neutralizing antibodies, peptides and other inhibitors of 
SARS-CoV without the use of live virus, pseudovirus assays using human 
immunodeficiency virus (HIV) vectors were commonly used (Chu et al., 2008b; Ni et al., 
2005; Yuan et al., 2004). These pseudovirus assays not only eliminate the risk of 
laboratory outbreaks but also allow for the study of inhibitors for animal SARS-CoV 
strains that were shown to be difficult to propagate in cell culture.  
Here, a viral entry assay was set up by using pseudoviruses packaged with SARS-
CoV S and CHO-ACE2 cells. The pseudoviruses in this assay are lentiviral pseudotyped 
particles encoding a luciferase reporter and expressing the SARS-CoV S on the surface. 
These pseudoviruses are produced by the co-transfection of 293T cells with plasmids 
pNL4.3-Luc-R-E- and pXJ3’-S, expressing the lentiviral particles and the SARS-CoV S 
respectively. The CHO-ACE2 cells express the receptor, ACE2, for S and mediate the 
entry of the pseudoviruses bearing S into the cells. Luciferase expressed from the 
pseudoviruses that enters the CHO-ACE2 cells were measured using a luminometer. A 
negative control experiment with pseudoviruses not packaged with any envelope protein 
and a positive control experiment with pseudoviruses packaged with the human SARS-
CoV S without any mAbs were set up (Figure 4.3A and B, column 1 and 2 respectively). 
The difference in the luciferase readings between the positive and negative control is set 
as 100 % viral entry. Different concentrations of the mAbs were tested for its inhibitory 
effect on the pseudoviruses packaged with S (human strain). The results showed that 150 
μg/ml of mAb 1A9 or 1G10 reduced S-mediated pseudovirus entry by more than 50% 




Fig. 4.3: Setting up of pseudovirus assay for performing neutralization test with mAbs. 
Pseudovirus packaged with S (HK39849 strain) were measured for the efficiency of entry into 
CHO-ACE2 cells at different mAb 1A9 and 1G10 concentration (100, 150 and 200 μg/ml) in the 
luciferase assay (A and B, respectively). A negative control experiment with empty virus and a 




To investigate whether mAb 1A9 and 1G10 affect the binding of pseudoviruses 
bearing S to CHO-ACE2 cells, we performed a virus binding assay. This assay was 
modified from the method previously described using influenza A viruses (Sui et al., 
2009). To determine if the mAbs can prevent virus attachment, pseudoviruses bearing S 
were allowed to attach to CHO-ACE2 cells at 4 °C for 2 h, in the presence of 150 μg/ml 
of mAb 1A9 or 1G10, before the unbound viruses were washed off. The amount of bound 
viruses to the cells was determined using a P24 ELISA kit. As shown in Fig. 4.4, the 
amount of bound viruses in the presence of both mAb 1A9 and 1G10 were not reduced 
(column 3 and 4, respectively), compared to the control experiment without any mAb 
(column 2). The result suggests that both mAb 1A9 and 1G10 do not affect the binding of 


















Fig. 4.4: Pseudovirus binding assay. Pseudoviruses packaged with S (HK39849 strain) were 
generated by co-transfection of pNL4.3-Luc-R.E. and pXJ3’-S expression plasmids in 293T cells. 
The pseudoviruses in the supernatant were used for infection of CHO-ACE2 cells at 4 °C for 2 h 
in the absence/presence of mAbs and the amount of virus that were bounded to the cells were 
determined using a HIV-1 P24 ELISA kit. 
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Next, the receptor-modified SZ3, Rp3 and Rf1 S were packaged into HIV-1 
pseudoviruses and the entry of the pseudoviruses into the CHO-ACE2 cells were shown 
to be as efficient as the pseudoviruses packaged with the human SARS-CoV S (Fig. 
4.5A). In the presence of varying concentrations (100 to 200 μg/ml) of mAb 1A9 and 
1G10, the extent of mAb inhibition on the different S-mediated entry was measured. 
Results indicate that both the mAb 1A9 and 1G10 inhibit the entry of pseudoviruses 
packaged with human SARS-CoV S as well as the receptor-modified bat and civet SL-
CoV S, in a dose-dependent manner (Fig. 4.5B and 4.5C, respectively). These results 
suggest that both mAb 1A9 and 1G10 have broad neutralizing activities against human 







Fig. 4.5: Cross-neutralization activity of mAb 1A9 and 1G10. (A) Pseudovirus packaged with 
S(HK39849), S(SZ3), S(Rp3) and S(Rf1) were tested for their efficiency of entry in the absence 
of mAb. (B, C) Pseudovirus packaged with S(HK39849), S(SZ3), S(Rp3) and S(Rf1) were 
measured for the efficiency of entry into CHO-ACE2 cells in the presence of different mAb 1A9 
and 1G10 concentrations, respectively, using a luciferase-based assay. 
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4.3 Generation of escape mutant virus of mAb 1A9 and 1G10 
To further delineate the mechanism of neutralizing activity by mAb1A9 and 
mAb1G10, SARS-CoV neutralization escape mutants were generated for the two mAbs. 
The selection concentrations that can reduce the virus titers by more than 3 logarithms 
were determined as 0.25 mg/ml for mAb 1A9 and 0.1 mg/ml for mAb 1G10 (Fig. 4.6A 
and 4.6B, respectively). Following 3 passages in VeroE6 cells in the presence of the mAb 
1A9 or mAb 1G10 selection concentration, the virus replication titer resumed to the level 
observed in the wild-type viruses (Fig. 4.6C and 4.6D, respectively). A plaque 
purification assay was performed and five clones were selected for amplification under 
the selection mAb concentration.  
A neutralization assay was then performed on the HK39849 wild-type viruses and 
the neutralizing concentration for mAb 1A9 and 1G10 were calculated using the Muench-
Reed formulae and determined as 1.5 mg/ml and 0.45 mg/ml, respectively. Following 
that, all the escape viruses were tested for their ability to escape the mAbs neutralizing 
concentration. The results showed that all the five escape virus clones for mAb 1A9 were 
no longer neutralized at the mAb 1A9 neutralizing concentration for the wild-type virus 
but could still be neutralized by mAb 1G10. Similarly, all the five escape virus clones for 
mAb 1G10 were not neutralized at the neutralizing concentration of mAb 1G10 but were 
still neutralized by mAb 1A9. These results indicate that the selected and amplified virus 
clones from the plaque purification were positive SARS-CoV escape mutants against 
their respective selection mAbs. 
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Fig. 4.6: Generation of escape SARS-CoV mutants for mAb 1A9 and 1G10. (A, B) Vero E6 
cells were infected with 100 TCID50 of SARS-CoV in the prescence of a range of dilutions of the 
mAb 1A9 and 1G10 respectively, for 1 h at 37 °C and replaced with fresh medium for incubation 
at 37 °C for two days. The titer of the virus is then determined using a TCID50 assay. The mAb 
concentration that can suppress the virus titer by more than 3 logarithms is ideal as selection 
concentration. (C, D) Escape viruses were passaged for three rounds in the presence of the 
selection concentration of mAb 1A9 and 1G10, respectively. Virus titers were measured after 





4.4 Identifying the mutation(s) on S in the mutant viruses that escaped the 
inhibition by mAb 1A9 and 1G10 
The viral RNAs were extracted for RT-PCR using S specific primers, and the 
cDNAs were cloned into TOPO vector for DNA sequencing of the S gene. Three 
individual mutations (H641Y or T706I and W869L) were identified in the TOPO clones 
of S from the mAb 1G10 escape virus clones while two individual mutations (N1056K 
and D1128A) were identified in the TOPO clones of S from the mAb 1A9 escape virus 
clones (Fig. 4.7). D1128 is found within the binding region of mAb 1A9 while N1056 is 
located upstream of this binding site. H641, T706 and W869 are not located near the 




Fig. 4.7: Schematic diagram showing S with the functional domains and the point mutations 
found in mAb 1A9 and 1G10 escape viruses. The double end arrows represent the binding sites 
of mAb 1A9 and 1G10. The arrows pointing upwards indicate the position of the mutations that 
were found to be commonly identified in the TOPO clones of S from the mAb 1A9 and 1G10 
escape viruses. RBD, receptor binding domain; FP, fusion peptide; HR1, heptad repeats 1 
domain; HR2, heptad repeats 2 domain; TMD, transmembrane domain. 
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4.5 Screening the mutation(s) for positive escape activity 
To verify which of the identified mutations on S contribute to the escape activity 
of the escape viruses, we screened S mutants bearing individual mutations for their entry 
activity into CHO-ACE2 cells using a pseudovirus assay. The results from the 
pseudovirus screening showed that there are only two escape mutations (N1056K and 
D1128A) that exhibited escape activity (Fig. 4.8). Both the mutations were identified in 
mAb 1A9 escape viruses. From the luciferase assay result shown in Fig. 4.8A, both mAb 
1A9 and 1G10 reduced pseudovirus entry by more than 40% at 150 μg/ml, except for 
pseudoviruses packaged with S bearing the N1056K or D1128A mutation. The 
pseudovirus packaged with S bearing the N1056K mutation showed 25% higher 
luciferase activity while pseudoviruses packaged with S carrying the D1128A mutation 
showed 30% higher luciferase activity. No escape activity was detected in S bearing 
mutations identified in the mAb 1G10 escape viruses (Fig. 4.8B). These results showed 
that only two out of the five identified mutations on S contribute to the escape activity of 
the viruses against the mAb used for their selection. 
 
Fig. 4.8: Pseudovirus entry assay. (A) Pseudovirus packaged with wild-type S, S(N1056K), 
S(D1128A) were measured for the efficiency of entry into CHO-ACE2 cells in the presence of 
0.15 mg/ml of mAb 1A9  and 1G10 in the luciferase assay. (B) Pseudovirus packaged with wild-
type S, S(H641Y), S(T706I) and S(W869L) were measured for the efficiency of entry into CHO-
ACE2 cells in the presence of 0.15 mg/ml of mAb 1A9  and 1G10 in the luciferase assay. A 
control experiment without antibody was used for normalization (i.e. it is set to 100%). 
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4.6 Amino acid residues N1056 and D1128 are important for mAb 1A9 
neutralizing activity 
In order to gain a better understanding of the mechanism underlying the escape 
activity of the S mutants bearing N1056K and D1128A, further studies on their binding 
efficiency and escape activity to mAb 1A9 were carried out. An additional S mutant 
bearing the double mutation (N1056A and D1128A) was cloned to examine if the 
mutations were synergistic in their escape activity from mAb 1A9. It was demonstrated 
by Western blot analysis that mAb 1A9 binds to S and S(N1056K) mutant but not as 
efficiently to S(D1128A) and S(N1056K, D1128A) mutants (Fig. 4.9A), indicating that 
mAb 1A9 has a lower binding affinity for the denatured form of the S mutants bearing 
the D1128A mutation. In addition, radiolabelled immuno-precipitations were carried out 
for S and the S mutants to study their interactions, in the native folded form, with mAb 
1A9. The results clearly showed that mAb 1A9 does not bind as well to S bearing the 
D1128A mutation as compared to its interaction with S and S(N1056K), suggesting that 
the native folded state of the S mutant bearing D1128A has a conformation that reduces 
the binding efficiency of mAb 1A9 (Fig. 4.9B).  On the other hand, mAb 7G12-6 that 
binds to the S1 domain can still bind efficiently to the S bearing the D1128A mutation in 
both Western blot analysis and immunoprecipitation assay. 
To confirm specific mAb 1A9 escape activity of the S mutants and investigate the 
synergy between the two mutations (N1056K and D1128A), we performed a dose-
dependent mAb 1A9 inhibition of S-mediated entry using a pseudovirus assay. The 
results showed that all three S mutants can be inhibited by mAb 1A9 in a dose-dependent 
manner but the escape activity of S(D1128A) was much higher than S(N1056K) and 
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S(N1056K, D1128A) showed enhanced escape activity compared to the two single aa 
















Fig. 4.9: Analysis of positive SARS-CoV escape mutations of clones selected with mAb 1A9. 
(A) 293T cells were transfected with expression plasmid for S, S(N1056K), S(D1128A), 
S(N1056K, D1128A) and mock transfected, and detected in Western blot using different mAbs 
indicated at the top of the blot. (B) 293T cells were transfected with expression plasmid for S, 
S(N1056K), S(D1128A), S(N1056K, D1128A) and mock transfected, followed by 
35
[S] 
radiolabeling and immunoprecipitation using the different antibodies indicated on the right. (C) 
Pseudovirus packaged with S, S(N1056K), S(D1128A) and S(N1056K, D1128A) were measured 
for the efficiency of entry into CHO-ACE2 cells at different mAb 1A9 concentration (100, 150 





Only a few studies have been carried out previously to investigate the cross-
neutralizing activities of SARS-CoV neutralizing mAbs due to the difficulties of studying 
the bat SL-CoV, which uses another host molecule as a receptor for entry (Ren et al., 
2008). Several research studies that generated neutralizing antibodies against the receptor 
binding domain of S were also unable to inhibit the bat CoV and early SARS-CoV strains 
(Rockx et al., 2008; Sui et al., 2005). A comparison between bat SL-CoV S and human 
SARS-CoV S suggests that the S2 domain is more highly conserved with more than 90% 
identity while the S1 region has low similarity of slightly more than 60% identity, 
suggesting a higher possibility for a neutralizing mAb targeting the SARS-CoV S2 region 
to be able to neutralize the bats SL-CoV (Table 4.1). In the present study, we showed that 
mAb 1A9 and 1G10, both targeting the S2 domain, can detect receptor-modified civet S 
(SZ3 strain) and bat S (Rp3 and Rf1 strains) (Fig. 4.2) and exhibit cross-neutralizing 
activities (Fig. 4.5B and C, respectively). 
In order to gain a better understanding of the neutralizing mechanism of mAb 
1A9 and 1G10, we generated escape viruses against the mAbs to look for escape 
strategies employed by the viruses against inhibition by the mAbs. We identified two 
mutations in the mAb 1A9 escape clones and three mutations in the mAb 1G10 escape 
clones (Fig. 4.7). The mutations in the mAb 1A9 escape clones were found near or within 
the binding site of the mAb, suggesting that the mechanism of inhibition could be via the 
disruption of binding activity between the mAb and S. The mutations found in the mAb 
1G10 were located further upstream of the HR1 domain, which may indicate an escape 
strategy that changes the HR1 conformation to facilitate interaction with the mAb-bound 
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HR2 domain for fusion to progress. The importance of upstream sequences to HR2 
inhibition was recently demonstrated in a MHV study that reported mutations in the HR1 
region in viruses that escape from HR2-derived peptide inhibition (Bosch et al., 2008a). 
Further analysis of the contribution of these mutations to the escape activity was 
performed using a pseudovirus assay. Our results suggest that the two mutations 
identified in mAb 1A9 escape clones were positively contributing to the escape activity 
of pseudoviruses bearing the S mutants (fig. 4.8). However, the three mutations identified 
in the mAb 1G10 escape clones did not contribute to any escape activity of the 
psudoviruses bearing these S mutants (Fig. 4.8). This may indicate that the single 
mutation was inefficient in the viral escape from mAb1G10. Such mutations may still 
contribute to low viral escape activity in the infectious virions but the fitness of these 
viruses may be compromised. This low viral escape activity may not be evidently 
detected in the pseudovirus assay.  
Since the mutations found in mAb 1A9 escape clones were detected to be 
positively contributing to the escape activity of pseudoviruses, we performed more 
experiments to understand the escape strategies. As shown in Fig. 4.9A and B, the 
binding of mAb 1A9 to S(D1128A) and S(N1056K, D1128A) mutants were clearly 
reduced, suggesting that the mutation D1128A reduces the binding affinity of mAb 1A9 
for the virus to escape inhibition by the mAb. However, the mutation N1056K does not 
reduce the binding activity of mAb 1A9 but could still escape from the mAb inhibition. 
To investigate the possibility of the synergism between the two mutations which 
contribute to escape activity, we performed a dose-dependent neutralization assay of the 
pseudoviruses bearing the single mutants as well as the double mutant. The results 
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showed that the pseudoviruses bearing the double mutation exhibited a higher escape 
activity than any of the two single mutants, suggesting that the N1056K mutation may 
synergize the mAb 1A9 escape activity of the D1128A mutation (Fig. 4.9C). The mAb 
1A9 binding site as well as the amino acids that were shown to be critical for its 
neutralizing activity (N1056 and D1128) were highly conserved among the human (early, 
middle and late phases strains), civet (SZ3 and PCC4 strains) and raccoon dog (SZ16 
strain) SARS-CoV and bat (Rp3 and Rf1 strains) SL-CoV, suggesting that this region 



















Fig. 4.10: Clustal W multiple sequence alignment of SARS-CoV and SL-CoV S proteins. 
The S region corresponding to the binding sites of mAb 1A9 to SARS-CoV S is aligned with the 
early (GZ02), middle (CHUK-W1) and late phases (HK39849) SARS-CoV strains, the civet 
SARS-CoV (SZ3 and PCC4), the raccoon dog SARS-CoV (SZ16) and the bat SL-CoV (Rf1 and 
Rp3). The amino acids that contribute to the escape activity to mAb 1A9 (N1056 and D1128) are 
highlighted in red in the protein sequence, while the binding site for mAb 1A9 is underlined. 
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CHAPTER 5: MECHANISM OF NITRIC OXIDE INHIBITION OF SARS-CoV 
 
5.1 Peroxynitrite has no effect on SARS-CoV replication (The experiments in 
this section were performed by our collaborator) 
It was previously demonstrated that nitric oxide (NO) treatment of SARS patients 
has beneficial effect and that NO inhibits SARS-CoV infection in in-vitro assays 
(Akerstrom et al., 2005; Chen et al., 2004b; Cinatl et al., 2003a; Keyaerts et al., 2004a). 
In this study, we try to understand the mechanism of nitric oxide inhibition of SARS-
CoV. It is first demonstrated by our collaborators that peroxynitrite has no effect on 
SARS-CoV. SIN-1, which produces peroxynitrite, was used in conjunction with a 
superoxide scavenger, MnTBAP, to determine if peroxynitrite was involved in the 
inhibition of SARS-CoV replication. SARS-CoV infected Vero E6 cells were treated 
with different concentrations of SIN-1, and it was observed that no significant inhibition 
of viral replication occurred (Fig. 5.1A). This suggests that SIN-1 administration had no 
effect on the replication cycle of SARS-CoV.  
Next, SARS-CoV infected Vero E6 cells were treated with different 
concentrations of MnTBAP together with SIN-1. MnTBAP removes the superoxide, 
resulting in a reduction in the amount of peroxynitrite and an increase in the amount of 
free NO. The results in Fig. 5.1B clearly demonstrate that with increasing amount of 
MnTBAP in presence of SIN-1 (400 µM), there is an inhibition in the production of 
progeny virus in a concentration-dependent manner. Although a slight reduction on the 
production of progeny virus was observed when the cells were treated with the highest 
concentration of MnTBAP used in this study (800 µM, Figure 5.1C), the reduction of 
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virus replication in cells treated with both SIN-1 and MnTBAP is significantly higher 
than those treated with MnTBAP alone. This slight reduction might be explained by the 
fact that the use of the superoxide scavenger resulted in an increase in intracellular free 

















Fig. 5.1: SIN-1 treatment has no anti-viral effect on SARS-CoV infected Vero E6 cells.  E6 
cells were infected with SARS-CoV at an MOI of 1.0, at 1 hpi cells were treated with different 
concentrations of SIN-1 and/or MnTBAP. (A) Cells treated with different concentrations of SIN-
1. 24 hpi, virus was harvested and titers determined. (B) Cells treated with 400 μM SIN-1 and 
different concentrations of MnTBAP. Virus was harvested 24 hpi and titers determined. (C) Cells 
treated with different concentrations of MnTBAP, virus was harvested 24 hpi and titers 
determined. 
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5.2 Treatment of NO donor leads to a reduction in the palmitoylation of the S 
protein of SARS-CoV 
In order to determine whether nitric oxide or its derivatives were reacting with the SARS-
CoV S protein, Vero E6 cells were infected with recombinant vaccinia virus carrying the 
S gene (rVV-L-S) and treated with the NO donor, SNAP, or a negative control, NAP. 
Following immunoprecipitation with nitro-tyrosine affinity sorbent (Cayman), which 
binds specifically to nitrated proteins, and detection of S by Western blot analysis, it was 
clearly demonstrated that S had been nitrated after stimulation with SNAP but not with 
NAP (Figure 5.2A). To determine whether the palmitoylation of S was affected by nitric 
oxide, cells infected with rVV-L-S were treated with either SNAP or NAP and then 
labelled with [
3
H]-palmitic acid. After immunoprecipitation of the S protein with an anti-
S rabbit polyclonal antibody, the amount of palmitoylated S protein detected in the SNAP 
treated cells was found to be greatly reduced when compared to the mock treated or NAP 
treated ones (Fig. 5.2B). On the other hand, if [
35
S]-methionine-cysteine labelling was 
used, there was no difference in the amount of total S protein immunoprecipitated for all 






















Fig. 5.2: Effect of SNAP on nitration and palmitoylation of S protein. Vero E6 cells were 
infected with rVV-L-S at an MOI of 0.1. At 1 hpi cells were treated with 400 μM SNAP or NAP. 
(A) At 24 h post-infection, the cells were lysed and immunoprecipitation was performed with 
nitro-tyrosine affinity sorbent. Western blot was then performed using rabbit anti-S polyclonal 
antibody. (B, C) At 24 h post-infection, cells were labeled with 400 μCi of [3H]-palmitic acid for 
2 h, or starved with methionine-cysteine (Met-Cys)-free medium for 30 min before being labeled 
with 22 μCi of [35S]-methionine-cysteine for 2 h. The cells were then lysed and 
imunoprecipitation was performed with rabbit S polyclonal antibody to detect the amount of 
radio-labeled S protein. 
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5.3 Nitric oxide reduces the cell-cell fusion activity of S   
An in vitro assay was used to examine the effect of nitric oxide on the cell-cell 
fusion activity of the S protein (Lip et al., 2006). In this case, the S-expressing cells were 
treated with SNAP or NAP before they were mixed with CHO-ACE2 cells stably 
expressing the ACE2 receptor. The formation of syncytia was observed 6 hrs later. Cells 
treated with SNAP showed no fusion (Fig. 5.3B), whereas cell-cell fusion was clearly 
visible in the NAP (Fig. 5.3C) or mock-treated cells (Fig. 5.3A). As expected, the mock-
infected cells showed no fusion as the S protein was not expressed (Fig. 5.3D). 
 
 
Fig. 5.3: SNAP interferes with cell–cell membrane fusion. A 293T-GFP stable cell line was 
infected with rVV-L-S and treated with SNAP or NAP 1 h post-infection. At 24 hpi cells were 
trypsinized and mixed with pre-plated CHO-ACE2 cells. 6 h after mixing the cell lines, 
syncytium formation was observed. (A) Infected cells, mock-treated (B) Infected cells, treated 
with 400 μM SNAP (C) Infected cells, treated with 400 μM NAP (D) Mock infected cells. 
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5.4 SARS-CoV S pseudoviruses produced in the presence of nitric oxide is less 
efficient in viral entry  
In order to investigate the effect of SNAP on the S-mediated entry of SARS CoV 
into cells, we used the HIV pseudovirus system to produce pseudoviruses with S on the 
surface as described in chapter 4. Pseudoviruses were produced from untreated cells or 
cells treated with SNAP (200 µM or 400 µM) or NAP (200 µM or 400 µM).  SNAP and 
NAP treatments did not affect the assembly of S on the pseudoviruses as Western blot 
analysis showed that similar amounts of S were incorporated into the pseudoviruses (Fig 
5.4A).  Similar to our previous observation, two forms of S were detected and these 
correspond to the unglycosylated and glycosylated forms of the protein. The entry of the 
pseudovirus into CHO-ACE2, which is stably expressing the S receptor ACE2 on the 
surface of the cells, was reflected by the luciferase activity in the CHO-ACE2 cells at 72h 
after infection.  As shown in Figure 5.4B, the luciferase activity in the cells infected with 
pseudovirus bearing S was significantly higher than those without S as the latter 
contained no viral envelope protein and could not enter the CHO-ACE2 cells.  The 
reading from the cells infected with pseudovirus bearing S was normalized to 100% for 
calculating percentage of infectivity. Treatment with 200 μM and 400 μM of NAP caused 
appropriately 15% and 25% reduction in infectivity respectively.  However, treatment 
with 200 μM and 400 μM of SNAP resulted in a significantly higher reduction, 
appropriately 70%, in infectivity. In order to exclude any effect on the binding of S to 
ACE2, a p24 ELISA kit (Perkin Elmer) was used to determine the concentration of virus 
bound to cells infected with the pseudoviruses which had been produced in cells either 
treated with 400 μM SNAP or 400 μM NAP. As shown in Fig. 5.4C, SNAP and NAP 
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treatment had no significant effect on the concentration of bound virus, indicating that the 

















Fig. 5.4: SARS-CoV S pseudoviruses produced in the presence of SNAP is less efficient in 
viral entry. Pseudoviruses produced under different conditions were purified and concentrated 
using ultra-centrifugation through a 20% sucrose bed. (A) The presence of S and HIV-1 p24 
proteins in the purified viruses were determined by Western blot analysis. (B) Purified viruses 
were used for the transduction of CHO-ACE2 cells and the degrees of viral entry were 
determined by measuring the luciferase activities. Percentages of infectivity were computed by 
normalizing the entry of untreated S-bearing pseudoviruses to 100%. Means and standard 
deviation from duplicate readings were shown. (C) Nitric oxide or its derivatives do not exert a 
noticeable effect on the binding of the SARS S protein to ACE2. Cells were infected with 
pseudotyped virus bearing the S protein, produced under SNAP or NAP treatment. A p24 ELISA 




It was previously shown by Akerstrom et al. that NO inhibits the replication cycle 
of SARS-CoV (Akerstrom et al., 2005). In tissues that are stressed or inflamed, both NO 
and O2 are elevated. Although SNAP predominantly increases the NO level in the cell, 
peroxynitrite can also be elevated when NO can react with endogenous O2. In this study, 
Our collaborators showed that unlike SNAP, treatment of SARS-CoV infected Vero E6 
cells with SIN-1 has no significant effect on the production of progeny virus (Fig. 5.1A), 
suggesting that peroxynitrite does not inhibit SARS-CoV replication. Moreover, if a 
superoxide scavenger (MnTBAP) is used to remove the O2
−
 and allow more NO to 
accumulate inside the SIN-1- treated cells, a significant inhibition of the virus replication 
was observed (Fig. 5.1B). This suggests that it is NO or a derivative of NO that inhibits 
the virus replication. Further studies were then carried out to understand the mechanism 
of NO inhibition of SARS-CoV. 
Petit et al. have demonstrated that palmitoylation of the SARS-CoV S protein 
plays a role in S-mediated cell–cell fusion (Petit et al., 2007). By substituting select 
cysteine clusters at the carboxyl terminus of the S protein for alanines, it was shown that 
palmitoylation of at least two cysteine clusters at the C-terminus was important in 
membrane fusion that occurred after binding of the S protein to its cognate ACE2 
receptor, critical to the infectivity of SARS-CoV. It has also been previously shown that 
NO or its derivatives have an effect on the palmitoylation of the rat myelin protein 
(Bizzozero et al., 2001). In agreement with both of these findings, our results in this work 
indicate that NO or its derivatives reduce the palmitoylation of the S protein and 
consequently exerts an effect downstream of the S protein binding to ACE2, which is 
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shown by the cell–cell fusion assay (Fig 5.2 and 5.3). However, the cell–cell fusion assay 
does not address the question of whether the under-palmitoylation of the S protein affects 
its expression, folding or incorporation into the mature virus particle. Hence, we created a 
HIV pseudovirus which incorporates S into the virus particle. The results showed that 
SNAP treatment of cells does not affect the expression or incorporation of the S protein 
but decreases the infectivity of the pseudovirus (Fig 5.4). 
In the same study, our collaborators also examined the production of viral RNA 
by real-time PCR analysis (Akerstrom et al., 2009). The results showed that SNAP pre-
treatment and post-treatment of SARS-CoV infected VeroE6 cells resulted in a reduction 
of the production of positive-stranded RNA as early as 3 h post-infection and the viral 
RNA levels remained low even after 24 h post-infection. It was also observed that SNAP 
treatment resulted in a different level of replicase poly-proteins cleavage products and a 
reduction in the expression of the N protein. These results suggest that NO or its 
derivatives may alter the substrate specificities of the 3CLpro to interfere with the 
production of the positive-strand RNA. 
In summary, the results presented here suggest that the effect of nitric oxide on 
the replication of SARS-CoV is at least two-fold: an effect on the production of viral 
RNA in the early steps of replication and a reduction in the palmitoylation of the S 
protein later in the replication cycle. What remains to be elucidated is whether both of 
these effects arise strictly from a direct effect of nitric oxide or its derivatives on viral 
proteins, or strictly from an effect on host factors which are subverted in the course of 
infection, or a combination of both. 
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CHAPTER 6: CHARACTERIZATION OF THE ORF8 REGION OF SARS-CoV 
 
6.1 Characterization of the viral-viral interactions of the ORF8 proteins 
6.1.1 Characterization of polyclonal antibodies to the SARS-CoV unique proteins 
8a and 8b  
As mentioned in Chapter 1.1.3, the ORF8 of SARS-CoV from the middle and late 
phases acquire a 29-nt deletion compared with virus strains from the early phase and the 
animal strains, resulting in the coding of two proteins, 8a and 8b, of 39 and 84 aa, 
respectively, instead of a single 8ab protein (Figs. 6.1A and B). In this study, we 
characterize these ORF8 proteins and gain a better understanding of their interactions 
with other structural and accessory proteins of SARS-CoV.  
Mouse polyclonal antibodies were raised against bacterially expressed GST-
fusion 8a and 8b proteins. To determine the specificity of these antibodies, Western blot 
analysis was performed to detect 8a, 8b and 8ab expressed in transiently transfected Vero 
E6 cells. As shown in Fig. 6.1C, mouse anti-8a polyclonal antibody specifically detected 
8a and 8ab whereas mouse anti-8b polyclonal antibody detected 8b and 8ab. 8a and 8b 
migrated close to their predicted molecular weight of 4.5 kDa and 9.6 kDa, respectively, 
whereas two forms of 8ab, ∼14 kDa (major) and ∼12 kDa (minor), were detected (Fig. 
6.1C). As the predicted molecular weight of 8ab is 13.8 kDa, the minor form is likely to 


















Fig. 6.1: Expressions of SARS-CoV 8a, 8b and 8ab proteins. (A) Schematic diagram showing 
the genetic differences in the ORF8 region of the SARS-CoV isolated from animals and humans 
infected during the middle phase of the SARS epidemic in 2003 (modified from Guan et al., 
2003). The animal isolates have an extra 29-nucleotides insertion such that the sub-genomic RNA 
encodes for a single protein, termed 8ab, whereas that of the human isolates (from the middle 
phase) encodes two proteins, 8a and 8b. Human isolates from early and late phases of the 
epidemic also have the 29-nucleotides insertion found in the animal SARS-CoV. (B) Alignment 
of the sequences of 8a, 8b and 8ab proteins used in this study. Mismatches between 8a and 8ab or 
8b and 8ab are boxed. The 8ab is reconstructed from a human isolate from the middle phase 
(SIN2774) by insertion of the 29-nucletoides found in a human isolate from the early phase 
(GZ02). (C)Western blot analysis was performed to detect 8a, 8b and 8ab proteins expressed in 
Vero E6 cells using cDNA constructs. The experiments were performed with either mouse anti-8a 
polyclonal antibody (upper panel, lanes 1–4) or mouse anti-8b polyclonal antibody (upper panel, 
lanes 5–8). Equal amounts of cells were used in each lane as verified by the level of endogenous 
actin (bottom panel). 
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6.1.2 Expression of 8a and 8b in SARS-CoV infected Vero E6 cells  
SARS-CoV 2003VA2774, an isolate from a SARS patient in Singapore, was used 
to infect Vero E6 cells as previously described (Tan et al., 2004a) and anti-8a or anti-8b 
polyclonal antibodies were used in indirect immunofluorescence experiments to 
determine the expression of 8a and 8b, respectively, in infected cells (Figs. 6.2A and B). 
The 8a and 8b proteins were detected in SARS-CoV infected cells and were found to be 
localized in the cytoplasm. The same antibodies were used to examine the detailed 
cellular localization of 8a, 8b and 8ab, expressed from DNA constructs, in Vero E6 cells 
(Figs. 6.2A and B). Whereas 8a and 8b were found in punctuate vesicle-like structures 
throughout the cytoplasm, 8ab was found to be diffused in the cytoplasm. Hence, there 
appears to be significant differences in the conformations of 8a and 8ab although 35 out 
of 39 aa of 8a is present in the 8ab protein (Fig. 6.1B). Similarly, 77 out of 84 aa of 8b is 


























Fig. 6.2: Cellular localizations of 8a and 8b in SARS-CoV-infected cells and Vero E6 cells 
transfected with DNA constructs for expressing 8a, 8b and 8ab. Specific mouse anti-8a and 
anti-8b polyclonal antibodies were used in indirect immunofluorescence experiments to 
determine the expressions of (A) 8a and (B) 8b, respectively. The top two panels showed the 
specific reactivities of the anti-8a and anti-8b antibodies to proteins expressed in SARS-CoV-
infected cells (right panels) as no unspecific staining was observed for the mock-infected cells 
(left panels). The bottom two panels showed the reactivities of the antibodies to 8a and 8ab (A) or 
8b and 8ab (B) expressed in Vero E6 by transfection of cDNA constructs. 
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6.1.3 Interactions of 8a, 8b and 8ab with other SARS-CoV proteins  
In order to further characterize the cellular properties of 8a, 8b and 8ab, co-
immunoprecipitation experiments were performed to determine if these proteins can 
interact with the SARS-CoV structural proteins, S, M, E and N, as well as two SARS-
CoV accessory proteins, 3a and 7a, which were previously shown to be expressed in 
SARS-CoV-infected cells (Fielding et al., 2004; Tan et al., 2004a). All these proteins 
were not tagged except for M, where the C terminus was fused with a HA tag because of 
the lack of a suitable antibody for the detection of M. 8a, 8b and 8ab were fused at their C 
termini with a myc tag so that it is possible to compare the relative expression of the three 
proteins in this experiment. N-terminal-tagged myc-GST was used as a negative control. 
The results showed that 8a-myc interacted strongly with S, 8b-myc interacted strongly 
with M, E, 3a and 7a and 8ab-myc interacted strongly with S, 3a and 7a (Table 6.1 and 
Fig. 6.3). These results showed that the binding profiles of 8a, 8b and 8ab are clearly 
distinct, suggesting that the conformations of the 8a and 8b proteins may be quite 
different from the 8ab protein. 
 
 
Table 6.1: The interactions between SARS-CoV 8a, 8b and 8ab with other viral proteins 








    S     E           M   N    3a       7a 
 
8a-myc   Strong     Weak          No            No    No       No 
8b-myc     No     Strong      Strong  No        Strong    Strong 
8ab-myc   Strong       No         Weak  No Strong    Strong  
 
a 
These proteins were immunoprecipitated using myc-polyclonal antibody and Protein A agarose. 
b 
These proteins were co-expressed with the bait proteins and co-immunoprecipitation 





Fig. 6.3: Interactions of 8a, 8b and 8ab with other SARS-CoV proteins. Cell lysates 
containing myc-GST (lane 1), 8a-myc (lane 2), 8b-myc (lane 3) or 8ab-myc (lane 4) and another 
SARS-CoV protein (S, E, M-HA, N, 3a or 7a) were immunoprecipitated with an anti-myc 
polyclonal antibody and protein A-agarose beads. (A) The amounts of S protein co-
immunoprecipitated (IP) by the myc-tagged proteins were determined using an anti-S monoclonal 
antibody (top panel). The amounts of S and myc-tag proteins in the lysates before co-
immunoprecipitation were also determined by Western blot (WB) with anti-S and anti-myc 
monoclonal antibodies, respectively (middle and bottom panels). The same experiments were 
performed for panels B–F except that different antibodies against the specific viral proteins were 
used, namely (B) anti-E mouse polyclonal; (C) anti-HA monoclonal (as them protein fused with a 
HA tag at the C terminus); (D) anti-N mouse polyclonal; (E) anti-3a mouse polyclonal; (F) anti-





6.2 8b down-regulates the small envelope protein (E) in SARS-CoV infected cells 
6.2.1 Over-expression of 8b down-regulates the expression of E protein  
While performing the co-immunoprecipitation experiments, we observed that the 
expression of E was significantly reduced in the presence of 8b. The co-transfections of 
pXJ-E and pXJ-8b-myc into 293 T cells were repeated using different amount of the pXJ-
8b-myc construct. As shown in Fig. 6.4A, the down-regulation of E expression was 
specific and dependent on the expression levels of 8b-myc (lane 3 and lanes 5–10). On 
the contrary, the expressions of E were similar when pXJ-E was co-transfected with 
control plasmid (pXJ-myc-GST) (lane 1) or pXJ-8a-myc (lane 2) or pXJ-8ab-myc (lane 
4). In order to determine if 8b has any effect on the expression of other SARS-CoV 
proteins, 8b was co-expressed with S (Fig. 6.4B, lane 1) or M-HA (Fig. 6.4B, lane 3) or 
N (Fig. 6.4B, lane 5) or 3a (Fig. 6.4B, lane 7) or 7a (Fig. 6.4B, lane 9). The results 
showed that 8b did not have any significant effect on the expression of these other viral 
proteins examined here. The down-regulation of E expression by 8b was also observed 
when untagged forms of 8b and E were co-expressed in Vero E6 and 293 T cells (Fig. 
6.4C, lanes 1 and 3). Indirect immunofluorescence experiments also showed that E and 




Fig. 6.4: Effects of 8b on the expression of the small structural protein, E. (A) 293T cells 
were co-transfected with 2 μg of pXJ-E and 0.1 μg of pXJ-myc-GST (lane 1), 1 μg of pXJ-8a-
myc (lane 2), pXJ-8b-myc (lane 3), pXJ-8ab-myc (lane 4), or decreasing amount of pXJ-8b-myc 
(lanes 5–10). Total cell lysates were subjected to Western blot analysis to determine the 
expression of E (middle panel) and myc-tagged proteins (top panel). Equal amounts of cells were 
used in each lane as verified by the level of endogenous actin (bottom panel). (B) 293T cells were 
co-transfected with 1 μg of pXJ-S and 1 μg of either pXJ-8b-myc or empty vector (lanes 1 and 2). 
Total cell lysates were subjected to Western blot analysis to determine the expression of 8b-myc 
(top panel) and S (lower panel). Equal amounts of cells were used in each lane as verified by the 
level of endogenous actin (middle panel). Similar experiments were performed with 1 μg of pXJ-
M-HA (lanes 3 and 4), 0.25 μg of pXJ-N (lanes 5 and 6), 0.4 μg of pXJ-3a (lanes 7 and 8) or 0.4 
μg of pXJ-7a (lanes 9 and 10). (C) Vero E6 or 293T cells were co-transfected with 2 μg of pXJ-E 
and 1 μg of pXJ-8b (lanes 1 and 3) or 1 μg of empty vector (lanes 2 and 4). Total cell lysates were 
subjected to Western blot analysis to determine the expression of E (top panel) and 8b (middle 
panel). Equal amounts of cells were used in each lane as verified by the level of endogenous actin 
(bottom panel). (D) Indirect immunofluorescence experiments were performed to determine the 
cellular localization of 8b and E in Vero E6 cells co-transfected with pXJ-8b and pXJ-E. The 
expression of 8b is represented by FITC staining (left panel), whereas the expression of E is 
represented by rhodamine staining (middle panel). The merged images showed that the 8b and E 
partially co-localized in co-transfected cells (right panel). 
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6.2.2 Expression of 8b did not reduce the transcription of the E gene  
In order to determine if the effect of 8b on the expression of E is due to inhibition 
of the transcription of the E gene, Northern blot analysis was performed to determine the 
mRNA level of E in the presence or absence of 8b protein. The results showed that the 
mRNA level of E was not decreased in 293 T cells co-transfected with pXJ-E and pXJ-
8b-myc (Fig. 5, lane 2) when compared to cells transfected with pXJ-E alone (Fig. 6.5, 
lane 1), but rather there appeared to be an increase in the mRNA level of E in the 
presence of 8b. This implies that the down-regulation of E protein expression by 8b is not 
due to a reduction of the transcription of the E gene and is likely to be post-translational. 
No signal was detected in un-transfected cells (Fig. 6.5, lane 3), showing that the 
hybridization probe is highly specific for mRNA of E. The experiment was repeated three 









Fig. 6.5: Effects of 8b protein on the transcription of the E gene determined by Northern 
blot analysis. Equal amount of total RNA (15 μg) isolated from 293T cells transfected with pXJ-
E (lane 1), pXJ-8b-myc and pXJ-E (lane 2) cDNA constructs or un-transfected 293T (lane 3) was 
separated on a denaturing agarose gel and transferred to nylon membrane. The amounts of E 
mRNA present were determined by hybridization with an E gene-specific probe (top panel). In 
order to verify that equal amounts of total RNA were loaded in each lane of the agarose gel 
before transfer, the amounts of 18S and 28S ribosomal RNA were visualized under UV light 
(bottom panel). 
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6.2.3 The 8b protein can bind E in SARS-CoV infected cells  
Co-immunoprecipitation experiment was also performed to determine the 
interaction between 8b and E in SARS-CoV infected cells. Lysates from mock-infected 
or SARS-CoV infected cells were immunoprecipitated using rabbit anti-8b polyclonal 
antibody (Fig. 6.6, lanes 4 and 6) or an irrelevant antibody (rabbit anti-HA polyclonal 
antibody, lanes 3 and 5). The results showed that the E protein present in the lysates from 
SARS-CoV-infected cells could bind specifically to the 8b protein (lane 6). No unspecific 










Fig. 6.6: Interaction between E and 8b in SARS-CoV-infected cells determined by co-
immunoprecipitation experiment. Lysates from mock-infected or SARS-CoV infected cells 
were immunoprecipitated using rabbit anti-8b polyclonal antibody (lanes 4 and 6) or an irrelevant 
antibody (rabbit anti-HA polyclonal antibody, lanes 3 and 5) and protein A-agarose beads. 
Western blot analyses were then performed to determine the amount of E (upper panel) or 8b 
(lower panel) present in the lysates before immunoprecipitation (lanes 1 and 2) and the immuno-





6.2.4 Expression of 8b and E are mutually exclusive in SARS-CoV infected cells  
Indirect immunofluorescence experiments were further performed to determine 
the localization of E and 8b in SARS-CoV infected cells. Strikingly, cells that were 
expressing high levels of 8b did not have detectable levels of E (Fig. 6.7). Two 
representative sets of data were presented and cells expressing high levels of 8b were 
marked with white asterisks. Hence, it appears that 8b can down-regulate the expression 
















Fig. 6.7: Expressions of E and 8b in SARS-CoV-infected cells determined by indirect 
immunofluorescence experiments. The expression of 8b was represented by FITC staining (top 
row), whereas the expression of E was represented by Rhodamine staining (middle row). The 
merged images showed that the expression of 8b and E were mutually exclusive (bottom row). 
Two representative sets of data were presented and cells expressing high levels of 8b were 




Genomic studies predicted that the reservoirs of SARS-CoV are bats, with the 
palm civet acting as the amplification media before spilling the virus over to the human 
population (Cheng et al., 2007; Graham and Baric, 2010; Song et al., 2005; Vijaykrishna 
et al., 2007). As the virus switched from host to host, genomic changes take place due to 
the high error rate of the viral RNA-dependent RNA polymerase and absence of a proof-
reading mechanism, allowing for the evolution of new strains and selection of the fittest 
strains (Domingo et al., 1996). During human-to-human transmission in the middle phase 
of the epidemic, the ORF8 region of the SARS-CoV acquired a 29-nucleotide deletion, 
resulting in the removal of the 8ab protein and the acquisition of 2 new proteins, 8a and 
8b (Guan et al., 2003). Whether this genomic change is a result of the instability of the 
genome or the acquisition of new functions for host adaptation remains to be addressed.  
In this study, we detected the expression of 8a and 8b in Vero E6 cells infected by 
a human SARS-CoV isolated from the middle phase (SIN2774; GenBank accession 
number AY283798) and showed that the cellular localizations of 8a and 8b are distinct 
from 8ab (Fig. 6.2). We used co-immunoprecipitation of over-expressed proteins in 
mammalian cells to determine the abilities of these proteins to interact with different 
SARS-CoV proteins and showed that the binding profiles of 8a, 8b and 8ab are different 
(Fig. 6.3). Although these viral–viral protein interactions need to be verified in infected 
cells, these observations implied that there are conformational differences between these 
protein when they are expressed as separate proteins (8a and 8b) and when they are 
expressed as a single fused protein (8ab). 
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It has been demonstrated that the palm civets are equally susceptible to the human 
SARS-CoV isolate BJ01 from the middle phase (with the 29-nt deletion) and the isolate 
GZ01 from the early phase (Wu et al., 2005). Using reverse genetic methods, Yount and 
co-workers also reported similar findings in the mouse model (Yount et al., 2005). These 
results suggested that the 8a, 8b and 8ab proteins are not essential for viral replication or 
pathogenesis in the mouse and palm civet models. However, we found that the expression 
of 8b can down-regulate the expression of E in a dose-dependent manner (Fig. 6.4A) and 
the expression of 8b and E in SARS-CoV-infected cells were mutually exclusive (Fig. 
6.7). Interestingly, the expression of E was not affected by either 8a or 8ab (Fig. 6.4A). In 
addition, Northern blot analysis showed that the mRNA level of E was not decreased in 
the presence of the 8b protein, suggesting that the effect of 8b on the expression of the E 
protein is likely to be post-translational (Fig. 6.5).  
Although the co-expression of SARS-CoV E and M is sufficient for the assembly 
of viral-like particles in the baculovirus system (Ho et al., 2004; Mortola and Roy, 2004), 
it was demonstrated by reverse genetic techniques that the E protein is not essential for 
the replication of SARS-CoV in Vero E6 cells (DeDiego et al., 2007). However, the 
deletion of the E gene from SARS-CoV attenuated virus replication significantly both in 
vivo and in vitro (DeDiego et al., 2007). In addition, it was reported that over-expression 
of SARS-CoV E can induce apoptosis in T cells (Yang et al., 2005b); thus, the down-
regulation of E may also have an effect on viral pathogenesis.  
An interesting question that arises from our observations concerns the regulation 
of 8b expression during SARS-CoV infection. 8a and 8b are encoded by the bicistronic 
subgenomic RNA 8 produced in SARS-CoV-infected cells (Marra et al., 2003; Snijder et 
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al., 2003). Because its translation initiation codon is not the first AUG in the subgenomic 
RNA, the 8b protein is likely to be expressed via an internal ribosomal entry mechanism 
or by a leaky ribosomal scanning mode of translation, as have been described for viral 
proteins encoded by other bicistronic or tricistronic coronaviral mRNAs (Liu and Inglis, 
1992; Senanayake and Brian, 1997; Thiel and Siddell, 1994). However, in order for 8b to 
be expressed via such mechanisms, activation of certain host translational machinery may 
be necessary (Komar and Hatzoglou, 2005; Stoneley and Willis, 2004). Indeed, we 
observed that 8b was only expressed in a fraction of the SARS-CoV-infected cells (Fig. 
6.7). This means that the effect of 8b on viral replication or pathogenesis is likely to be 
only modulative as viral replication in those cells that did not express high levels of 8b 
will be normal. However, this modulating mechanism is not functional in the animal 
SARS-CoV because 8ab does not appear to have any effect on the expression of E. In 
future studies, it will be crucial to determine the underlying mechanism regulating the 
expression of 8b and its temporal expression during the viral replication cycle. 
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CHAPTER 7: SARS-CoV 8b REDUCES VIRAL REPLICATION BY DOWN-
REGULATING E VIA AN UBIQUITIN-INDEPENDENT PROTEOSOME 
PATHWAY 
 
7.1 Inhibition of the protein 8b-mediated rapid degradation of the E protein by 
proteasome inhibitor 
In Chapter 6, we found that the SARS-CoV E was down-regulated by 8b in a 
post-translational manner. In this study, we aim to understand the mechanism of down-
regulation of E by 8b. First, we explore the possibility of a proteasome-mediated down-
regulation of E by 8b. To determine whether proteasome inhibitor, MG132, could inhibit 
the protein 8b-mediated degradation of the SARS-CoV E, co-expression of protein 8b 
with E in transfected cells in the presence or absence of the inhibitor was carried out. 
Analysis of the E expression by Western blot with antibodies to E showed that the 
addition of MG132 (50 μM) blocked the rapid degradation of SARS-CoV E (Fig. 7.1, top 
panel). However, addition of 50 μM MG132 did not significantly affect the accumulation 











Fig. 7.1: Inhibition of protein 8b-mediated rapid degradation of the SARS-CoV E protein 
by the proteasome inhibitor, MG132. 293T cells expressing the SARS-CoV E alone (lane 1) or 
co-expressing with 8b (lanes 2 and 3) were incubated with 50 μM MG132 (lane 3), and harvested 
at 18 h post-transfection. Total cell lysates were separated on 17.5% SDS-PAGE gels and 
analyzed by western blot with appropriate antibodies. 
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7.2 Knockout of lysine residues on 8b does not prevent its polyubiquitination and 
ability to down-regulate E 
In a previous study, 8b was shown to undergo both monoubiquitination and 
polyubiquitination (Le et al., 2007). The host ubiquitin-proteasome pathway is a 
commonly exploited pathway by viruses for their own protein level regulation (Banks et 
al., 2003) and the role of an E3 ligase is to catalyze the transfer of an activated ubiquitin 
from an E2 to the lysine residue of the target protein (Banks et al., 2003; Ciechanover and 
Ben-Saadon, 2004; Hershko and Ciechanover, 1998; Wilkinson, 2000). To explore the 
possibility of 8b acting as an E3 ligase, a lysine knockout mutant of 8b, 8b(K4,26,81R), 
was generated by substituting of the three lysine residues in 8b with arginine residues.  
As shown in Fig. 7.2A, both 8b and 8b(K4,26,81R) underwent monoubiquitination and 
polyubiquitination (Fig. 7.2A, lanes 2 and 3). The monoubiquitinated product of 8b-myc 
was detected at ~17 kDa while the polyubiquitinated products of 8b-myc appear as a 
ladder. However, the monoubiquitinated 8b was somewhat reduced in the lysine 
knockout mutant (Fig. 7.2A, lane 3). Thus, a novel mechanism might be involved in the 
polyubiquitination of 8b while the lysine residues contribute partially to the 
monoubiquitination of 8b.  
In addition, 8b(K4,26,81R) down-regulated the expression of E as well as 8b (Fig. 
7.2B, lane 2 and 3). Since the polyubiquitination of 8b cannot be abolished by lysine 
knockout, it cannot be ascertain if the polyubiquitination of 8b is important for the 8b-
mediated down-regulation of E.  However, the monoubiquitination of 8b is not essential 




Fig. 7.2: Lysine knockout mutant of 8b undergoes polyubiquitination and down-regulates E. 
(A) 293T cells were transfected with cDNA constructs for expressing flag-ubiquitin (flag-Ubi) 
and 8b-myc or 8b(K4,26,81R)-myc. The cells were harvested at 16 h post-transfection, lysed and 
subjected to immunoprecipitation (IP) with anti-myc mouse monoclonal antibody and protein-A 
beads. The amounts of polyubiquitinated 8b-myc or 8b(K4,26,81R)-myc were determined by 
Western blot (WB) analysis with an anti-flag rabbit polyclonal antibody (1
st
 panel, lanes 1-4). A 
darker film exposure was included (1
st
 panel, lanes 5-8). The amounts of myc-tagged and flag-





panels). Anti-actin monoclonal antibody was used to verify that equal amount of lysates were 
used in each lane (4
th
 panel). (B) 293T cells were transfected with cDNA constructs for 
expressing E-HA, 8b-myc and 8b(K4,26,81R)-myc. The expressions of 8b and E were 
determined by Western blot analysis using anti-myc antibody (1
st
 panel) and anti-HA antibody 
(2
nd
 panel) respectively. Anti-actin monoclonal antibody was used to verify that equal amount of 






7.3 Substitution of K64 to R on E increases the protein stability by reducing the 
polyubiquitination of E 
To investigate the importance of the lysine residues on E and its 
polyubiquitination, three substitution mutants E(K54R), E(K64R) and E(K54,64R), were 
generated. As shown in Fig. 6.10A, the amounts of E protein were increased in both the 
E(K64R) and E(K54,64R) transfected cells when compared to wild-type E transfected 
cells (Fig. 7.3A, lane 1, 3 and 4). On the other hand, the expression of E(K54R) was the 
same as wild-type E. This result suggests that the K64R substitution can increase the 
protein stability of E.  
A pulse-chase labeling experiment was performed in a similar manner as reported 
by Nal et al. (Nal et al., 2005). Consistently, the results showed that E(K64R) and 
E(K54,64R) decayed at slower rates than wild-type E while E(K54R) has a similar decay 
rate (Fig. 7.3B). The intensities of specific bands in the autoradiographs were quantified 
using an imaging densitometer and the percentages of remaining proteins after different 
times of decay were plotted.  As shown in Fig. 7.3C, the half-lives of E(K64R) and 
E(K54,64R) are greater than 3 h while that of wild-type E and E(K54R) are less than 1 h.  
Next, ubiquitination assay was performed to investigate the effects of K54R and 
K64R substitutions on the polyubiquitination of E. 293T cells were co-transfected with 
plasmids expressing flag-ubiquitin and E, E(K54R), E(K64R) or E(K54,64R), and an 
immunoprecipitation experiment was performed to pull-down proteins associated with 
the flag-tagged ubiquitin. The results showed that the K54R substitution does not affect 
the polyubiquitination of E(K54R) (Fig. 7.3D, lanes 2 and 3) but K64R substitution 
reduces the polyubiquitination of E(K64R) and E(K54,64R) (Fig. 7.3D, lanes 4 and 5). 
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Hence, the increase in the stabilities of E(K64R) and E(K54,64R) is correlated with a 









Fig. 7.3: Substitution of K64 to R on E increases its stability by reducing its 
polyubiquitination. (A) 293T cells were transfected with 1 μg of cDNA constructs for 
expressing E-HA, E(K54R)-HA, E(K64R)-HA or E(K54,64R)-HA and their protein expression 
levels were detected using anti-HA antibody (1
st
 panel). Anti-actin monoclonal antibody was used 
to verify that equal amount of lysates were used in each lane (2
nd
 panel). (B) Transfected cells 
were starved at 24 h post-transfection at 37°C for 30 min in methionine- and cysteine-free 
medium. Cells were pulsed for 15 min with medium containing 
35
S-labelled methionine and 
cysteine amino acids and chased for 0-6 h before lysis, and subjected to IP with anti-HA 
monoclonal antibodies and protein-A beads. (C) A graph showing the amounts of 
35
S radio-
labeled E-HA, E(K54R)-HA, E(K64R)-HA and E(K54,64R)-HA remaining at 0.5-6 h after 
expression. (D) 293T cells were transfected with cDNA constructs for expressing flag-ubiquitin 
(flag-Ubi) and E-HA, E(K54R)-HA, E(K64R)-HA or E(K54,64R)-HA. The cells were harvested 
at 16 h post-transfection, lysed and subjected to IP with anti-flag mouse monoclonal antibody 
beads. The amounts of ubiquitinated E-HA, E(K54R)-HA, E(K64R)-HA or E(K54,64R)-HA 
were determined by Western blot analysis with an anti-HA rabbit polyclonal antibody (1
st
 panel). 
The amounts of HA-tagged and flag-tagged proteins in the lysates before IP were determined by 




 panels). Anti-actin monoclonal antibody was used to verify that 




7.4 Both lysine residues on E are important for 8b-mediated E degradation  
To determine if the lysine residues on E are important for the 8b-mediated 
degradation pathway, the expressions of E, E(K54R), E(K64R) and E(K54,64R) were 
determined in the absence or presence of 8b (Figure 7.4A). The intensities of specific 
bands in the autoradiographs were quantified using an imaging densitometer and the 
percentage reduction in E expression in the presence of 8b was computed.  As shown in 
Figure 7.4B, both E(K54R) and E(K64R) were less sensitive to 8b-mediated degradation 
than wild-type E, with E(K54R) being less sensitive than E(K64R).  As the double 
substitution mutant, E(K54,64R), was the least sensitive to 8b-mediated degradation, it 





















Fig. 7.4: Both lysine residues on E are involved in the 8b-mediated down-regulation of E. 
(A) 293T cells were transfected with cDNA constructs for expressing E-HA, E(K54R)-HA, 
E(K64R)-HA or E(K54,64R)-HA in the absence or presence of 8b-myc and harvested at 24 h 
post-transfection. The amounts of HA-tagged and myc-tagged proteins expressed were 




 panels).  Mock transfected cells were used as 
negative control (lanes 5 and 10). (B) The expression levels of E-HA, E(K54R)-HA, E(K64R)-
HA and E(K54,64R)-HA were quantified with a densitometer and their expression levels in the 
presence of 8b relative to that in the absence of 8b are presented in the graph. 
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7.5 Expression of 8b increases with time in SARS-CoV infected Vero E6 cells  
In chapter 6, 8b of SARS-CoV were found to be expressed in Vero E6 cells using 
both Western blot and immunofluorescence assays (Keng et al., 2006). However, Oostra 
et al. reported that they could not detect 8b in SARS-CoV infected cells at 8 h post-
infection (hpi) (Oostra et al., 2007a). To address this discrepancy, the expressions of S 
and 8b in Vero E6 cells were analyzed at different time-points post infection (Fig. 7.5).  
The results showed that S was expressed early during infection and could be detected in 
almost all the cells at 8 hpi (Fig. 7.5, M-P). However at the 8 hpi, only a small percentage 
of cells have a weak expression of 8b (Fig. 7.5, F). At 24 and 32 hpi, the 8b expression 
increased and could be detected in a larger percentage of infected cells (Fig. 7.5, G and 
H, respectively). This is consistent with our previous results (Keng et al., 2006) and 













Fig. 7.5: 8b has a higher expression at late-stage infection of Vero E6 cells. Vero E6 cells 
were either infected with SARS-CoV (E-H, M-P) at M.O.I. of 1 or mock-infected as negative 
control (A-D, I-L). Cells were harvested at 1, 8, 24 and 32 hpi, fixed using 4% paraformaldehyde 
and permeabilized with 0.5% Triton-X 100. Expression of 8b and S were detected using anti-8b 
(A-H) and anti-S polyclonal antibodies (I-P), respectively. 
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7.6 8b is a negative modulator of SARS-CoV replication  
Cells stably-expressing GFP (as control) and GFP-8b were generated to determine 
the effect of 8b on SARS-CoV replication. As shown by Western blot analysis (Fig. 
7.6A), GFP-8b (lane 2) is expressed at a much lower expression than GFP (lane 1). To 
determine if the level of GFP-8b expressed in the stable cell line is sufficient to down-
regulate E, the stable cell lines were transfected with the pXJ3’-E plasmid. As shown in 
Fig. 7.6B, the expression of E was down-regulated in GFP-8b expressing cells (lane 3) 
but not in the control cells expressing GFP (lane 2).  
Next, the replication of SARS-CoV in these two stable cell lines was compared. 
The stable cell lines were infected with SARS CoV at an MOI of 0.1, and at 24 hpi, the 
supernatant was titrated out on a 96 well plate containing Vero E6 cells. The amount of 
virus was deduced by the 50 % tissue culture infective dose (TCID
50
), which was 
calculated from the cytopathic effect (CPE) induced in cell culture by different dilutions 
of the harvested virus as previously described in reference (Akerstrom et al., 2005). As 
shown in Figure 7.6C, the amount of virus produced by the GFP-8b cells was about 10-
fold lower than the GFP-expressing cells, suggesting that 8b has a negative effect on the 
SARS-CoV replication. The difference in viral titers is statistically significant (p < 0.05).  
To determine if GFP-8b or GFP affects the entry of SARS-CoV into cells, a HIV 
pseudovirus assay that was described in chapter 4 is used (Fig. 7.6D). Luciferase readings 
of both stable cell lines infected with HIV pseudotyped virus bearing S (HIV-Luc-S) 
were similar.  As would be expected, very low readings were obtained for cells infected 
with control pseudovirus without envelope (HIV-Luc). This suggests that the difference 
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in virus titers observed is not due to a change in the viral entry into cells expressing either 
GFP or GFP-8b. 
 
Fig. 7.6: Ectopic 8b expression reduces viral replication in Vero E6 cells. (A) Cells 
stably expressing GFP and GFP-8b were harvested and lysed and subjected to Western 
blot analysis. Expressions of GFP and GFP-8b in the stable cell lines were detected using 
an anti-GFP antibody. (B) GFP-8b and GFP stable cells were transfected with a cDNA 
construct for expressing E, harvested and lysed at 24 h post-transfection. Expressions of 
GFP and GFP-8b were detected using an anti-GFP antibody (1st panel).  The amount of E 
in the cell lysates was detected using anti-E antibody (2nd panel). Anti-actin monoclonal 
antibody was used to verify that equal amounts of lysates were used in each lane (3rd 
panel). (C) A graph showing the titers of the virus produced by GFP and GFP-8b cells. 
The average and standard deviation of readings from 12 independent experiments are 
plotted. Statistical analysis was performed using Student’s t test assuming unequal 
variance and the difference between GFP and GFP-8b cells was found to be significant (p 
< 0.05). 
 134 
7.7 E is down-regulated in SARS-CoV infected GFP-8b expressing cells  
To investigate the effect of 8b on the expression level of E during SARS-CoV 
infection, GFP-8b and GFP cells were infected with SARS-CoV at different multiplicity 
of infection (M.O.I.) and harvested at 18 hpi. At M.O.I of 0.1, the expression of S in the 
GFP-8b cells (Fig. 7.7, lane 1 and 2) was much lower than GFP cells and this is probably 
a result of the lower viral replication in the GFP-8b cells as observed above.  At M.O.I. of 
5, the expressions of S in both GFP-8b and GFP-expressing cells were similar (lanes 3 
and 4).  However, the expression of E was significantly lower in the GFP-8b cells 
compared to the GFP cells (lanes 3 and 4). This result suggests that GFP-8b down-








Fig. 7.7: Expression of E is down-regulated in SARS-CoV infected cells stably expressing 
GFP-8b. Vero E6 cells stably expressing GFP and GFP-8b were infected with SARS-CoV at 
M.O.I. of 0.1 (lanes 1 and 2) and M.O.I. of 5 (lanes 3 and 4). Cells were harvested and lysed at 18 
hpi and the expressions of S and E in the cell lysates were detected using anti-E (1
st
 panel) and 
anti-S (2
nd
 panel) antibodies, respectively.  
 
 135 
7.8 Effects of 8b on the transcription of host genes 
To identify potential host proteins involved in the reduction of viral replication in 
the GFP-8b expressing cells, an oligo-nucleotide microarray analysis was performed. The 
host gene profiles of GFP and GFP-8b cell lines were compared to identify host genes 
that were increased or decreased by 8b. When compared to cells expressing GFP only, 
the GFP-8b cells have 78 genes down-regulated by more than 4 folds and 59 genes up-
regulated by more than 4 folds (data not shown). Microarray analysis was performed for 
another GFP-8b stable clone, named as GFP-8b*, which has a lower expression of the 
GFP-8b protein (Fig. 7.8A, lanes 1 and 2). Unlike GFP-8b, the production of progeny 
SARS-CoV in GFP-8b* cells was found to be the same as in GFP cells (data not shown).  
Hence, the gene profile of GFP-8b* cells was compared to GFP-8b cells to exclude host 
mRNAs that are increased/decreased by GFP-8b but not involved in the regulation of 
viral replication. This comparison revealed that 15 host genes were down-regulated more 
than 2-fold in GFP-8b compared to GFP-8b* cells and 4 host genes were up-regulated 
more than 2-fold in GFP-8b compared to GFP-8b* cells (Table 7.1).  
Next, quantitative PCR (qPCR) was performed to validate the results from the 
microarray analysis. For the down-regulated genes, there were no commercially available 
qPCR primers for 3 of them (DKFZp586D0518, DKFZp451E0119 and FLJ12280 fis 
genes). qPCR was performed for the other 12 genes and 7 of them were found to be 
down-regulated to a greater extent in GFP-8b cells than GFP-8b* cells (Fig. 7.8B). These 
are NTS, VDUP1, THBS1, GPM6A, KIAA1199, DTR and DAB2.  As for the 4 up-
regulated genes, only two of them (HLF and MYOZ1) were up-regulated a greater extent 
in GFP-8b cells than GFP-8b* cells (Fig. 7.8C). 
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Table 7.1: Host genes with different mRNA expression in GFP-8b and GFP-8b* cells as 
identified by microarray analysis
a 
             
Genes   Affymetrix ID  Ratio of mRNA expression to GFP
b
    Fold difference
c 
              GFP-8b        GFP-8b*             
Down-regulated 
NTS   206291_at    0.13  0.67  5.2 
VDUP1 (TXNIP) 201010_s_at    0.01  0.04  4 
THBS1   201110_s_at    0.06  0.23  3.8 
DKFZp586D0518 215253_s_at    0.08  0.29  3.6 
DKFZp451E0119 1566096_x_at    0.14  0.5  3.6 
SNK (PLK2)  201939_at    0.2  0.67  3.4 
GPM6A  209470_s_at    0.09  0.27  3 
INHBA   210511_s_at    0.22  0.59  2.7 
FLJ12280 fis  213909_at    0.22  0.59  2.7 
DLG2 (MPP2)  206253_at    0.25  0.59  2.4 
KIAA1199  212942_s_at    0.03  0.07  2.3 
DSCR1 (RCAN1) 208370_s_at    0.17  0.38  2.2 
BAI3   205638_at    0.19  0.38  2 
DTR (HBEGF)  203821_at    0.26  0.53  2 
DAB2   210757_x_at    0.25  0.5  2 
 
Up-regulated 
HLF   204754_at    6  2.6  2.3 
MYOZ  (MYOZ1) 219509_at    5.3  2.5  2.1 
ID2   201565_s_at      3.8  1.9  2 
TSLRP (LRRC6) 206483_at    3.2  1.6  2  
 
a
 Only genes that are up- or down-regulated in GFP-8b cells by > 2 fold than in GFP-8b* cells, 
are short-listed in the table. 
b
 The ratio of genes transcription signals in GFP-8b or GFP-8b* cells to that in GFP control cells. 
c
 The fold difference in the signal of the target genes between the GFP-8b and GFP-8b* cells. For 
down-regulated genes, the fold difference is GFP-8b*/GFP-8b and for upregulated genes, the fold 









































Fig. 7.8: Effects of 8b the transcriptions of host genes. (A) GFP-8b, GFP-8b* and GFP stable 
cells were harvested, lysed and subjected to IP with anti-8b polyclonal antibody and protein-A 
beads. The amounts of GFP-8b in the cell lysates of GFP-8b and GFP-8b* stable cells were 
detected by anti-GFP mouse monoclonal antibody. (B) Quantitative PCR was performed to 
validate the results from the microarray analysis (Table 1).  A graph is plotted using the relative 
quantification (RQ) values for the down-regulated genes in GFP-8b and GFP-8b* cells, 
normalized to GAPDH and using GFP cells as the reference for normalization. (C) As described 
above, a graph is plotted for the up-regulated genes in GFP-8b and GFP-8b* cells. 
 138 
7.9 Discussion 
In the previous chapter, we have shown that 8b can down-regulate E in SARS-
CoV infected cells (Keng et al., 2006). It was also reported that 8b can be 
monoubiquitinated and polyubiquitinated (Le et al., 2007). It is widely known that lysine 
residues are important for the binding of ubiquitin to a protein for ubiquitination 
(Hershko and Ciechanover, 1998). The results showed that the lysine residues in 8b are 
not required for its polyubiquitination or ability to down-regulate E (Figure 7.2).  
Furthermore, the degradation of E by 8b is dependent on both K54 and K64 in E while 
the half-life and polyubiquitination of E in the absence of 8b is only dependent on K64 
(Figures 7.3 and 7.4).  Thus, the 8b-mediated degradation of E, which can be inhibited by 
proteasome inhibitors (Fig. 7.1), seems to involve an ubiquitin-independent proteasome 
pathway. Several ubiquitin-independent proteolytic functions of the proteasome have 
been recently reported (Orlowski and Wilk, 2003). Although many of the ubiquitin-
independent pathways have yet to be precisely defined, a recent study showed that more 
than 20% of cellular proteins are degraded by the proteasome via ubiquitin-independent 
pathways (Baugh et al., 2009). 
Recently, a study using reverse genetics techniques showed that deletion of group 
specific genes 6, 7a, 7b, 8a, 8b and 9b from the SARS-CoV genome reduced its 
replication titer by 5-10 fold in human CaCo2, Huh7.5.1 and Huh-7 cells while deletion 
of E resulted in a 100 to 1000-fold reduction, compared to cells infected with wild-type 
SARS-CoV (DeDiego et al., 2007; DeDiego et al., 2008). A time-course study revealed 
that 8b is expressed at late time-points post infection (~32 hpi) (Figure 7.5).  By 
comparing Vero E6 cells stably expressing GFP-8b or GFP alone, progeny virus 
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production was found to be significantly reduced in the presence of ectopic expression of 
8b (Figure 7.6).  This reduction is not due to any difference in the viral entry into the cells 
expressing GFP and GFP-8b.  However, the expression of E in SARS-CoV infected cells 
is down-regulated in cells stably expressing GFP-8b when compared to GFP-expressing 
cells (Figure 7.7). This is consistent with our earlier observation that infected cells with 
high level of 8b have low level of E and suggests that 8b reduces viral replication by 
down-regulating the expression of E protein. 
Gene profiling was used to determine the effects of 8b on host transcription. By 
comparing the profile of the GFP-8b stable cell-line with that of another clone, GFP-8b*, 
host genes that are regulated by 8b in a dose-dependent manner was shortlisted (Table 
7.1). Independent validation by qPCR showed that there are 7 down-regulated genes and 
2 up-regulated genes whose expressions may contribute to SARS-CoV replication 
(Figure 7.8).  Some of these host genes have been implicated in the replication of other 
viruses.  For example, thrombospondin-1 (THBS1) has also been shown to be down-
regulated by cytomegalovirus infection (Cinatl et al., 1999) and hepatitis leukemia factor 
(HLF) has been shown to control hepatitis B virus transcription activity (Ishida et al., 
2000). In a recent study, a reduction in the expression of the thioredoxin interacting 
protein (VDUP1/TXNIP) was shown to reduce the replication and secretion of hepatitis C 
virus (Blackham et al., 2010). Further investigations are needed to determine the roles of 
these proteins in regulating SARS-CoV replication. 
Taken together, our results suggest that the over-expression of the SARS 
coronavirus 8b reduces viral replication by down-regulating E via an ubiquitin-
independent proteasome pathway.  In virus evolution, rapid mutation is constantly taking 
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place to achieve a strain which can have optimal replication titer for both efficient 
transmission and the ability to evade the host immune response (Bonhoeffer and 
Sniegowski, 2002; Vossen et al., 2002). Based on the results obtained using Vero E6 cells 
over-expressing 8b, it is speculated that the ability of 8b to reduce viral replication could 
be a mechanism to prevent the over-production of virus, after reaching an optimal viral 
titer, so as to reduce the pathogenesis of the host. However, future studies need to be 
performed to determine if 8b can modulate viral replication during natural infection. 
Interestingly, another SARS-CoV accessory protein, 7b, was recently shown to be an 
attenuating factor (Pfefferle et al., 2009a). One unanswered question is whether the 
replication of a SARS-CoV without 8b in the natural host will be higher than that of the 
wild-type virus. Previous studies have shown that the deletion of 8b and several other 
accessory proteins, namely 6, 7a, 7b, 8a and 9b, from the SARS-CoV genome reduced 
viral replication in cell cultures by 5-10 fold (DeDiego et al., 2007; DeDiego et al., 2008). 
Thus, it is possible that the weak down-regulation of viral replication by 8b can be 
counter-balanced by other accessory proteins. For example, Chen et al. have shown that 
the 8a protein can increase viral replication (Chen et al., 2007b). Thus, the SARS-CoV 
could have acquired the 8a and 8b proteins to fine-tune its replication in the human host. 
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CHAPTER 8: FINAL CONCLUSION AND FUTURE DIRECTIONS 
 
Several studies have reported the importance of the SARS-CoV viral-viral protein 
interactions in replication complex assembly as well as viral assembly. It was 
demonstrated that the interaction between M and N or M and E is essential for viral 
assembly (Ho et al., 2004; Huang et al., 2004b). Critical viral-host interactions leading to 
viral entry, suppression of host immune response and host apoptosis have also been 
reported. The interaction of S with host ACE2 has been shown to be important for SARS-
CoV entry (Li et al., 2004a; Simmons et al., 2004). The research efforts described in this 
thesis attempt to gain a better understanding of the viral-viral and viral-host interactions 
that contribute to the replication of the SARS-CoV. In this thesis, we focus on exploring 
the feasibility of disrupting a critical virus-host interaction, of S with ACE2, as a strategy 
to prevent the SARS-CoV entry and delineating the importance of the viral-viral 
interaction of the ORF8 proteins for the virus replication. Results of our studies are 
summarized below: 
 
a) It was demonstrated that one of the five polyclonal antibodies generated against the 
various regions in the ectodomain of SARS-CoV S exhibits a strong neutralizing 
activity against SARS-CoV infection in vitro. This polyclonal antibody, rabbit 
αSΔ10, specifically targets the domain within the amino acid residues 1055 to 1192 
of S. 
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b) Monoclonal antibodies generated against the S fragment encoding aa 1055 to 1192 
were found to have SARS-CoV neutralizing activities and target either the N-terminal 
of HR2 domain or the region immediately upstream of the HR2 domain. 
c) Two of these mAbs, mAb 1A9 and mAb 1G10, were both found to have cross-
neutralizing activities against civet SARS-CoV (SZ3 strain) and bats SL-CoV (Rp3 
and Rf1 strains). 
d) Using escape viruses generated with mAb 1A9, two amino acids, N1056 and D1128, 
located near and within the binding sites of mAb 1A9 were identified to be important 
for its neutralizing activity. 
e) It was shown that a reduction in the palmitoylation of S was one of the mechanisms 
employed by NO for the inhibition of SARS-CoV replication. 
f) The cellular localization and interactions of the ORF8 proteins, 8a, 8b and 8ab, with 
other SARS-CoV proteins were shown to be different from each other. 
g) The SARS-CoV 8b was demonstrated to down-regulate the small envelope E protein 
in both the infected and transfected cells via a post-translational pathway. 
h) The mechanism of down-regulation of E by 8b was shown to be via an ubiquitin-
independent proteasome pathway. 
i) Viral replication was shown to be decrease by 10-fold more in cells stably expressing 
the GFP-8b protein compared to control cells expressing GFP alone. 
j) Vero E6 ells stably expressing the 8b protein had 7 genes that were up-regulated and 
2 genes that were down-regulated by more than 2 fold, when compared to normal 
cells. These genes may be involved in the 8b-mediated reduction of viral replication 
via the down-regulation of E. 
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In the first part of this study, we have generated and used monoclonal and 
polyclonal antibodies to characterize novel neutralizing epitopes within the highly 
conserved S2 domain of the SARS-CoV S protein (Keng et al., 2005; Lip et al., 2006). 
Two representative mAbs were shown to have cross-neutralizing activities against civet 
SARS-CoV as well as bat SL-CoV. Overall, our results have significant implications for 
the development of vaccine and antiviral therapeutics in the event of a re-emergence of 
SARS-CoV or another pathogenic coronavirus from bat reservoirs. Further work is 
required to humanize the mAbs and determine their efficacies in an in vivo infection 
model. In addition, mutation at two residues (N1056 and D1128) in S seems to allow the 
virus to escape neutralization by the mAb 1A9. As these residues have not been 
previously documented to play a role in viral fusion, it will be very interesting to employ 
biophysical or structural methods to examine the precise mechanisms by which they 
contribute to the fusion between viral and host membranes. The fitness of the escape 
viruses also needs to be examined in vitro and in vivo. 
In the second part of this study, we have compared the expression, cellular 
localization and viral-viral interaction profile of the accessory proteins encoded by ORF8 
of SARS-CoV (Keng et al., 2006). Interestingly, we observed that the 8a, 8b and 8ab 
proteins seem to participate in different viral-viral interactions and 8b can down-regulate 
the expression of E during infection via an ubiquitin-independent proteasome pathway 
(Keng et al., 2011). The ectopic expression of 8b also reduced viral replication in Vero 
E6 cells and perturbed the transcriptional level of several host proteins. The contribution 
of these host proteins to SARS-CoV replication remains to be determined so does the 
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mechanism for their regulation by 8b and/or 8ab. Our studies provide interesting insights 
into the potential involvement of these poorly characterized accessory proteins in viral-
viral and viral-host interactions, and suggest that 8b may have evolved to act as a negative 
modulator of SARS-CoV replication. Further studies that use reverse genetics techniques 
and an appropriate animal model will be required to compare the viral replication and 
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Appendix 1: Primers for constructions of plasmids for expression of S and S mutants 
Primer   Sequence     Application 
 
SS03-56  5’-ACGGATCCACCATGTTTATTTTCTTATTA-3’  Cloning full-length S 
SS03-57  3’-GTAGGCCTATGTGTAATGTAATTTGAC-5’  Cloning full-length S 
SS03-62  5’-AAGGATCCAGATCAGACACTCTTTATTT-3’  Cloning SΔ1 
SS03-63  3’-AAAATCTCGAGTTGTAGAGCACAGAG-5’  Cloning SΔ1 
SS03-60  5’- CAGGATCCTCAACCTTTAAGTGCTATG-3’  Cloning SΔ2 
SS03-61  3’- CTATCTCGAGTCAGGTAATATTTGTGAAA-5’ Cloning SΔ2 
SS03-68  5’- CTGGATCCTTTTCGCTTGATGTTTC-3’  Cloning SΔ3 
SS03-69  3’- TATTACTCGAGGGAGAAAGGCACATT-5’  Cloning SΔ3 
SS03-101 5’- CTGGATCCTCTTTTATTGAGGACTTGC-3’  Cloning SΔ9 
SS03-102 3’- TGAACTCGAGCTCCTGGGATGGCACAT-5’  Cloning SΔ9 
SS03-103 5’- AGGGATCCCACCTTATGTCCTTCC-3’  Cloning SΔ10 
SS03-104 3’- AAACCTCGAGAGGCCATTTAATATATTGC-5’ Cloning SΔ10 
SS03-111 3’- CAGGATCCTTAACAAGAGCATGCACCCT-5’ Cloning SΔ11 
SS03-112 3’- CCGGATCCTTAATACCAAGGCCATTTAATA-5’ Cloning SΔ12 
SS03-113 3’- GAGGATCCTTAGCCTGAAATGTCGCCAA-5’ Cloning SΔ13 
SS03-114 3’- TGGGATCCTTATGTAATTAACCTGTCAATT-5’ Cloning SΔ14 
SS03-115 3’- AGGGATCCTTAGGTAACTCCAATGCCATT-5’ Cloning SΔ15 
SS03-116 3’- TCGGATCCTTACCTCTTAGTTGGCTTTAG-5’ Cloning SΔ16 
SS04-100 3’-TGGGATGGGTAGCCCTTTCCACAAA-5’  Cloning SΔ50 
SS04-101 5’-AGGGCTACCCATCCCAGGAGAGGA-3’  Cloning SΔ50 
SS04-102 3’-CGAGGGAACACATACGTGACATGTAG-5’  Cloning SΔ51 
SS04-103 5’-CGTATGTGTTCCCTCGTGAAGGTGT-3’  Cloning SΔ51 
SS04-104 3’-GAAAAGAAGTATGCTTTGCCTTCATG-5’  Cloning SΔ52 
SS04-105 5’-AAGCATACTTCTTTTCTCCACAAATAATT-3’ Cloning SΔ52  
SS04-106 3’-TTAGCGACGTCGCCAAGATCAACATC-5’  Cloning SΔ53 
SS04-107 5’-TTGGCGACGTCGCTAAAAATTTAAATGAA-3’ Cloning SΔ53 
SS04-108 3’-GGCCATTTCTCATTGAGGCGGTCAAT-5’  Cloning SΔ54 
SS04-109 5’-TCAATGAGAAATGGCCTTGGTATGTTT-3’  Cloning SΔ54 
SS04-94  3’-CGAACGGATTGTTGAAATGGTTGAAATG-5’ Cloning SΔ55 
SS04-95  5’-TTCAACAATCCGTTCGAGATCCTAAA-3’  Cloning SΔ55 
SS04-96  3’-ATGTCTAAATCAGTGAAATCAGAAACAT-5’ Cloning SΔ56 
SS04-97  5’-TCACTGATTTAGACATTTCACCTTGCT-3’  Cloning SΔ56 
SS04-98  3’-GATGTTTTAACATCACGGCCAAATTG-5’  Cloning SΔ57 
SS04-99  5’-GTGATGTTAAAACATCTGAAATATTAGAC-3’ Cloning SΔ57 
SS04-77  3’-CAGAGCTCTTATGTGTAATGTAATTTGACAC-5’ Cloning (SΔ50-57) 
CT08-14           5’-GAGTATGTCGACACTTCTTAT-3’   Cloning S(H641Y) 
CT08-15           3’-ATAAGAAGTGTCGACATACTC-5’    Cloning S(H641Y) 
CT08-16          5’-ACTATAGAAGTAATGCCTGTT-3’   Cloning S(T706I) 
CT08-17           3’-AACAGGCATTACTTCTATAGT-5’   Cloning S(T706I) 
CT08-18           5’-TGGATTGACATTTGGTG-3’    Cloning S(W869L) 
CT08-19           3’-CACCAAATGTCAATCCA-5’    Cloning S(W869L) 
CT08-20           5’-CCAGGAGAGGAAATTCA-3’    Cloning S(N1056K) 
CT08-21           3’-TGAATTTCCTCTCCTGG-5’    Cloning S(N1056K) 
CT08-22           5’-TGCCTCATTCAAAGAAGA-3’   Cloning S(D1128A) 






Appendix 2: Primers for constructions of plasmids for expression of ORF8 proteins and mutants 
Primer   Sequence     Application 
 
8a_forward 5’-CGGGATCCACCATGGGAATGAAACTTCTC-3’ Cloning 8a and 8ab 
8a_reverse 3’-CCGCTCGAGCTAGTGTTGTACC-5’         Cloning 8a 
8b_forward 5’-CGGGATCCACCATGGGAATGTGCTTGAAG-3’ Cloning 8b 
8b_reverse 3’-CCGCTCGAGCCATTTGTTCGTTTATT-5’  Cloning 8b and 8ab 
8a_delN15F 5’-CGGGATCCACCATGGGAATGAAACTTCTC-3’ Cloning 8aΔN15 
8b_delN26F 5’-CGGGATCCACCATGGGAGTTTTACCTTT-3’  Cloning 8bΔN26 
CT07-11 5’-CGGGATCCATGTGCTTGAGGAT-3’   Cloning 8b(K4R) 
CT07-07 5’-AGGTAAAACCCTTCCTAG-3’           Cloning 8b(K26R) 
CT07-08 3’-CTAGGAAGGGTTTTACCT-5’   Cloning 8b(K26R) 
CT07-10 3’-CCGCTCGAGCCAATTTGTTCGTCTATT-5’  Cloning 8b(K81R) 
 
 
Appendix 3: Primers for constructions of plasmids for expression of E protein and mutants 
Primer   Sequence     Application 
 
SS03-42  5’-AGGGATCCACCATGTACTCATTCGTTTC-3’  Cloning E 
SS03-48  3’-TAGTTCTCGAGGACCAGAAGATCAGGAA-5’ Cloning E 
CT06-01 5’-TTAGTAAGACCAACGGTTT-3’   Cloning E(K54R) 
CT06-02 3’-AAACCGTTGGTCTTACTAA-5’    Cloning E(K54R) 
CT06-03 5’-CGTGTTAGAAATCTGAACT-3’   Cloning E(K64R) 
CT06-04 3’-AGTTCAGATTTCTAACACG-5’   Cloning E(K64R) 
 
 
